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FOREWORD 
Guillain-Barre syndrome (GBS) is a neurological disease characterised by ascending paralysis 
that can lead to respiratory muscle compromise and death. Although the exact trigger of GBS 
is unknown, case control studies have shown that it often follows an acute infectious illness. 
In recent years, serological and cultural studies have suggested that Campylobacterjejuni is 
the infectious agent most commonly associated with the development of GBS. Culture 
confirmation of C. jejuni infections has been achieved in up to 50% of GBS patients, in spite 
of the fact that many GBS patients with antecedent Campylobacter infection are likely to have 
already cleared their stools of the organism by the time neurological symptoms begin. 
Campylobacter infection is now classified as the most common cause of bacterial food 
poisoning in the Western world. In Tasmania, over 400 cases are notified each year. Given 
this prevalence it is not clear why only a small number of patients with C. jejuni enteritis 
develop GBS whilst the majority do not. Two possibilities exist; the first being that 
susceptibility is determined by host-specific factors; the second is that bacterial strain-specific 
factors determine whether patients develop GBS. The aim of this investigation is to determine 
the importance of the second factor. The specific objectives being to define specific bacterial 
markers that might be used to determine those strains of Campylobacter associated with the 
development of. GBS. 
The way in which infection with C. jejuni leads to GBS is unknown, however, there is 
evidence suggesting that Gml ganglioside in the core of the lipopolysaccharide of certain 
strains of C. jejuni may stimulate an immune response to this epitope in infected patients. It is 
hypothesized that this immune response may then lead to an autoimmune peripheral 
neuropathy because the Gml in the bacteria is identical to that in the nerve cell. 
This study investigated the epidemiology of Campylobacter infection within the Tasmanian 
community by collecting isolates from patients notified to the Department of Health in 
Tasmania. This culture collection was then used to develop a robust method for speciation of 
isolates. This included development of a multiplex PCR for the hippurate gene/16S rRNA 
gene with subsequent dot blot hybridisation using labeled probes. Using this system, 237 
enteritis strains were identified as C. jejuni, 10 C. co/i, 2 C. lari and 1 C. upsaliensis. 
C. jejuni serotype 0:19 appears to be over-represented in most published studies of GBS but 
campylobacters of this serotype do not account for all Campylobacter isolates from GBS 
patients. Potential markers of GBS-associated campylobacters investigated in the present 
study included the use of a Cholera Toxin Binding Assay for Gml -like epitopes in bacteria 
cell walls, a PCR for serotype 0:19 strains and Pulsed Field Gel Electrophoresis (PFGE). 
While 33% of all Tasmanian strains were found to be Gml positive, no isolates were found to 
belong to the serotype 0:19. Further, computer-assisted analysis of PFGE profiles showed no 
similarity between GBS strains of C. jejuni and Tasmanian strains of Campylobacter. 
Subtractive hybridisation was used to produce a DNA library containing sequences that are over-
represented in GBS-associated strains of C. jejuni. This library has been used to screen GBS and 
non-GBS-associated strains of C. jejuni. A unique DNA sequence, present only in the GBS-
associated strains, has been identified and a PCR-based assay developed to detect this gene (Veh). 
The gene has homology to a sequence (Cj1013c), determined as part of the recently completed 
C. jejuni genome sequencing project, which is a gene of unknown function. Further studies to 
define gene function have been hampered by the lack of a suitable mutagenesis system for 
C. jejuni. Veh has been cloned in a shuttle vector to enable its mobilisation into other transfer 
systems. 
It is hoped that in the future, identification of Campylobacter strains containing the Veh gene will 
lead to prompt treatment of patients infected with these strains thereby decreasing the incidence 
of GBS and its associated morbidity and mortality. 
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CHAPTER ONE 
LITERATURE REVIEW 
1.1 Background 
The genus Campylobacter was first proposed in 1963 (Sebald and Veron, 1963) to reclassify 
Vibrio fetus and "related vibrios"(King, 1957) that possessed distinct cultural characteristics 
separating them from the true vibrios. This original description contained just two species; 
Vibrio fetus and Vibrio bubulus. While the type strain for this new genus, Campylobacter 
fetus, had been known since the early 1900's as a cause of abortion and dysentery in cattle 
and domestic animals, it was not until 1947 that an association with human disease was made 
following their isolation from blood cultures (Vinzert, Dumas and Picard, 1947). It was 
discovered that the species V. bubulus differed from V. fetus in having both a high optimum 
growth temperature and a predominantly clinical presentation in those infected, of diarrhoea. 
Initial isolates of V. bubulus were obtained from blood cultures and it was proposed that 
isolation from faecal specimens would be possible if a culture medium could be made that 
suppressed the growth of normal flora of the intestinal tract (King, 1962). Over 10 years later 
in 1973, a study in Brussels used the fact that campylobacters are smaller in size than most 
other bacteria and by using a filter to capture the larger bacteria, campylobacters were 
cultured successfully for the first time from faecal samples in 5.1% of children with diarrhoea 
compared to only 1.3% of children without diarrhoea (Butzler et al, 1973). These results 
were confirmed, and a selective medium developed in 1977 which increased isolation rates of 
Campylobacter sp. to 7.1% in patients with diarrhoea (Skirrow, 1977). Campylobacter jejuni 
is now recognised as the most frequent bacterial agent of diarrhoea in developed countries, 
often exceeding the combined total for diarrheal illness caused by Salmonella sp., Shigella 
sp. and Escherichia coli 0157:H7 (Blaser, 1997). 
With improved culture techniques, and soon after Skirrow's culture media was routinely 
used, a study was published describing the association of Campylobacter isolated from a 
patient with diarrhoea and the subsequent development of Guillian Barre Syndrome (GBS) 
(Rhodes and Tattersfield, 1982). Since that report numerous studies have shown the 
association between GBS and a preceding gastrointestinal infection with Campylobacter 
jejuni (Hughes and Rees, 1997). 
Within 25 years of the first campylobacters being isolated from faecal samples, the genus had 
been expanded to include 21 species and subspecies. Smaller laboratories still perform 
culturing techniques as used in the late 1970's and 80's, and therefore only the common 
species are routinely isolated resulting in under-reporting of the true incidence of other 
3 
campylobacters causing diarrhoea and their possible link with neuropathies such as GBS. 
Recently a report was published describing the association of Campylobacter upsaliensis 
with the related neurological condition, acute motor axonal neuropathy (Ho et al, 1997) and 
the association of Campylobacterjejuni with other non-GBS neuropathies such as Miller-
Fisher Syndrome (Salloway eta!, 1996). 
1.2 Reservoir of Infection 
Campylobacter species and Arcobacter species are found in the intestinal tract of many 
domesticated and wild animals. Those animals used for food production such as poultry, 
cattle, sheep, swine and goats are therefore a major source of human infection. For example, 
Campylobacter species have been isolated in up to 80% of raw chickens sold in the UK 
(Cony and Atabay, 2001). Consumption of undercooked poultry or improper handling of raw 
meat are both possible sources of infection. Human to human transmission by a food handler 
with a diarrheal illness has also been documented (Olsen eta!, 2001). The organisms can also 
be carried by human pets such as dogs, cats and birds (Blaser, 1997). Consumption of 
unpasteurised milk (MMWR, 2002) and contaminated water supplies (de Boer, 1996) have 
also been implicated. 
1.3 Taxonomy 
The taxonomy of the campylobacters and related bacteria has been extensively revised, 
particularly over the last decade. An extensive polyphasic study using DNA-rRNA 
hybridisations to determine relative phylogenetic positions with subsequent cross referencing 
of information with phenotypic and genetic data has produced the taxonomic structure 
currently in use (Vandamme et al, 1992). This study has grouped campylobacters into the 
rRNA superfam. ily VI comprising three main rRNA homology groups. Group one contains 
the genera Campylobacter (21 species and subspecies), group two, Arcobacter (4 species) 
while rRNA group three contains the genus Helicobacter (24 species) and the genus 
Wolinella (1 species) (On, 2001). 
A separate group of saprophytic, sulpur-reducing strains of organisms has subsequently been 
added to the rRNA superfamily VI with 16S rRNA gene sequencing analysis clearly showing 
their close relationship to Arcobacter species (Figure 1.1). These organisms now belong to 
the new genus Sulfurospirillum which currently contains four species. Another closely 
related saprophytic bacterium isolated from activated sludge, Dehalospirillum multivorans, 
possesses many of the characteristics of the genus Sulfurospirillum and will likely be 
included in this new genus in the future (On, 2001). 
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Figure 1.1:  Dendrogram showing relationships between members of the RNA 
Superfamily VI based upon 16S rRNA gene sequences and neighbor-joining 
clustering, 
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CoopyArfucha subsp. venereal: 
Caavykobachar hiryiniestinaks subs!). lair:ono 
Carapykabachar lanienas 
* CoMpf/0147C1C1 canal:us 
▪Calapidobachar curraar 
*Campy/al:We/ sharaa 
•Cal•Pilobacter foams 
•Campylabacter sputa/um 	 by. Memos 
nacpylabactav vacuum 	 by. paraarealytivos 
avapidobaciaer &minis 
•CalappbArcle gracilis 
*Campy/mbar-hal upsafiensis 
Calairkducter MAW/kw 
* CdOlPfilthelaCI cal 
• Campfkrbacie • lad 
Caapylabactar cof 	 var. hyvilei 
Caawilabacter jajuni 	 setup. doirivi 
Compidobecier yajuni 	 subsp.. 141.071 
LE 
litaticobacier born 
lielicabecter helomani 
Ile&obocier suit 
Nelicobacte; hefty/nail 
Harobacharleks 
lielrobactef salcvaanis 
lidicobacter bizzazerarati 
lielicobacter acincrychis 
lialicabacter macesfrinde 
lielcobactef pylori 
▪Nafrobacter pedal= 
NeaficolucKr passe/anus 
liancobecter chalecyritts 
lialkobacto arlentiare 
Nafcabociar fennel:ye, 
lielicabacter frogonhao 
ilidicobachat aauridanea 
lialcobactef hepaticas 
lialicabactef 
lialcobectar caais 
▪ Nefrathacter aimed 
Makabactet rappini 
lialicobachw exahabe 
Nencabachr OphAanicus 
Heicabacter sancta 
Walineas succinageoes 
Type 1 
Type 2 
Sequences were obtained via Genbank and a multiple alignment obtained using BioNumerics 
software (Applied Maths, Kortrijk, Belgium) (Adapted from On, 2001) 
* Species pathogenic for humans 
1.3.1 Description of the pathogenic genera 
• Campylobacters are curved, S-shaped, or "seagull shaped" bacteria, 0.2 - 0.9 gal wide and 
0.5 - 5.0 gm in length. Spherical or coccoid bodies may form in old cultures or in cultures 
exposed to air for prolonged periods (Nachamlcin, 1995). They are non-spore forming Gram-
negative bacilli and display a characteristic rapid darting motility. They may possess either a 
unipolar unsheathed flagellum or bipolar flagella (Blaser, 1989). The majority of the species 
require a microaerophilic atmosphere for growth at 37°C, while some species will only grow 
in anaerobic conditions at 37 °C and others only in the presence of increased concentrations of 
hydrogen (On, 1996a). The G+C content of the DNA ranges from 29 to 45% (Versalovic and 
Fox, 1999). 
Arcobacters are slightly curved, curved, S-shaped or "seagull shaped" bacteria that are 0.2 - 
0.9 pm wide and 1.0 - 3.0 gm in length. As with campylobacters, arcobacters are motile but 
only ever display a unipolar unsheathed flagellum. This genus will grow at temperatures that 
are lower than required for Campylobacter, with most strains growing at 15 °C, 25 °C and 
30°C, with variable growth at 37°C (Nachamkin, 1995). They also differ from the genus 
Campylobacter in being aerotolerant and in their fatty acid profiles (Lambert et al, 1987). All 
isolates described in a recent study of this genus grew in aerobic conditions at 25°C (On, 
1996a). 
Helicobacters are helical, curved or straight Gram-negative rods 0.3 to 1.0 grn wide and 1.5 
to 5.0 gm long. They differ from campylobacters and arcobacters due to the presence of 
sheathed flagella. Some species possess a unipolar flagellum (H. cinaedi and H. fennelliae) 
or multiple unipolar or bipolar lateral flagella (H. pylori). The organisms are microaerophilic 
with optimum growth at 37 °C. The G+C content of the DNA ranges from 30 to 48% 
(Versalovic and Fox, 1999). 
1.3.2 Differentiation of species 
As the organisms in RNA superfamily VI are asaccharolytic, very few tests are available for 
the differentiation of the individual species. Tests such as the optimum growth temperature 
and atmospheric growth conditions are therefore relied upon for speciation. Appendix A 
outlines the major differentiating characteristics and tests used for identification of organisms 
in this group that are pathogenic for humans. 
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1.4 Clinical Significance 
The predominant infection by far seen in humans with this group of bacteria, is diarrhoea 
with abdominal pain, fever and sometimes vomiting. The organisms may occasionally be 
isolated from blood cultures, with rare extra-intestinal infections occurring in patients with 
some type of predisposing condition. 
1.4.1 Campylobacter jejuni subspecies jejuni 
C. jejuni subsp. jejuni is the most commonly isolated bacterial species associated with 
diarrhoea. Thus, it accounts for approximately 400 cases of reported gastroenteritis in 
Tasmania each year (an infection rate of approximately 1/1000) and approximately 11,000 
throughout Australia. This rate is compared with 6,500 Salmonella and 700 Shigella cases for 
the same time period (CDI, 1997) and corresponds to infection rates seen in other developed 
nations such as the United Kingdom and USA (Nachamlcin, 1995). 
C. jejuni may be found comprising part of the normal intestinal flora of both wild and 
domesticated animals including most of the animals used in food production (eg. poultry, 
cattle, sheep and swine). The organisms can also be carried by human pets such as dogs, cats 
and birds (Blaser, 1997). 
Although infections are seen throughout the year, there is a marked increase in prevalence in 
the summer months and early autumn. Infection occurs following ingestion of improperly 
cooked food (primarily poultry) but is also linked to contaminated milk and water (Tauxe, 
1992). Infections display a bi-modal age distribution with the highest incidence seen in 
infants and young children with the second peak in adults 20 - 30 years old (Engberg et al, 
2000). Epidemiological evidence shows that the majority of isolations are sporadic but that 
large outbreaks from a single strain have also been reported (Jones et al, 1993; Jackson et al, 
1996). 
The incubation period following ingestion of C. jejuni, calculated from outbreak 
investigations, is 24-72 hours, but incubation periods of greater than 1 week can occur 
(Blaser, 1997). Prodromal symptoms are often non-specific and can include headache, 
myalgias, chills and fever and may persist for more than 24 hours. 
A spectrum of illness is seen associated with gastroenteritis, ranging from asymptomatic to 
severe. The major symptoms include abdominal cramping and fever followed by diarrhoea 
(with or without erythrocytes/leucocytes) lasting from several days to more than one week. 
The diarrhoea may initially be watery with more than eight bowel movements on the worst 
day of illness and will frequently contain blood. The abdominal pains associated with 
infection have been known to mimic acute appendicitis. Illness usually peaks over a 24-48 
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hour period, slowly improving and resolving over the following week but relapses have been 
reported in up to 20 % of cases (Blaser, 1997). Faecal excretion of C. jejuni can still occur 
during the convalescent stage. In a Norwegian study, carriage rates of C. jejuni averaged 37.6 
days (range 15-69 days) (Kapperud et al, 1992). In another study, C. jejuni could be isolated 
from two thirds of patients at 2 weeks post-infection, from one third of patients at 4 weeks 
and from 4% at 6 weeks (Nachamkin, 1997). 
Extra-intestinal infections also occur and may include bacteremia, reactive arthritis, bursitis, 
urinary tract infection, meningitis, endocarditis, peritonitis, erythema nodosum, pancreatitis, 
abortion and neonatal sepsis (B laser, 1990). Guillain-Barre syndrome (GBS) appears to be 
strongly associated with Campylobacter infection as one of the sequelae of infection (Hughes 
and Rees, 1997). 
Bacteremia occurs in 1.5/1,000 intestinal infections with the highest rate in the elderly 
(Slcirrow et al, 1993) but with deaths being reported rarely (Tauxe, 1992). 
Studies comparing developed and developing countries have shown a marked difference in 
features of C. jejuni infections. While in developed countries it is typical to have only 0-1 
infections/lifetime seen principally in young adults, greater than 5 infections/lifetime are seen 
in developing countries with children less than 2 years of age being mainly affected. 
Widespread immunity is absent amongst adults in developed countries but present in adults in 
developing countries (Calva et al, 1988). Also in developed countries, illness manifests itself 
as inflammatory diarrhoea with the principal vehicle of transmission being under-cooked 
poultry. In developing countries, the illness manifests as a simple diarrhoea and the vehicle of 
transmission is unknown (Blaser, 1997). 
As the majority of infections are self-limiting, antimicrobial intervention is not usually 
warranted. Treatment may be considered however where there is evidence of extra-intestinal 
infection, in compromised patients or persons with severe symptoms including bloody 
diarrhoea and/or fever. The current drug of choice in erythromycin but fluoroquinolones and 
tetracyclines are used as alternatives (Blaser, 1995). 
1.4.2 Campylobacter colt 
It is estimated that approximately 5-10% of cases of diarrhoeal illness caused by 
campylobacters are due to C. co/i. (Nachamlcin, 1995). Clinically, the illness caused by this 
species is indistinguishable from that seen with C. jejuni. This species has also been 
associated with indwelling device-related bacteremia (Hsueh eta!, 1997). The species has 
been isolated from the intestinal tract of pigs, poultry, bulls, sheep and birds (On, 1996a). 
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1.4.3 Campylobacter fetus subspecies fetus 
(previously Campylobacter fetus subspecies intestinalis) 
The first reported cases of human illness due to this species were in 1947 (Vinzert, Dumas 
and Picard, 1947). A distinguishing feature of this subspecies, and the most common 
presentation in humans, is bacteremia. In a review of 91 cases of bacteremia, 50 were due to 
C. fetus, 10 due to C. jejuni and the remaining 31 of uncertain speciation. The predominant 
clinical presenting features in patients with C. fetus bacteremia were fever in 96% of patients, 
diarrhoea/nausea/vomiting/abdominal pain in 38%, hepatosplenemegaly/jaundice in 44%, a 
mortality rate of 26%, with 96% of patients > 14 years of age and having an underlying 
disease process in 72% of the time (Guerrant eta!, 1978). Compare this with bacteremia due 
to C. jejuni (diarrhoea/nausea/vomiting/abdominal pain being the predominant feature in 80% 
of cases, fever in 60%, hepatosplenamegaly/jaundice in 10%, mortality of 20%, only 30%> 
14 years old with the majority: 60% being < 1 year old (Guerrant et al, 1978). 
C. fetus also has a predilection for the vascular endothelium. There have been 15 reported 
cases of C. fetus associated aneurysms predominantly in the abdominal aorta (Montero et al, 
1997), endocarditis (Loeb et al, 1966) and thromophlebitis (Carbone, Heinrich and Quinn, 
1985). 
Other extraintestinal infections include spontaneous peritonitis (Elcuaz et al, 1998), septic 
abortion (Rettig, 1979), abscesses, meningitis, septic arthritis and salpingitis (Mishu, Patton 
and Tauxe, 1992) and prosthetic hip joint infections (Yao, Ng and Campbell, 1993). 
1.4.4 Campylobacter upsaliensis 
(previously CNW Campylobacter) 
A thermophilic Campylobacter was first isolated from dog faeces in 1983. It was 
subsequently isolated from humans with gastroenteritis (Goossens et al, 1990). Isolation from 
a breast abscess (Gaudreau and Lamothe, 1992) and from a case of abortion have also been 
reported (Gurgan and Diker, 1994). While most patients that develop gastroenteritis from C. 
jejuni and C. co/i acquire their infections from improperly cooked poultry, the reservoir of C. 
upsaliensis seems to be the family pet, with carriage rates of 5% in cats and 29% in dogs 
(Hald and Madsen, 1997). Possible further evidence for this comes from a reported case 
involving the isolation of C. upsaliensis from the faeces of a patient with diarrhoea and from 
his healthy dog. Both isolates were shown to be the same strain by plasmid analysis, protein 
profiles, immunotyping, antibiotic susceptibility pattern and phenotypic characterisation 
(Goossens, Vlaes and Butzler, 1991). 
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1.4.5 Campylobacter lari 
(previously Campylobacter laridis, NARTC') 
In 1980, a new species was proposed for those campylobacters that differed from other 
thermophilic strains by their resistance to nalidixic acid and halotolerance (Skirrow and 
Benjamin, 1980). The species name C. laridis, later changed to C. lari, was chosen as the 
majority of isolates were obtained from seagulls (genus Larus) (Benjamin eta!, 1983). 
Although the organism had been isolated from a number of different avian and mammalian 
species, it had not been associated with illness (Roberts, 1983). In 1985, a report was 
published describing six cases of human illness associated with C. lari; four cases of 
enteritis, one with severe cramping abdominal pain and one of terminal bacteremia in an 
immunocompromised host (Tauxe et al, 1985). While extra-intestinal infections are rare, a 
fatal case of septic shock was recently reported in an 81 year old immunocompetent man with 
a prosthetic joint infection and bacteremia caused by this species (Werno et al, 2002). Large 
waterborne infections affecting over 100 individuals have also been described (Nachamlcin, 
1995). 
1.4.6 Other pathogenic Campylobacter and Arcobacter species 
While early isolations of Campylobacter concisus were found from the human oral cavity 
(Tanner eta!, 1981) and increased numbers were associated with inflamed gingival crevices 
(Moore et al, 1985), the pathogenic role of this species in periodontal disease has remained 
unclear. Subsequently, published reports of C. concisus from faecal samples in patients with 
gastrointestinal disorders began to emerge (Vandamme et al, 1989) but years later the same 
research group questioned the role of C. concisus in gastrointestinal disorders when no 
statistically significant difference was found in isolation rates from children with diarrhoea 
compared with the control group (13.2% vs 9% respectively). A large number of those strains 
tested were isolated from children attending a day care centre. DNA fingerprinting using 
arbitrary primers showed that the majority of children harboured their own unique strain of 
C. concisus and the prevailing diarrhoea was not due to an epidemic strain (Van Etterijck et 
al, 1996). Confirmation of the status of C. concisus as a normal commensal of the human gut 
was later reported in a study in which 45 strains of C. concisus were isolated in nearly 
equivalent proportions from 1,376 faecal samples from both patients with diarrhoea and 
healthy controls (Engberg et al, 2000). This species has however been implicated as a cause 
of diarrhoea in immunocompromised AIDS patients (Snijders eta!, 1997). 
Another species implicated in gastroentestinal infections is Campylobacter hyointestinalis 
subspecies hyointestinalis, isolated from humans experiencing watery, non-bloody diarrhoea 
and ranging in age from 8 months to 79 years old (Edmonds et al, 1987) as well as from cases 
of proctitis in homosexual males (Fennell et al, 1986). 
Campylobacter mucosalis (previously Campylobacter sputorum subspecies mucosalis), a 
Well documented cause of porcine necrotic enteritis and ileitis (On, 1996a), has also been 
isolated from two children (12 and 18 months of age) presenting with mild diarrhoea and 
loose stools but without gross blood in faeces (Figura eta!, 1993) while Campylobacter 
jejuni subspecies doylei (previously `NINIC group'), first isolated in Australia in 1985 from 
children less than 5 years of age with diarrhoea (Steele, Sangster and Lanser, 1985), has also 
been reported from AIDS patients with diarrhoea (Snijders eta!, 1997). 
Consumption of contaminated water during travel and person-to-person transmission have 
resulted in human enteritis being attributed to Arcobacter butzleri (previously Campylobacter 
butzleri) (Kiehlbauch eta!, 1991a). Cases of bacteremia, endocarditis and peritonitis have 
also been reported (Nachamkin, 1995). This species has been reported to comprise up to 16% 
of all campylobacter-like organisms causing diarrhoea (Taylor et al, 1991) but is frequently 
not isolated as optimum growth conditions have yet to be determined (Nachamkin, 1995). 
The second pathogenic species of this genus, Arcobacter cryaerophilus (previously 
Campylobacter cryaerophilia), has also been reported to cause diarrhoea and bacteremia in 
humans (Nachamkin, 1995). It has been isolated from the gastrointestinal tract of pigs, bulls, 
sheep, horses and found in sewage (On, 1996a). 
A number of Campylobacter species have been associated with periodontitis. C. rectus 
has been isolated from the complex subgingival flora found in cases of periodontitis 
along with Campylobacter gracilis (previously Bacteroides gracilis) (Tanner et al, 1981) as 
has Camplyobacter showae (previously Wolinella curva subspecies intermedius) and 
Campylobacter curvus (previously Wolinella curva) (On, 1996a). 
Extra-intestinal infections of these uncommonly isolated species of Campylobacter are rare. 
C. curvus was isolated from lung, jaw and neck infections (Finegold and Jousimies-Somer, 
1997) as well as from peritoneal fluid (Wexler eta!, 1996). C. rectus (previously Wolinella 
recta) has been isolated in association with Actinomyces viscosus from a patient with an 
actinomycotic chest wall mass (Spiegel and Rtelford, 1984). 
A number of isolations of C. gracilis have been reported from serious deep-seated infections 
such as soft tissue abscesses, appendicitis/peritonitis/intra-abdominal abscesses, 
parapharyngeal abscess, and empyema as well as bacteremia and wound infections 
(Molitoris, Wexler and Finegold, 1997). 
Campylobacter sputorum biovar sputorum is regarded as a commensal of the human 
gastrointestinal tract, with clinical isolations being rare. Published reports include isolation 
from a leg abscess, another from a case of infantile diarrhoea (Roop eta!, 1985) and from an 
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axillary abscess (On et al, 1992). Isolation from AIDS patients with diarrhoea has also been 
noted (Snijders et al, 1997). 
1.4.7 Non pathogenic campylobacters and arcobacters 
The following species have not been associated with any known human diseases to date: 
Campylobacter fetus subsp. veneralis 
Campylobacter coli var. hyoilei 
Campylobacter hyointestinalis subsp. lawsonii 
Campylobacter sputorum biovar fecalis 
Campylobacter sputorum biovarparaureolyticus 
Campylobacter helveticus 
Campylobacter lanienae 
Arcobacter nitrofigilis 
Arcobacter ski rrowii 
1.5 Techniques for isolation 
1.5.1 Selective agars 
Many different formulations have been described since the first selective agar was produced 
by Skirrow in 1977. The earlier media containing blood were subsequently found to be 
inhibitory to the growth of campylobacters and so were replaced by charcoal based media 
containing a combination of antimicrobial agents to which C. jejuni and C. coll are resistant. 
These include as the selective agent, antifungals such as amphotericin B, anti-Gram positive 
bacterial agents such as vancomycin and anti-coliform agents such as cephalothin or 
cefoperazone. Over the following years, other non C. jejuni/coli campylobacters were found 
to be associated with gastroenteritis. Isolation of many of these new species was impeded by 
the fact that they were susceptible to the new selective agarose formulae. The true incidence 
and clinical spectrum of the newer campylobacters is therefore yet to be established as most 
laboratories routinely culture for C. jejuni and C. coll only on commercially available media. 
The antibiotics in the more widely used media formulations are given in Table 1.1 and 
the ability of various routine selective media in isolating members of the genus 
Campylobacter and Arcobacter are summarised in Table 1.2. 
A number of different studies have examined the efficacy of these selective media for the 
isolation of C. jejuni and C. co/i. One study screened 1,980 faecal specimens from patients 
with gastroenteritis and found 161 Campylobacter strains (148 C. jejuni, 12 C. co/i, 
1 C. upsaliensis) (Endtz eta!, 1991a). The three media used in this study: Slcirrow medium 
(SKM), Charcoal cefoperazone deoxycholate agar (CCDA) and Charcoal based selective agar 
(CSM) enabled the highest isolation rates of campylobacters, with no statistical difference 
between these three formulations (80%, 83% and 87% of strains isolated respectively). Each 
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of the media examined did not necessarily grow the same strains and the best isolation rates 
were produced with a combination of media and filtration methods. CSM and CCDA were 
also found to have the highest rates of isolation of C. co/i. The lowest recovery rate of 
campylobacters was found when using the filtration method with only 61% of 
campylobacters being detected. This method however was the only one to grow the single 
C. upsaliensis detected. This study also found that the two media, CSM and CCDA, 
possessed the lowest number of faecal contaminants allowing for easier recognition of 
Campylobacter organisms. 
Several of the selective media such as blood free, semi-solid motility medium (SSM) and 
SKM were devised for use at 42 °C and have poor selective qualities at 37°C, whereas CSM 
and CCDA show good selective properties at 37°C (Endtz eta!, 1991a). 
1.5.2 Enrichment broths 
The use of an enrichment broth is extremely useful when trying to isolate low numbers of 
campylobacters from convalescent GBS patients. In a study by Taylor et al (1988), 
dramatically improved isolation rates were obtained in GBS patients showing an increase of 
31% over conventional plating techniques when testing patients more than 20 days after the 
onset of gastroenteritis. 
A number of enrichment broth formulations have been produced for the recovery of 
campylobacters. These include: Campy-thio broth [CT] (Blaser eta!, 1979), Campylobacter 
enrichment broth [CEB] (Martin et al, 1983), Preston enrichment broth (Bolton and 
Robertson, 1982), Bruce-Zochowslcy medium [BZ] (Hodge and Terro, 1984), Alkaline 
peptone water [APW] (Phillips and Nash, 1985) and Semi-solid motility media [SMTM] 
(Chan and MacKenzie, 1982). 
A number of comparative studies have been published. Thus Martin et al (1983), improved 
isolation rates by 46.3% on samples kept at 4°C for 3 weeks with CBE enrichment broth over 
the commonly used enrichment broth at that time, Campy-thio broth [CT]. Agulla et al 
(1987), compared CT, APW, CEB and BZ. Unlike a previous study by Martin eta! (1983), 
their four enrichment broths did not improve isolation rates from fresh faecal samples of 
acute gastroenteritis patients. They proposed that enrichment broths would only be useful 
when attempting to detect low numbers of viable organisms. They did however note that CEB 
and BZ produced slightly better isolation rates compared to the other media tested. 
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Table 1.1:  Antibiotic supplements used in selective agars for Campylobacter 
s ecies 
MEDIA ANTIBIOTIC SUPPLEMENT 
Slcirow medium [SKM] Vancomycin (10 mg/L), Trimethoprim (5 
m! 	, Pol 	 in 2,500 IU/L Slcirow, 1977 
Charcoal cefoperazone 
deoxycholate agar [CCDA] 
Cefoperazone (32 mg/L) 
' Bolton, Hutchinson and Coates, 1984 
Charcoal based selective agar 
[CSM1 
Vancomycin (20 mg/L), Cefoperazone (32 
mg/I), Cycloheximide (100 mg/L) 
Cefoperazone (32 mg/L) 
Trimethoprim lactate (50 mg/L) 
Vancomycin (10 mg/L), Trimethoprim (5 
mg/L), Polymyxin (2,500 IU/L), Cephalothin 
15 mg/L), Amphotericin B (2 mg,/L) 
Karmali et al, 1986 
Goosens et al, 1989 
. 
Blaser eta!, 1979 
Blood free, semi-solid 
motility medium [SSM] 
Campy BAP [BAP] 
Cefoperazone,amphotericin 
Teicoplanin [CAT] 
Cefoperazone (8 mg/L), Amphotericin B (10 
mg/L), Teicoplanin (4 mg/L) 
Engberg et al, 2000 
Table 1.2:  Growth of Campylobacter species and Arcobacter species 
ORGANISM SKM CCDA CSM SSM BAP FILTER 
C. jejuni subsp. jejuni G G G G G G 
C. jejuni subsp. doylei * X X X X G 
C. co/i G G G G G G 
C. fetus subsp. fetus * G G G X G 
C. fetus subsp. venerealis * * G 
Clan * G G G G G 
C. upsaliensis * X X X X G 
C. hyointestinalis subsp. 
hyointestinalis 
* X X X X G 
C. hyointestinalis subsp. 
lawsoni 
* * * * G 
C. concisus * X X X X G 
C. curvus * * * * * G 
C. rectus * X X X X G 
C. gracilis * X X X X G 
C. mucosalis * X X X X G 
C. sputorum by. sputorum * * * * X G 
C. sputorum by. bubulus * * * * X G 
C. sputorum by. fecalis * * * * X G 
C. showae * * * * * G 
C. helveticus * * * * * G 
C. hyoilei * * * * * G 
A. nitrofigilis * * * X G 
A. butzleri * G G G G G 
A. skirrowi * * * * G 
A. ayaerophilus * G G G G G 
X: NO GROWTH, G: GROWTH, *: UNKNOWN 
Adapted from (Endtz eta!, 1991a) (On, 1996a) 
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Sjogren, Lindblom and Kaijser (1987) evaluated SMTM against CEB as both an enrichment 
broth and transport medium. They found that SMTM improved isolation by 8% over the 
other media. Another advantage noted was the ability of campylobacters to survive for long 
periods in SMTM thus emphasising the usefulness of this medium as a transport medium. 
After initial inoculation and incubation at 42°C for 24 hours, viable organisms were still 
found after 1 month at room temperature. Also the enrichment culture yielded a more 
luxuriant growth as compared to isolation on primary plating (Chan and MacKenzie, 1982). 
1.5.3 Filtration 
Butzler eta! (1973) first used membrane filters to isolate campylobacters from faecal 
samples. They noted that due to the small .size of these bacteria, they could pass through 0.45 
gm and 0.65 gm cellulose filters while the larger enteric bacteria were trapped. The method 
involves placing a filter on the surface of a non-selective agarose plate such as horse blood 
agar, making a suspension in Bruce/la broth and placing 10 drops of the solution onto the 
filter surface. After the fluid has passed through the filter, it is then discarded and the agar 
plate incubated normally. A large study by Steele and McDermott (1984) of 1000 diarrhoea 
faecal samples, found that the filtration system isolated all 45 of the campylobacters grown 
on their selective agarose plates at 42 °C with five addition non-C. jejuni Campylobacter 
strains being isolated by the filter system alone. 
In another study, 0.65 gm cellulose acetate membrane filters were found to be superior to 
0.45 gm cellulose triacetate filters for the recovery of campylobacters (Wells et al, 1989). 
Early studies isolating C. upsaliensis from blood cultures of bacteremic paediatric patients 
with gastroenteritis, failed to isolate campylobacters using routine media directly from faecal 
samples as the strains were susceptible to the antibiotics employed in routine agarose plates 
at that time (Lastovica, Le Roux and Penner, 1989). Some investigators have used modified 
agarose formulae to grow C. upsaliensis (Walmsley and Karmali, 1989) but poor growth of 
C. upsaliens. is on the newer media is still being reported (Hald and Madsen, 1997). Current 
studies such as the incidence of campylobacters in AIDS patients with enteritis, still rely on 
the filtration technique for the isolation of C. upsaliensis, C. concisus and C. mucosalis 
(Snijders eta!, 1997). 
One of the major disadvantages of the filtration system is that a larger number of organisms 
are required for growth as compared to selective agars. It has been found that > 10 5 cfu/m1 of 
campylobacter bacteria are required for detection; much more than the required number for 
selective agars (Goossens et al, 1990). 
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1.5.4 Growth Conditions 
1.5.4 (a) Incubation temperature 
The family Campylobacteraceae possesses many members with varying optimal growth 
temperatures. The arcobacters tend to grow better at lower temperatures such as 25-30°C, 
thermophilic campylobacters proliferate at 42°C with the remainder of 12 or so other species 
and subspecies growing best at 37°C. 
As it has been believed for many years that only the thermophilic group of campylobacters 
(C. jejuni subsp. jejuni, C. coli, C. lari and C. upsaliensis) cause human disease, most 
laboratories only incubate selective media at 42°C. Species that have been associated with 
diarrhoea that would not grow at this temperature include C. jejuni subsp. doylei, C. fetus 
subsp. fetus, C. hyointestinalis subsp. hyointestinalis, C. concisus, C. sputorum biovar 
sputorum, A. butzleri and A. cryaerophilus. 
Table 1.3 summaries the incubation temperature range and atmospheric gas requirements for 
the growth of campylobacters and arcobacters from a number of different studies. 
1.5.4 (b) Incubation time 
While it is still common practice in many diagnostic laboratories to incubate selective media 
for only 48 hours, some studies have found that incubating for up to 72 hours increases 
yields. In one such study, the rate of isolation was increased by an average of 18% across all 
the selective media tested (Endtz eta!, 1991a). Growth of the slower growing 
campylobacters, such as C. mucosalis, requires incubation for up to 5 days. 
1.5.4 (c) Atmospheric gas conditions 
The majority of campylobacters will grow in a microaerophilic atmosphere containing — 5 % 
02 , 10 % CO2 and 85 % N2. Some Campylobacter species such as C. sputorum, C. concisus, 
C. mucosalis, C. curva, C. rectus and C. hyointestinalis may also require hydrogen in the gas 
mixture for isolation. As some studies have shown variable concentrations of hydrogen in gas 
mixtures when using commercial gas-packs, an evacuation and replacement method with a 
bottle gas of known concentration is recommended (Kiehlbauch eta!, 1995). 
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Table 1.3: Incubation temperature and atmospheric gas mixture for 
growth of Campylobacter and Arcobacter species 
ORGANISM m02 
15°C 
m02 
25°C 
02 
25°C 
m02 
30°C 
02 
37°C 
m02 
37°C 
ANO2 
37°C 
m02 
42°C 
C. jejuni subsp. jejuni - - 01 01 99 01 
C. jejuni subsp. doylei - - 01 * 01 99 01 - 
C. co/i - - 01 * 01 99 01 + 
C. fetus subsp. fetus - 01 * 01 99 25 - 
C. fetus subsp. venerealis - 01 * 01 99 73 - 
C. lari - - 01 * 01 99 01 
C. upsaliensis - - 01 * 01 99 01 + 
C. hyointestinalis subsp. hyointestinalis - 01 * 01 99 01 
C. hyointestinalis subsp. lawsonii - * * * * 
C. concisus - - 01 (+) 01 99 99 (-) 
C. curvus - - * * * * * * 
C. rectus - - 01 * 01 01 99 * 
C. gracilis 01 * 01 01 99 * 
C. mucosalis - - * + - + + (+) 
C. sputorum by. sputorum - - * + - + + + 
C. sputorum by. bubulus - - * + - + V + 
C. sputorum by. fecalis - - * V - + + 
C. showae - - * * * * * * 
C. helveticus - - * * * * * * 
C. hyoilei * * * * * * * * 
A. nitrofigdis + + * * * * * - 
A. butzleri + + 99 * 99 99 99 
A. ski rrowii + + * * * * * 
A. cryaerophilus + 99 * 50 58 16 - 
• 01-99 : percentage positive, +: positive result, -: negative result 
• (+) 70-90% positive, (-) 20-33% negative, V: 50-66% positive. 
• m02 : microaerophilic, 02 : aerobic, ANO2 : anaerobic 
• *: not known 
Adapted from (On eta!, 1992), (On, 1996a), (Nachamicin, 1995) 
1.5.5 Detection by Polymerase Chain Reaction (PCR) 
While the application of PCR to the detection of organisms in faeces is problematic due to 
the presence of PCR inhibitors, the advantages of decreased turn around time and the 
detection of bacteria in a metabolic state less amenable to culture on selective media (ie sub-
lethally damaged cells, viable but non-culturable cells or even dead cells) have encouraged 
researchers to apply PCR to the direct detection of Campylobacter species in faeces. In one 
such study, primers were designed to detect and differentiate C. jejuni and C. co/i. All 20 
culture positive isolates (18 C. jejuni and 2 C. co/i) were detected and correctly identified 
(Linton et al, 1997). 
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A large scale PCR-based study utilising a detection and identification algorithm consisting of 
a screening PCR and subsequent species identification by PCR-enzyme-linked 
immunosorbent assay was applied to 3,378 faecal samples (Lawson et al, 1999). Results from 
this study showed that the sensitivity of PCR based methods was comparable to current 
culture techniques with PCR yielding 492 positive samples compared with 464 positive 
cultures. In addition, mixed infections with C. jejuni and C. co/i were detected in 19 samples 
and 1 with C. jejuni and C. upsaliensis that was not apparent from culture. Detection rates of 
the infrequently isolated strains of Campylobacter species were also increased using PCR. Of 
the 11 samples PCR positive for C. upsaliensis , only 2 were detected by culture. Three 
samples were also PCR positive for C. hyointestinalis but only 1 culture positive. 
1.6 Epidemiological investigations 
1.6.1 Serotyping 
Two major serotyping schemes are used for the campylobacters. The first, described by Lior 
eta! (1982), detects heat-labile bacterial surface antigens such as flagella and can detect 
>100 serotypes of C. jejuni, C. colt and C. lari. The second is the 0 typing system of Penner 
et al, (1980) which is based upon the heat-stable lipopolysaccharide antigens. This system 
can detect 60 types of C. jejuni and C. co/i (Patton and Wachsmuth, 1992). 
Using these techniques it has been shown that C. jejuni strains associated with GBS are 
confined to a relatively small number of serotypes, namely 0:1, 0:2, 0:10,0:19, 0:41 and 
0:64. In one Japanese study by Kurolci et al (1993), it was found that 10 of the 12 strains 
tested belonged to serotype 0:19. In another study from USA, serotype 0:19 accounted for 
35% of strains tested from GBS patients, significantly higher than the 2% normally found in 
patients with uncomplicated gastroenteritis (Mishu, Patton and Blaser, 1993). 
Serotyping is performed in only a few reference laboratories because of the time and expense 
needed to maintain quality serotyping anti-sera. While commercially available heat-labile 
antigens are available, they have been shown to be of poor quality (Nicholson and Patton, 
1993). 
1.6.2 Ribotyping 
Polymorphism of DNA coding for 16S rRNA (ribotyping) has been used successfully to 
discriminate between stains of C. jejuni subsp. jejuni, C. jejuni subsp. doylei, C. colt, C. lari, 
C. fetus subsp. fetus and C. upsaliensis (Moureau et al, 1989) as well as separating 
arcobacters from campylobacters (Kiehlbauch et al, 1991b). Its discriminating power has 
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been shown to surpass serotyping, the "gold standard" of epidemiological typing schemes for 
the genus Campylobacter (Fitzgerald, Owen and Stanley, 1996) but not the newer DNA 
techniques of Pulsed Field Gel Electrophoresis (PFGE) and PCR. 
1.6.3 Pulsed Field Gel Electrophoresis (PFGE) 
Genomic DNA digested with infrequent cutting restriction endonucleases and resulting 
fragment separation by PFGE has proved to be a valuable epidemiological tool. The 
technique has been used for typing C. jejuni in outbreaks of gastroenteritis and to detect the 
source of infection (Hanninen eta!, 1998; Gibson, Lorenz and Owen, 1997; Olsen eta!, 
2001) and for typing C. fetus (Rennie eta!, 1994; Fujita eta!, 1995) and C. hyointestinalis 
(Salama et al, 1992). The technique has been shown to be more discriminative than the 
Preston Biotyping scheme utilised in many reference laboratory as an epidemiological tool 
when typing Campylobacter strains (Dawkins eta!, 1994; Jones et al, 1993) and when 
compared to serotyping (Gibson, Lorenz and Owen, 1997). A recent study in Denmark 
compared PFGE; Penner heat-stable serotyping; automated ribotyping (RiboPrinting); 
random amplified polymorphic DNA typing (RAPD); restriction fragment length 
polymorphisms of the flagellin gene,fla A (fla-RFLP) and denaturing gradient gel 
electrophoresis offla A (fla-DGGE). A collection of 90 isolates of C. jejuni from poultry, 
cattle, and sporadic human clinical cases as well as strains from a waterborne outbreak of 
gastroenteritis were tested. While all methods identified the outbreak strain, when comparing 
unrelated strains, RAPD and PFGE were found to be the most discriminatory methods 
followed byfla-RFLP, RiboPrintinglla-DGGE and serotyping (Nielsen et al, 2000). 
Genetic methods have begun to be employed to analyse non-related GBS strains of C. jejuni 
from around the world. While some studies have shown the clonal nature of some serotypes 
associated with GBS (Wassenaar et al, 2000), studies utilising various genetic methods to 
determine a possible serotype-independent epidemiological marker have been rare. A broad 
scale study involving 11 GBS strains from China, Denmark, Mexico, Thailand, United Arab 
Emirates and USA were compared to 47 control strains from cases of gastroenteritis. The 
molecular analysis was performed with Multilocus Enzyme Electrophoresis (MLEE), PFGE, 
RiboPrinting andfla typing (Endberg eta!, 2001). This study which contained GBS-
associated strains from serotype HS: 2, HS: 4, HS: 5, HS: 19, HS: 37, HS: 41 and HS: 53 
with controls from the same serotypes, showed that GBS-associated strains are a heterogenic 
population of strains and do not constitute a unique population across serotypes. For 
example, dendrograms of PFGE results clearly showed GBS-related strains being spread 
amongst control strains. 
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1.6.4 PCR based 
A number of different PCR based epidemiological typing schemes have been developed. 
Fujimoto et al (1997), used PCR to amplify the flagellin gene (flaA) with subsequent 
digestion with restriction endonucleases Ddel, Mbol, Msel and Alul to detect differences in 
C. jejuni strains isolated from patients with Guillain-Barre Syndrome and patients suffering 
from gastroenteritis. Genetic variability using the flagellin genes (flaA andflaB) was 
confirmed in an Egyptian study which found that serogroups could be further subdivided 
using this method (Mohran eta!, 1996). A report by Harrington, Thomson-Carter and Carter 
(1997) demonstrated recombination within and between flagellin loci of natural strains 
suggesting that a typing scheme based on restriction fragment length polymorphism analysis 
of PCR-amplified flagellin genes cannot be considered as a stable method for long-term 
monitoring of pathogenic Campylobacter strains. 
Differentiation of strains by random amplified polymorphic DNA (RAPD) analysis has 
proved to be a useful PCR technique in a number of Campylobacter studies (Madden, Moran 
and Scates, 1996; Hilton et al, 1997). 
Comparison of serotype 0:19 C. jejuni strains associated with GBS and from patients with 
gastroenteritis have been typed using RAPD PCR analysis and shown to be closely related to 
one another. In contrast, other serotypes show great variability with this technique (Fujimoto 
eta!, 1997). This study identified a 1.4 kb fragment which was specific for serotype 0:19. 
This was later developed into a PCR technique to specifically identify 0:19 strains from 
other serotypes allowing for rapid identification of a serostrain seen more regularly in GBS 
patients than other serotypes (Misawa, Allos and Blaser, 1998). 
1.6.5 Multi Locus Sequence Typing (MLST) 
With decreasing costs of DNA sequencing, epidemiological methods based upon sequence 
data would inevitably follow. One such method which compares genetic variation in 
sequence data from seven house-keeping genes, is Multi Locus Sequence Typing (MLST). 
Typically, nucleotide sequences of —450 bp internal fragments of these seven loci are 
determined and the sequence type (ST) defined by the alleles present at the seven loci (Day et 
al, 2001). Population lineages can then be determined by the extent of the variation within 
these alleles (Pitt and Saunders, 2000). This technique can be performed on live or killed 
bacteria and purified DNA extracts. Being an easily standardised technique, MLST 
information can be easy stored and compared between laboratories with dedicated web sites 
already storing MLST data and protocols (http://m1st.zoo.ox.ac.uk) (Dingle et al, 2001). 
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A recent study utilised MLST to characterise isolates of Staphylococcus aureus from 
asymptomatic nasal carriage and from episodes of severe disease (Day et al, 2001). Their 
results showed that isolates causing disease were not drawn randomly from the carriage 
population, but were usually confined to a number of distinct MLST groups. 
Another study evaluated the newer molecular subtyping approaches (Multilocus DNA 
Fragment Typing [MLDF], MLST, sequencing of 16S rRNA gene and PFGE) in a Neisseria 
meningitidis outbreak setting. With 16S rRNA gene sequencing and PFGE providing the 
highest sensitivity and specificity of the typing methods studied, both tests were adopted into 
their epidemiological protocol (Mayer et al, 2002). 
1.7 Guillain-Barre Syndrome 
1.7.1 Clinical Features 
Guillain-Barre Syndrome (GBS) covers a group of clinical syndromes in which idiopathic 
peripheral neuropathy causes acute or sub-acute weakness of at least two limbs. This 
progresses and plateaus within 4 weeks of presentation. Previous studies had found that > 
95% of cases present in this manner and patients with neuropathies progressing past 4 weeks 
are delineated chronic demyelinating polyradiculoneuropathies (Ashby et al, 1978). 
GBS normally affects the motor, sensory and autonomic nerves supplying the limbs and may 
include the respiratory muscles and facial, bulbar and ocular motor nerves. Symptoms 
typically begin with weakness, sensory disturbance or pain and most patients develop rapidly 
progressive symmetrical weakness, that is worse in lower limbs than the upper limbs. Most 
patients experience numbness, tingling and pain and many have bladder disturbances, facial 
weakness and difficulty swallowing. CSF protein levels are raised in 80% of patients. 
Autonomic disturbances are also common with fluctuations in heart rate, blood pressure and 
bowel function (Hadden and Gregson, 2001). 
While GBS is a self-limiting disease in the majority of patients, the condition does have a 
mortality rate of 10% and — 25% of patients require artificial ventilation. While plasma 
exchange and intravenous therapy have hastened early recovery, up to 10% of patients are 
still left with severe disabilities up to 48 weeks later (Hughes and Rees, 1997). 
Until recently, GBS was defined as a single homogenous clinical entity but researchers now 
believe that the syndrome can be separated into four distinct groups: 
•:• Acute inflammatory demyelinating polyneuropathy (ADP); the most frequently 
encountered pattern of GBS seen in Europe, North America and Australia (Asbury, 
2000), is characterised by an immune-mediated attack on myelin with varying degrees of 
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lymphocytic infiltration. With severe cases of AIDP, there is also axonal degeneration 
(Griffin et al, 1996). 
+ Acute motor-sensory axonal neuropathy (AMSAN); previously called axonal GBS in 
which the axon appears to be the target of the immune system, is found less frequently 
than ADP in Europe and North America but is common in China (Griffin et al, 1995) 
and Japan (Yuki et al, 1990). This form is usually severe involving both the motor and 
sensory fibres. 
Acute motor axonal neuropathy (AMAN); a more benign form of GBS which presents 
with mainly motor neuron involvement (Griffin et al, 1996). 
+ Miller-Fisher syndrome (MFS), is characterised by acute onset of unsteadiness of gait 
(ataxia), loss of reflexes (areflexia) and an inability to move the eyes, usually associated 
with non-reactive pupils (opthalmoplegia) (Fisher, 1956). 
1.7.2 Epidemiology of GBS 
A number of epidemiological studies from around the world have been published over the 
last 40 years. Annual prevalence rates range throughout these studies from 0.4 to 4 cases per 
100,000 population (median, 1.3) (Hughes and Rees, 1997). A study in Australia by Storey et 
al (1989), had an prevalence rate of 0.9/100,000. 
In the vast majority of these studies, males are more commonly affected than females 
(— 1.25:1) with a bimodal age distribution having a peak in young adults and also in the 
elderly. The incidence has been found to be lower in children than adults, with the highest in 
the elderly, possibly due to failure of suppression autoimmunity in this age group. 
Other studies have found that the AIDP form of GBS appears to affect an older population in 
Western countries, whereas the AMAN form tends to be found primarily in children and 
young adults (McKhann et al, 1993). 
While most studies have not been able to identify a seasonal relationship for GBS, studies in 
northern China have shown annual summertime peaks with the AMAN form of GBS (Ho et 
al, 1995). 
Up to two thirds of cases of GBS have an antecedent illness. Of these, respiratory infections 
are found to be the most commonly reported antecedent illness followed by gastrointestinal 
infections, of which C. jejuni is the most frequently identified cause (Hughes and Rees, 
1997). A documented outbreak of Campylobacterjejuni gastroenteritis in Jordan during 
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1978 affecting >5,000 people subsequently produced 16 cases of GBS, 8 to 24 days after the 
onset of diarrhoea (Khoury, 1978). In contrast to the age distribution of GBS, Campylobacter 
spp. infections in developed countries are found at slightly higher rates in males compared to 
females and a bimodal age distribution with peaks in the <1 year old and a second lower but 
broader peak in the 15 to 30 years of age (Blaser, 1997). 
Infections with Cytomegalovirus, Epstein-Barr virus, Varicella-zoster virus and Mycoplasma 
pneumoniae have also been implicated (Hadden and Gregson, 2001) . GBS following 
vaccination has also been reported with rabies and swine influenza vaccines (Hughes and 
Rees, 1997). 
1.7.3 Campylobacter jejuni and GBS 
The first reported case of GBS associated with Campylobacter infection was published by 
Rhodes and Tattersfield (1982). 
1.7.3 (a) Serological studies 
As reports suggest that the median duration of excretion of Campylobacter in stools of 
infected patients is only 16 days and GBS patients present 1 to 3 weeks post infection, the 
majority of studies have relied upon serological assays to determine an association between 
Campylobacter and the development of GBS. The most commonly used technique utilises 
enzyme-linked immunosorbent assays (ELISA) to measure antibody response to infection. 
The antigens used in these tests have been protein rich antigens that detect antibodies to 
common, cross-reactive epitopes and are not serotype specific (Nachamkin, Allos and Ho, 
1998). 
Serum IgG, IgM and IgA rise rapidly in response to Campylobacter infection with IgA 
beginning to decline during the first few weeks followed by a decline in IgM and IgG 3 to 4 
weeks post infection (Blaser and Duncan, 1984). IgA has also been detected in faeces and 
urine of some patients but only in the first few weeks after acute infection (Lane et al, 1987). 
While detection of a fourfold rise in titre is useful to confirm a recent infection with 
Campylobacter in GBS patients, acute sera are frequently unavailable. Serological studies 
have therefore relied upon comparing antibody levels in GBS patients with a general 
population control group. 
Table 1.4 summarises the previously published associations between C. jejuni enteritis and 
GBS. Serological evidence of past infection with Campylobacter in these studies range from 
13 - 66 % (median: 33%) of patients presenting with GBS. The youngest patient, who 
subsequently recovered completely, was a 2 year old girl with a severe case of GBS. The 
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Table 1.4: Documented associations between GBS and Campylobacter jejuni 
infections 
REFERENCE CASE (C) 
OR 
SERIES (S) 
AGE 
& 
SEX 
% POSITIVE 
FOR 
C. JEJUNI 
INFECTION 
INTERVAL B/W 
DIARRHEA & 
ONSET OF GBS 
(days) 
CULTURE (C), 
SEROLOGY 
(S), 
OR BOTH (B) 
Rhodes and Tattersfield, 1982 C 45/M 15 B 
Molnar, Mertgola and Erkko, 
1982 
C 421M 13 C 
Constant, Bentley and 
Denman, 1983 
C 34/F >10 C 
Speed, Kaldor and Cavanagh, 
1984 
C 161M 10 B 
Kaldor and Speed, 1984 S (n = 56)  
C 34/M 
22/F 
38 
21 
21 
S 
C 
C 
Pryor et al, 1984 
Wroe and Blumhardt, 1985 C 271M 7 C 
De Bont et al, 1986 C 2/F 9 S 
Speed eta!, 1987 S (n = 45) 49 C 
Kohler and Goldblatt, 1987 C 69/M 13 C 
Ropper, 1988 S (n = 106)  
S (n - 100)  
C 38/M 
81/M 
60/M 
4 
14 
6 
8 
12 
C 
. S 
C 
C 
S 
Winer eta!, 1988 
Sovilla, Regli and Francioli, 
1988 
Clavelou eta!, 1989 C 307M 
62/M 
74/M 
12 
10 
15 
S 
S 
B 
Yuki et al, 1990 C 25/M 
83/F 
7 
7 
S 
S 
Gruenewald eta!, 1991 S (n = 17) 18 S 
Kuroki et al, 1991 C 7/M 
9/M 
10/F 
11/M 
13/M 
14/M 
14/M 
C.)  U
  
C
O
 U
  
CQ  C
.)  U
  
Boucquey et al, 1991 S (n = 45) 13 S 
van der Meche eta!, 1992 S (n = 129) 36 S 
Gregson, Koblar and Hughes, 
1993 
S (n = 42) 36 S 
Kuroki eta!, 1993 S (n = 46) 41 B 
Mishu eta!, 1993 S (n = 116) 36 S 
Enders et al, 1993 S (n = 38) 39 S 
Vriesendrop eta!, 1993 S (n = 58) 17 S 
Rees eta!, 1995 S (n = 103) 26 B 
Ho eta!, 1995 S (n = 38) 66 S 
Koga eta!, 2001 S (n=220) 17 S 
M = Male, F = Female, n = number of patients. Adapted from Hughes and Rees, 1997. 
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oldest patient, was an 83 year old with severe axonal degeneration who remained bedridden 3 
years after her illness. 
With the recent attempt to separate GBS into clinical subgroups, Ho et at (1995) found that 
raised antibody levels were detected in both the AIDP and AMAN types of GBS in patients 
from China. 
1.7.3 (b) Cultural studies of GBS 
As many patients have ceased excreting Campylobacter in their faeces by the time symptoms 
of GBS develop, culture studies are not widely utilised. However, a number of well 
documented cases summarised in Table 1.4 clearly supports the association of a recent 
enteritis with C. jejuni and development of GBS. There was an average of 10.3 days (range 
5-21) duration between the onset of gastroenteritis and the onset of neuropathic symptoms in 
these studies compared with the 9.5 days (range 9-12) seen in serological studies. 
Many studies have been performed to determine the convalescent excretion of 
campylobacters following acute diarrhoeal illness. In one study of children in Thailand, the 
duration of excretion was found to be 14 +/- 2 days for children < 1 year old and 8 +/- 2 days 
for children 1-5 years old (Taylor et al, 1988). Similarly, in children less than 5 years of age 
in a Mexican study excretion was found to continue for 7 days (range 7-26)(Calva et al, 
1988). In other studies longer excretion times have been found. In one Norwegian study, the 
average excretion time was 37.6 days (range 15-69)(Kapperud et al, 1992). Differing culture 
techniques, incubation temperatures, atmospheric gases and frequency of sampling all play a 
part in the variations found between studies therefore highlighting the need for optimum 
conditions when culturing for low numbers of Campylobacter in GBS patients. 
The optimum number of samples required from patients with GBS has also been studied. It 
was found by Kuroki et al (1993) while studying 14 GBS patients, that 57% of patients grew 
Campylobacter in only the first sample tested. This increased to 93% after 2 samples were 
tested and all 14 patients grew Campylobacter after 3 samples had been tested, thus 
emphasising the need for multiple sampling. 
1.7.3 (c) Molecular mimicry theory of GBS pathogenesis 
The cell wall of C. jejuni has been found to contain high molecular weight smooth-form 
lipopolysaccharides (LPS) in one third of serotype reference strains (as is also found in the 
members of Enterobacteriaceae)(Preston and Penner, 1987). This consists of an 0-specific 
polysaccharide chain, which is a polymer of repeating oligosaccharide units, a core 
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oligosaccharide (OS) and lipid A (Figure 1.2). The remaining two thirds of serotype reference 
strains have a low molecular weight LPS. Once thought to be similar to the rough form of 
LPS found in members of the family Enterbacteriaceae, the structure has been found to 
closely resemble lipo-oligosaccharides (LOS) found in Neisseria spp. and Haemophilus spp. 
(Aspinall et al, 1993). 
Comparison of lipid A in different Gram negative genera reveal a similar architecture. While 
there are variations at the genus level in the type of hexosamine present, degree of 
phosphorylation, presence of phosphate substituents and most notably the nature, chain 
length, number and location of fatty acyl chains present, each Gram negative species has a 
unique type of lipid A (Moran, 1995). 
The core region of LPS can be separated into two distinct regions, the inner core and the 
outer core. Within a bacterial species, chemical variation in this core region is greater than 
that of lipid A but more limited than the 0-specific chain. For example, E. coli can be divided 
into five types of core regions (R1-R4 and K12) but over 100 serotypes based on the 0- 
specific chain have been identified (Moran, 1997). 
Within the core region there is greater variation, with the outer core varying more than the 
inner core region (as seen in Figure 1.3 which shows the variation within the core regions of 
GBS associated Campylobacter serostrains 0:1, 0:4, 0:2, 0:10). The core structure of a 
serostrain 0:3, which has never reported to be associated with GBS is included for 
comparison (Moran, 1997). 
Gangliosides are sialic acid containing glycosphingolipids present in the plasma membrane of 
vertebrate tissues which are particularly abundant in the nervous system (representing 10% of 
the total lipid content). 
Serum antibodies against gangliosides have been reported in 30% of GBS patients (Mishu 
and Blaser, 1993). Autoantibodies are frequently detected in sera of GBS patients in the acute 
phase of illness, especially Gml but other antibody specificities detected are, GD lb, GT1a, 
GQ lb and LM1, as well as but with.lower frequency asialoGM1, GM2, GM3, GDla and 
GT lb (Schwerer et al, 1995). 
It was first demonstrated by Yulci et al (1993), that the antibodies produced against a 
commonly encountered GBS associated serotype of C. jejuni (0:19), cross reacted with Gml 
gangliosides. Further investigations have found similarities in core structure of this serotype 
to gangliosides Gml, GD la, GT la and GD3 (Aspinall eta!, 1994a). 
Mimicry of gangliosides by core OS of C. jejuni LPS, as well as the relationship between 
C. jejuni infection and induction of ganglioside-antibodies in GBS, suggest that LPS from 
certain strains could act as cross-reactive antigens for anti-ganglioside B cells. Furthermore, 
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Figure 1.2: Schematic representation of the architecture of C. jejuni cel wal : A) 
high molecular weight LPS and B) low molecular weight LOS 
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Figure 1.3: Core structure of C. jejuni serostrains. 
OUTER CORE 	 INNER CORE 
PEA LGalliAc— Gal— Gal —I— LINiep— Ill p— Kdo 
I 	 I 	 I 	 I lieu Ac Gal 	 Gle 	 Qc 
0:1 
OUTER CORE 	 INNER CORE 
PEA 
Ilieu Ac— Gal— Gal —I—  LDHep— LD ep—Kdo 
I 	 I 	 I Gal I 	 Glc 	 Glc 
0:2 
lieu Ac 	 I 	 PEA 	 Neu Ac 
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(P)GaINAc —GaINAc —G& 	 LD ep—Kdo 
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0:3 
Glc: D-glucose, Gal: D-galactose, P: 0-phosphoryl group, PEA: 0-phosphoethanolamine, 
Kdo: 3-deoxy-D-manno-2-octulosonic acid, LDHep: L-glycero-D-manno-heptose, 
QuiNAc: N-acetyl-D-quinovosamine, GaINAc: N-acetyl-D-galactoseamine, GluNAc: N-acetyl-D-
glucosamine, NeuAc: N-acetyLneuroaminic acid 
Adapted from Moran, 1997. 
A 
laboratory animals injected with C. jejuni LPS have been found to produce auto-antibodies 
against gangliosides (Ritter et al, 1996). 
Other serotypes associated with GBS have also been found to contain an outer core region 
with similarities to gangliosides. For example, the terminal pentasaccharide of serostrain 0:4 
mimics GD la and the termini of core OS in 0:23 and 0:36 mimic the same tetrasaccahride 
present in GM2 (Aspinall eta!, 1993). The same similarities have been noted in strains from 
MFS, ie. a C. jejuni 0:10 strain associated with MFS possessed core OS structure that 
mimics ganglioside GD3 (Salloway eta!, 1996). Figure 1.4 demonstrates the similarities 
found between human ganglioside Gml and the two types of core structures found in 
serostrain 0:19, one of Campylobacter serostrains frequently associated with GBS. 
1.8 Summary 
Numerous culture and serological studies have suggested that C. jejuni is the infectious agent 
most commonly associated with the development of GBS. With Campylobacter infection 
being the most common cause of bacterial food poisoning in the Western world, it is 
somewhat surprising that such a small number of patients progress to develop this 
neurological condition. Two possibilities exist; the first being that susceptibility is 
determined by host specific factors; the second is that strain-specific factors determine 
whether patients develop GBS. 
Evidence has emerged recently that suggests certain C. jejuni strains possess structures in 
their cell wall lipopolysaccharides that mimic gangliosides, particularly Gml, as found in 
vertebrate nervous tissue. Infections with these strains elicit an autoimmune response in GBS 
patients with serum antibodies to these gangliosides being reported in many cases. While 
many serotypes possess these structures, certain serotypes, in particular Penner serotype 
0:19, appear to be over represented in most studies of GBS. It should be noted that not all 
serotype 0:19 C. jejuni infections progress to GBS, not all GBS patients with a prior 
Campylobacter infection have detectable levels of anti-ganglioside antibodies in their serum 
and up to one third of all strains isolated from cases of gastroenteritis possess Gml like 
epitopes in their bacterial cell walls but do not progress onto GBS. Further subtyping of these 
strains is therefore needed to identify other bacterial factors that may contribute to their 
neuropathogenic nature. 
The aim of this investigation was to obtain an overall view of Campylobacter infection in 
Tasmania comparing prevalence rates of GBS with cases of Campylobacter gastroenteritis. 
Full speciation of isolates was performed and characterisation of the known GBS associated 
markers, Gml and serotype 0:19, was determined to allow potential neuropathogenic strains 
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Figure 1.4: The structure of human ganglioside Gm! and Campylobacter jejuni 
serostrain 0:19 cel wal core region. 
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Neu Ac I I	 1 
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0:19 
Glc: D-glucose, Gal: D-galactose, PEA: 0-phosphoethanolamine, Kdo: 3-deoxy-D-manno-2- 
octulosonic acid, LDHep: L-glycero-D-manno-heptose, GalNAc: N-acetyl-D-galactoseamine, NeuAc: 
N-acetylneuroaminic acid 
Adapted from Moran, Appelmelk and Aspinal, 1996. 
to be identified. Furthermore, specific bacterial markers were sought by using Pulsed-Field 
Gel Electrophoresis (PFGE) and Subtractive Hybridisation to highlight regions of the 
Campylobacter genome of interest. Finally, production of a more accurate and rapid 
Polymerase Chain Reaction (PCR) assay has been developed for the detection of those 
strains which trigger the autoimmune response seen in GBS. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials and Equipment 
Al materials and equipment used in this study along with the suppliers from which they 
were obtained are listed in Tables 2.1 and 2.2 respectively. Al chemicals used were analytical 
reagent grade. Al solutions were stored and used at room temperature unless otherwise stated. 
Table 2.1: Reagents and suppliers 
MATERIALS SUPPLIERS 
Acetic acid BDH Laboratory Supplies, England 
Cat. No.: 100015N 
Acrylamide Promega 
Cat. No.: 32179 
AdvanTageTm cDNA PCR Kit Clontech, CA., USA. 
Cat. No.: K1905-Y 
AdvanTageTm PCR Cloning Kit Clontech, CA., USA. 
Cat. No.: K1901-1 
Agarose NA Pharmacia Biotech, Sweden 	 - 
Cat. No.: 17055402 
Agarose Prep. (LMP) Pharmacia Biotech, Sweden 
Cat. No.: 80113007 
Ammonium acetate ICN Biomedicals, Sydney, Aust. 
Cat. No.: 100651-17 
Ammonium persulphate Biorad 
Cat. No.: 161-0700 
Amplitaq Gold® DNA Polymerase 
with GeneAmp 
Roche Molecular Systems Inc., USA 
Part No. N808-0243 
Anti-Cholera Toxin (Rabbit) Sigma Chemical Co., USA 
Cat. No.: C3062 
Anti-Digoxigenin-alkaline phosphatase 
conjugate 
Boehringer Mannheim, Germany 
Cat. No.: 1093274 
Antimicrobial susceptibility disc 
Cephalothin 30 ug 
Oxoid, UK. 	 . 
Cat.No.: A KF30 
Antimicrobial susceptibility disc 
Nalidixic acid 30 ug 
Oxoid, UK. 
Cat. No.: A NA30 
Anti-Rabbit IgG (Whole Molecule) 
Peroxidase Conjugate 
Sigma Chemical Co., USA 
Cat. No.: A9169 
API Campy bioMerieux, France. 
Cat. No.: 20800 
Bacto-tryptone Difco Laboratories, USA 
Cat. No.: 211705 
BigDyeTM Terminator v3.0 Cycle Sequencing 
Read Reaction Kit 
ABI Prism, Applied Biosystems 
Cat. No.: 4390242 
Bisacrylamide Promega 
Cat. No.: V3143 
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MATERIALS SUPPLIERS 
Biotinylated probe synthesis Biosearch Technologies, Inc., Australia 
Blocking Reagent Boehringer Mannheim, Germany 
Cat. No.: 1096176 
Blue-White SelectTM Screening Reagent 
(X-gal/IPTG) 
Sigma Chemical Co., USA 
Cat. No.: B3928 
Boric Acid Merck, Germany 
Cat. No.: 1.12015.1000 
Bromophenol Blue International Biotechnologies Inc, USA 
Cat. No.: 74040 
Campylobacter Agar Oxoid, UK. 
Cat. No.: CM 739 
Campylobacter Antibiotic Supplement Oxoid, UK. 
Cat. No.: SR 174 
Cholera Toxin B Subunit (Choleragenoid) Sigma Chemical Co., USA 
Cat. No.: C9903 
Chloroform ICN Biomedicals, Sydney, Aust. 
Cat. No.: 510710 
Columbia Blood Agar supplemented with 
Horse Blood, NAD and Haematin 
Oxoid, UK. Cat. 
No.: CM331 
Coomassie brilliant Blue — R250 ICN Biomedicals, Sydney, Aust. 
Cat. No.: 190682 
CSPD Boehringer Mannheim, Germany 
Cat. No.: 1755633 
dATP, dCTP, dGTP, d'TTP (100 nM) Promega Corporation, USA 
Cat. No.: U1240 
DIG DNA labelling kit Roche Molecular Systems Inc., USA 
Cat No. 1175037 
DyeExTM Spin Kit QIAGEN 
Cat. No.: 63206 
EDTA, di-Sodium Salt International Biotechnologies Inc, USA 
Cat. No.: 70182 
Ethanol (ethyl alcohol) BDH Laboratory Supplies, England 
Cat. No.: 10107.7Y 
Ethidium Bromide Sigma Chemical Co., USA 
Cat. No.: 8751 
Ficoll ICN Biomedicals, Sydney, Aust. 
Cat. 194824 
Gas Generating Kit Oxoid, UK. 
Cat. No.: BRO56A 
Glycine ICN Biomedicals, Sydney, Aust. 
Cat. 808822 
Gml monosialoganglioside lmg Sigma Chemical Co., USA 
Cat. No.: G7641 
HybondTM -N+ nylon nucleic acid transfer 
membrane 
Amersham Pharmacia Biotech, Sweden 
Cat No.: 203B 
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MATERIALS SUPPLIERS 
Hippuric acid (Sodium salt) Sigma Chemical Co., USA 
Cat. No.: H9380 
iso-Amyl alcohol BDH Laboratory Supplies, England. 
Cat. No.: 100383L 
Kanamycin monosulfate Sigma Chemical Co., USA 
Cat. No.: K4000 
Lambda DNA-PFGE markers Boehringer Mannheim, Germany 
Cat. No.: 1378961 
Laemmli Sample Bufer Biorad 
Cat. No.: 161-0737 
Lysed blood sensitivity agar Oxoid, UK. 
Cat. No.: CM409B 
Maleic Acid ICN Biomedicals, Sydney, Aust. 
Cat. No.: 102233 
2-Mercaptoethanol ICN Biomedicals, Sydney, Aust. 
Cat. No.: 190242 
Methanol BDH Laboratory Supplies, England. 
Cat. No.: 10158.4W 
Microcentrifuge Polypropylene Tubes 
(Eppendorf) 1.5 mL 
Robbins Scientific Corp., USA 
Part No.: 1012-00-0 
Microcentrifuge Polypropylene Tubes 
(Eppendorf) 0.6 mL 
Quality Scientific Plastics, USA 
Cat. No.: 502-PLN 
Microtubes & Caps with 0 Ring 
1.5 mL Screw Cap 
Quality Scientific Plastics, USA 
Cat. No.: 515 
Microtitre trays: NUNC-Immuno Plate Nalge Nunc International 
Cat. No.: 442404 
Mineral Oil ICN Biomedicals, Sydney, Aust. 
Cat. No.: 151694 
Nichrome wire (Nikrothal 80) Kanthal Pty. Ltd., Aus 
Ninhydrin Sigma Chemical Co., USA. 
Cat.No.: N4876 
N-laurylsarcosine, Sodium salt ICN Biomedicals Inc, USA 
Cat. No.: 190289.17 
Oligonucleotide synthesis GeneWorIcs Pty. Ltd, Australia 
OPD Peroxidase Substrate Tablet Set 
SIGMA FASTTm 
Sigma Chemical Co., USA. 
Cat. No.: P-9187 
Parafilm American National Can. 
PCR-Select Bacterial Genome Subtraction 
Kit 
Clontech, CA, USA. 	 . 
Cat. No.: K1809-1 
Phenol:chloroform:isoamyl alcohol (25:24:1) Life Technologies, GIBCOBRL, USA. 
Cat. No.: 15593-031 
Phosphate Bufered Saline Oxoid, UK. Cat. No.: BR14a 
Polaroid Black and White Film (665) Polaroid, USA 
Polyamp DuofitTM  Water for Injections BP ASTRA Pharmaceuticals Pty. Ltd., NSW, 
Australia 
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MATERIALS SUPPLIERS 
Proteinase K AMRESCO. 
Cat. No.: E634 
pUC-19 DNA/HpaII Molecular weight 
marker (100 ug/200 uL) 
Bresatec Ltd., Adelaide, Australia 
Cat. No.: DMW-P1 
QIAamp Tissue Kit QIAGEN 
Cat. No.: 29306 	 . 
QIAexpress UA Cloning Kit QIAGEN 
Cat. No.: 32179 
QIAquick PCR Purification Kit QIAGEN 
Cat. No.: 28106 
Restriction Endonuclease Alul Boehringer Mannheim, Germany 
Cat. No.: 10239275 
Restriction Endonuclease Sal Boehringer Mannheim, Germany 
Cat. No.: 348783 
Restriction Endonuclease Smal Boehringer Mannheim, Germany 
Cat. No.: 220566 
Saline, Sterile 2.5 mls Oxoid, UK. 
Cat.No.: OXTM931 
Skim Milk Powder Diploma, Australia 
Silver Stain Plus Biorad 
Cat. No.: 161-0449 
Sodium Chloride Sigma Chemical Co., USA 
Cat. No.: S9888 
Sodium Citrate BDH Laboratory Supplies, England. 
Cat. No.: 10242 
Sodium Dodecyl Sulfate (SDS) Sigma Chemical Co., USA 
Cat. No.: L4390 
Strepavidin-alkaline phosphatase Conjugate 
150U 
Boehringer Mannheim, Germany 
Cat. No.: 1093266 
Storage vials for bacteria (Microbank) Pro-Lab Diagnostics, Canada 
Cat. No.: PL160 
Sulfuric Acid BDH Laboratory Supplies, England. 
Cat. No.: 7034825 
SuRE/Cut Bufer A Boehringer Mannheim, Germany 
Cat. No.: 1417959 
SuRE/Cut Bufer H Boehringer Mannheim, Germany 
Cat. No.: 1417991 
TEMED — tetramethylenediamine Biorad 
Cat. No. 1610801 
Tris-base ICN Biomedicals Inc, USA 
Cat. No.: 103132 
Tris-Cl International Biotechnologies Inc, USA 
Cat. No.: 70162 
Xylene cyanol ICN Biomedicals Inc, USA 
Cat. No.: 806801 
Yeast extract Oxoid, UK. 
Cat No.: L21 
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Table 2.2:  Equipment and suppliers 
EQUIPMENT SUPPLIERS 
Anaerobic jar, 3.4 litre Oxoid, UK. 
Cat. No.: HP11 
Anaerobic jar catalyst Oxoid, UK. 
Cat. No.: BR42 
Bench waterbath Mgw Lauda 
Model No.: C36D 
Biological Safety Cabinet Class II CLYDE-APAC 
Model No: BH 2000 Series 
Centrifuge (Microfuge) Eppendorf 
Cat. No.: 5415C 
Colorimeter (Vitek) HACH Company, USA. 
Prod. No.: 52-1210 
Dynatech MR5000 Spectrophotometer Dynatech, Guernsey, Channel Islands 
Cat. No.: DL 1000 
Dualwave Microwave Oven NEC 
Model No.: N513M 
Finnpipete® Pipetes Labsystems 
Freezer — Ultra Low ( - 80°C) SANYO 
Model. No.: MDF-U4086S 
Gene Navigator Control Unit Amersham Pharmacia Biotech, Sweden 
Part No.: 18-1026-17 
Gene Navigator Electrophoresis Unit Amersham Pharmacia Biotech, Sweden 
Part No.: 18-1019-20 
Gene Power Supply Amersham Pharmacia Biotech, Sweden 
Model No.: GPS 200/400 
Hybridisation Incubator Robbins Scientific 
Model No.: 2000 
HypercasseteTM Amersham Pharmacia Biotech, UK 
Cat. No.: 11643 
HyperfilmTM -MP Autoradiography film Amersham Pharmacia Biotech, UK 
Cat. No.: 3103K 
MINIPROTEANO3 Cel Electrophoresis 
Equipment 
Biorad 
Cat. No.: 525BR 
Photoautomat 
Wild MPS 46/52 
Wild Leitz, Ltd., Switzerland 
Polaroid MP-4 Land Camera Polaroid, USA 
Perkin Elmer DNA Thermal Cycler Perkin Elmer 
Model No.: 9600 
Perkin Elmer DNA Thermal Cycler Perkin Elmer 	 . 
Model No.: 480 
RFLP Main & Advanced Computer Program American Applied Biotechnology, USA 
Spectophotometer : Ultraspec I Amersham Pharmacia Biotech, Sweden 
Prod. No.: 80-2097-62 
UV Transiluminator 
i 
UVP Inc., USA 
Model No.: TM36 
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2.2 Sample Collection and Storage 
Campylobacter isolates were collected from the Microbiology departments of the five 
major pathology providers in Tasmania which are; 
i) Royal Hobart Hospital 
ii) Launceston General Hospital 
iii) Hobart Pathology 
iv) Launceston Pathology 
v) North West Pathology 
In total, 249 isolates were obtained from faecal samples from patients presenting with 
gastroenteritis and one isolate was from blood cultures. 
All faecal strains were originally isolated on Oxoid Campylobacter media, with antibiotic 
supplement CAT SR174 added, after being incubated at 42°C in an Oxoid 3.4 litre anaerobic jar 
with catalyst. Campylobacter gas generating kits were used to generate a microaerophilic 
atmosphere. 
All isolates were subcultured onto horse blood agar (HBA) on arrival at the testing laboratory and 
incubated for 48 hours at 42°C in a microaerophilic atmosphere. The total growth on the agar 
plate was then removed with a sterile swab and inoculated into a Pro-Lab Diagnostics Microbank 
storage tube. These were then stored - 80°C. 
2.3 Bacterial Culture 
2.3.1 Campylobacter species 
All Campylobacter species were subcultured onto horse blood agar from the Microbank storage 
tubes held at - 80°C and grown at 42°C for 48 hours in an Oxoid 3.4 litre anaerobic jar with an 
atmosphere generated by the Oxoid Campylobacter gas generating kit. Poor growing strains were 
subcultured and regrown at 37°C under the same atmospheric conditions. Repeated subculturing 
was kept to a minimum and experiments were always performed on fresh subcultures from the 
original - 80°C stock culture. 
2.3.2 Escherichia coli 
Escherichia coli used in cloning experiments were grown on LB/X-gal/IPTG agarose plates 
containing 50 pg/mL of kanamycin (as prepared in Appendix B). Transformed Escherichia coli 
were grown overnight at 37°C in aerobic atmospheric conditions. 
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2.4 Campylobacter Biochemical Identification 
2.4.1 Hippurate Hydrolysis 
All isolates were tested for hippurate hydrolysis as described by Hwang and Ederer, (1975). This 
was performed by adding a loopful of organism to 0.4 mL of sodium hippurate in phosphate 
buffer (pH 7.0). This suspension was incubated at 37°C for 2 hours and 0.2 mL of 3.5% ninhydrin 
added. The colour change was then read following a 10 minute incubation at 37°C. Positive 
reactions were indicated by a strong violet colour, with clear or pale violet recorded as a negative 
reaction. A control strain of C. jejuni and C. co/i was included during testing as positive and 
negative controls respectively. 
2.4.2 Sensitivity Testing 
Sensitivity testing of isolates was performed against nalidixic acid (30 pg) and cephalothin 
(30 lig) antibiotic disks using the CDS method (Bell, 1975). A 0.56 mm diameter nichrome wire 
was stabbed into a single colony of the organism to be tested and the wire then used to inoculate a 
2.5 mL sterile saline solution. The saline solution was then poured onto a lysed sensitest agar and 
poured off. The agar plate was allowed to dry at RT and the two antimicrobial discs placed onto 
the agar surface. Following incubation overnight at 42°C in a microaerophilic atmosphere 
produced by Oxoid Campylobacter gas generating kits, the radius of growth inhibition was 
recorded. Organisms were reported sensitive if the radius of growth inhibition was > 6 mm and 
resistant if < 6 mm. 
All isolates with a positive hippurate test and which were sensitive to nalidixic acid and resistant 
to cephalothin were designated C. jejuni subsp. jejuni (Cowan and Steel, 1993). 
2.4.3 Extended Biochemical Testing 
All isolates not identified as C. jejuni subsp. jejuni were further identified by the commercially 
available identification kit, API Campy (bioMerieux). Fresh overnight cultures of bacteria were 
used to inoculate prepackaged biochemical strips followed by appropriate incubation as per kit 
instructions. Following reading of test results at 48 hours, an octal code number generated by the 
test results was compared to the API database program and a percentage probability of 
identification produced. 
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2.5 Nucleic Acid Extractions 
The Qiagen Q1Aampe Tissue DNA extraction kit was used to purify bacterial DNA. The 
"Bacterial Protocol" as outlined in the QIAampe Blood and Tissue Kit Handbook was performed 
without modification. 
2.6 Polymerase Chain Reaction 
2.6.1 Laboratory Practices 
Appropriate laboratory practices were employed at all times during testing as outlined by 
standard molecular biology procedures to reduce the risk of carryover contamination. Laboratory 
coats were worn at all times in designated laboratory areas and disposable gloves used when 
handling all reagents and apparatus. Materials used, such as pipette tips and microfuge tubes were 
sterilised in sealed autoclave bags prior to use by standard autoclave procedures for 15 minutes at 
121°C. Prevention of contamination was achieved by using plugged pipette tips at all times and 
changing pipette tip between the addition of each reagent to prevent cross-contamination of 
reagents. Reagents were stored in aliquots of working volume concentrations at —20 °C and 
thawed just prior to use at room temperature. 
Polymerase Chain Reaction assays were performed in a physical containment class 2 (PC2) 
• laboratory located within the Pathology Department of the Royal Hobart Hospital. The laboratory 
is divided into three separate rooms with interconnecting portals for one way transference of 
prepared reagents for contamination minimisation. Room one was designed for preparation of 
reagents used in PCR which are free of nucleic acid. Prepared reagents were passed through the 
portal into the second room. DNA extraction and inoculation into prepared PCR reagents 
occurred in Class II biological safety cabinets in room two and was amplicon free. PCR 
amplification was performed on Perkin Elmer DNA Thermal Cyclers followed by product 
detection by gel electrophoresis in room three. 
2.6.2 Primer Selection 
Primer selection for the serotype 0:19 specific PCR (DNA gyrase subunit B gene) was chosen 
from the literature as outlined in Table 2.3. All other primers were designed in this study using 
gene sequences obtained from Genbank using the nucleotide search engine at the National Centre 
for Biotechnology Information (NCBI) web page. (http://www.ncbi.nlm.nih.gov) 
Designed primers were compared for specificity against the Genbank database using the 
computer program Basic BLAST also accessed at the NCBI site. 
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Table 2.3: Details of primers chosen and designed 
Primer 
Name 
Length Amplified 
Region 
Sequence (5' to 3') Product 
Size 
Reference 
Hippurate 
Sense 
Hippurate 
Antisense 
23 n.t. 
23 n.t. 
Hippurate gene 
GenBank: cjhippurc 
(1554— 1931 b.p.) 
GGACTTCGTGCAG 
ATATGGATGC 
GCACTTCCATGAC 
CACCTCTTCC 
377 b.p. This 
study 
16S rRNA 
Sense 
16S rRNA 
Antisense 
23 n.t. 
28 n.t. 
16S rRNA gene 
GenBank: 
Campylobacter & 
Arcobacter species 
GGAGGATGACAC 
T/ATTTCGGT/AGC 
G 
TCA/GCC/GGTATT 
GCT/GT/GCTCT/AT 
TGTATAC/TC/GC 
842 b.p. This 
Study 
GyrB 
Sense 
GyrB 
Antisense 
(0:19) 
GyrB 
Antisense 
(Non 0:19) 
18 n. t. 
18 n.t. 
18 n.t. 
DNA gyrase subunit 
B 
(1222— 1673 b.p.) 
CAAGCTATACTGC 
CTTTG 
TCAAGATCTTTTA 
AAATT 
TCAAGATCTTTTA 
AAATC 
451 b.p. 
Misawa, 
Allos and 
Blaser, 
1998 
3.21 
Sense 
3.21 
Antisense 
17 n.t. 
18 n.t. 
GAT CGC TAC GCA 
GGT TC 
GGT GCC TTG TTC 
GTC TTG 
162 b.p. This 
study 
Primer 1 
Nested 
Primer 1 
Nested 
Primer 2R 
22 n.t. 
22 n.t. 
20 n.t. 
Adaptor 1 and 2R 
Subtractive 
Hybridisation Kit 
CTAATACGACTCA 
CTATAGGGC 
TCGAGCGGCCGCC 
CGGGCAGGT 
AGCGTGGTCGCGG 
CCGAGGT 
Variable CLONTECH 
Laboratories 
Inc. 
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Primer 
Name 
Length Amplified 
Region 
Sequence (5' to 3') Product 
Size 
Reference 
Veh18 AATNCTATCATCA 
Sense 18 n.t. AAATG 569 b.p 
Vehl9 CAATNCTATCATC 
Sense 19 n.t. AAAATG 570 b.p This 
Veh gene Study 
Veh20 GCAATNCTATCAT 
Sense 20 n.t. CAAAATG 571 b.p 
VehRev GAGGTCTTTAAGG 
Antisense 20 n.t. TGTTTTC 
n.t. = nucleotides, b.p. = base pairs 
2.6.3 Product Controls 
All PCR tests were performed with DNA extracted from appropriate standard strains of 
C. jejuni for a positive control and water as a negative control. 
2.6.4 Product Detection 
Amplified DNA was detected using agarose gel electrophoresis. PCR amplified nucleic acid 
samples were mixed with 1/10 volume of loading buffer (final concentrations: 10mM Tris-HC1, 
pH 8.0; 1 mM EDTA; 3% (w/v) ficoll; 0.05% bromophenol blue; 0.05% xylene cyanol). 20.0 !IL 
samples were then loaded into lOmm wells of a 3% molecular biology grade agarose gel in 1 X 
TAE buffer (0.04 M Tris-acetate; 0.001 M EDTA). The staining agent, ethidium bromide, was 
incorporated into the gel at a concentration of 1.0 Rg/mL. Each electrophoresis run included the 
molecular weight marker (pUC-19 restricted with Hpall). 
The products were separated by horizontal electrophoresis in 1 X TAE buffer at 100 V for 60 
minutes. Visualisation of the separated products was achieved using a UV transilluminator and 
the results photographed using a Polaroid MP-4 land camera with Polaroid type 665 film. A 
positive result was defined as the presence of a band of the appropriate molecular weight. 
2.7 Cholera Binding Inhibition EIA For The Detection Of Gm! Epitopes On 
Bacterial Cell Walls 
This method was a modification of that of Sack et al, 1998. 
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2.7.1 Preparation of test Campylobacter 
Bacteria were grown on Horse Blood Agar (HBA) for 24 hours in a gas pack jar (Oxoid) with 
Campy gas packs (Oxoid) at 42°C. The bacteria were harvested into 2 ml of Phosphate Buffered 
Saline (PBS) (pH 7.2, 0.01M) and transferred to a test tube. The concentration of the bacteria 
was then adjusted with PBS until a transmission equaling 10% on a Vitek colorimeter was 
obtained. This solution was then transferred into a sterile 1.5 ml Eppendorf tube and placed into a 
boiling water bath for 15 minutes. 
The suspension was then held at 4 °C until testing was performed. Bacterial lipopolysaccharides 
(LPS) are extremely stable under these conditions and can be stored there for extended periods of 
time. 
2.7.2 Preabsorption of Cholera B subunit to Bacterial LPS 
Plates were prepared for testing by placing 100 gL of the boiled bacterial suspensions (2.7.1) 
into wells of a microtitre plate followed by 100 tL of Cholera B subunit (0.2 gg/ml, diluted with 
PBS). The tray was covered with parafilm and incubated at 37 °C for 1 hour. Following 
incubation, the OD at 490 nm of the suspension was determined on a Dyntech MR5000 
spectrophotometer and the test carried out only if sufficient bacteria were present, as indicated by 
an OD of greater than 0.1. 
2.7.3 Testing mictotitre tray 
A microtitre tray was coated with Gm! ganglioside (Sigma) (1gg/mL in PBS) at 4 °C for 24 hours 
and then washed with 3 changes of PBS for 30 seconds each. The trays were blocked with 200 pit 
of 5% skim milk in PBS at RT for 1 hour. Following 3 washes with PBS for 30 seconds, 100 gL 
of suspension from the preparation tray was transferred to the corresponding testing tray well, 
covered with parafilm and incubated at 37 °C for 2 hours. The tray was washed as described above 
and rabbit anti-Cholera toxin (Sigma) (diluted 1/1250 in PBS) was added to each well, covered in 
parafilm and incubated at 37°C for 1 hour. The tray was washed as described above and anti-
rabbit peroxidase conjugate (Sigma) (diluted 1/1250 in PBS) was added to each well, covered 
with parafilm and incubated at 37°C for 1 hour. The tray was then washed as described previously 
and 100 gL of substrate added to each well (Sigma Fast — OPD) prior to incubation at RT for 10 
minutes in the dark. The colour development was stopped by the addition of 100 gL 3M H2SO4 
and the OD read at 490 nm. 
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A C. jejuni Gml positive strain (ATCC 700297) and C. jejuni Gml negative strain (ATCC 
43431) were included in each assay batch. Positive strains inhibit the development of colour and 
are defined as strains which inhibit the OD by >50% relative to the negative controi. 
2.8 Dot Blot Hybridisation 
Dot blot hybridisation was performed in two separate experiments. Firstly, biotinylated 16S 
rRNA probes were used to identify Campylobacter species with strepavidin-alkaline phosphatase 
as the conjugate. Secondly, digoxigenin labeled probes were used in cloning experiments using 
anti-digoxigenin-alkaline phosphatase as the conjugate. 
2.8.1 DNA Preparation 
Details of the reagents used in the dot blot hybridisation assay are supplied in appendix C. 
DNA samples were first denatured by heating at 95 °C for 10 minutes. A 4 [IL sample was 
spotted onto a labeled segment of HybondTM -N+ nylon nucleic acid transfer membrane along 
with positive and negative control strains and bound by exposing to UV on a UV transilluminator 
for one minute on both sides of the membrane. 
2.8.2 Probe preparation 
In-house digoxigenin labeling of DNA was performed using the DIG DNA Labeling Kit - 
Boehringer Mannheim according to manufacturers instructions. Biotinylated probes were 
synthesized by Biosearch Technologies, Inc., Australia. 
2.8.3 Hybridisation 
The membrane was placed into prehybridisation buffer and incubated in a hybridisation oven at a 
temperature appropriate for the probe being tested. This was then incubated for 1 hour, followed 
by overnight incubation in prehybridisation buffer containing the appropriate probe. 
The membrane was washed twice in wash solution 1 for 5 minutes at room temperature, 
followed by two 15 minute washes in wash solution 2 at the same temperature used for the 
probe incubation. Two final washes were given in solution 3 for 5 minutes at room temperature. 
The membrane was then blocked in blocking solution for 30 minutes at room temperature 
followed by incubation with the conjugate in blocking solution for 15 minutes at room 
temperature. Two 15 minute washes in wash solution 3 were performed at room temperature 
before a final wash in detection buffer for 5 minutes at room temperature. 
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2.8.4 Detection 
Membranes were then incubated in 2 mLs of detection buffer containing the substrate CSPD 
(1:100 dilution of stock) for 5 minutes at room temperature and blotted briefly on blotting paper 
before being sealed in a plastic bag and incubated at 37°C for 15 minutes. The membrane was 
next placed in a HypercassetteTM and exposed to HyperfilmTM -MP autoradiography film for 1 
hour and processed by a Wild Leitz, Photoautomat Wild MPS 46/52 developer in the Medical 
Imaging department of the RHH. A positive reaction was defined as the presence of a black spot 
present on the x-ray film similar in intensity to the positive control strain. 
2.9 Pulsed-Field Gel Electrophoresis 
2.9.1 Preparation and standardisation of DNA 
Details of the reagents used for pulsed-field gel electrophoresis are supplied in Appendix D. 
Preparation of Campylobacter DNA and subsequent restriction endonuclease digests were 
adapted from the original method by Smith and Cantor, 1987. 
Campylobacters were grown overnight on a HBA plate and the active growth was removed using 
a sterile swab and placed into 10 mLs of PIV solution until a transmission of 70% (equivalent to 
a MacFarland 1.0 standard) was achieved, as determined by a Vitek colorimeter. This suspension 
was then transferred to a centrifuge tube and spun at 540 g for 10 minutes. The supernatant was 
discarded and the deposit resuspended in 300111, of PIV solution. An equal volume of molten 2.4 
% LMP agarose was then added and the subsequent mixture dispensed into block moulds and 
allowed to set for 15 minutes. 
2.9.2 Bacterial cell disruption and protein degradation 
Bacterial agar plugs were pushed out of the block moulds into 300 !IL of ESP solution in a 
sterile Eppendorf tube and incubated in a 56°C waterbath overnight. The agarose block was then 
removed from the tube, washed 6 times at room temperature in 10 mls volume of TEl solution 
over a 6 hour period. 
2.9.3 Endonuclease digestion 
Agarose blocks were cut in half and were are equilibrated in 2, 30 minute washes in 400 !IL of 
the appropriate restriction buffer. (SuRe/Cut Buffer A for Smal and SuRE/Cut Buffer H for 
Sall). This solution was replaced with 25 pl of restriction buffer containing 30 to 40 units of 
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restriction endonuclease and incubated at the appropriate temperature overnight (Smal incubated 
at 26°C and Sall incubated at 37°C). 
2.9.4 Electrophoresis 
Quarter blocks containing 90 tig of intact genomic DNA were loaded into 5mm x lmm wells of a 
1.2% agarose gel.(Agarose NA, Pharmacia Biotech). Each electrophoresis run included a 
molecular weight marker (Lambda DNA: PFGE Marker 1: Boehringer Mannheim). 
Electrophoresis was performed at 170 V on a Gene Navigator system (Amersham Pharmacia 
Biotech) in three phases; 5 second pulse times for 10 hours, 20 second pulse times for 10 hours 
and 80 second pulse times for 4 hours. 
All electrophoresis was carried out in half strength TBE at 8.0 °C. Gels were then stained in 
ethidium bromide (0.5 pg/mL in lx TBE) for 30 minutes and RFLP patterns visualised on a UV 
transilluminator and the results photographed. DNA fragments ranging in size from 50 kb to 500 
kb were typically seen and easily separated using this procedure. 
2.9.5 Analysis 
RFLP software package from AAB (Advanced American Biotechnology) was used to detect and 
calculate molecular weights of individual bands seen on electrophoresis gels. Patterns of type 
strains were also stored in its database for comparison of new strains and dendrograms produced 
to show relative similarities between strains. 
By using the unweighted-pair group method with arithmetic averages (UPGMA) using simple 
band match and a tolerance of 3.2%, dendrograms were produced to demonstrate the relationship 
between Tasmanian strains and to compare with PFGE profiles of GBS related strains from 
around the world. 
2.10 Subtractive Hybridisation 
2.10.1 DNA subtraction 
The CLONTECH PCRSelectTM  Bacterial Genome Subtraction Kit was used according to the kit 
instructions with the following modifications. The tester DNA used was extracted from a 
GBS associated Campylobacter jejuni (ATCC 700297: Serotype 0:19) and the reference driver 
DNA from a Campylobacter jejuni serotype not associated with GBS (ATCC 43431: Serotype 
0:3). Also the restriction endonuclease supplied with the kit was replaced with Alul. 
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2.10.2 Cloning 
Cloning of the subtractive library produced from the subtractive hybridisation experiment was 
performed with the pT-Adv 3.9 kb cloning vector using the AdvanTAgeTm PCR Cloning Kit from 
CLONTECH Laboratories, Inc. according to the kit instructions. 
The expression vector pQE 30 UA was used on clone 3.21 according to QIAGEN QIAexpress 
UA Cloning Kit instructions. 
2.11 SDS-Polyacrylamide Gel Electrophoresis 
Bacterial whole cell protein profiles were produced by SDS-PAGE according to the method of 
Hames (1990). 
2.11.1 Gel Preparation • 
Polyacrylamide gels containing a 5% stacking gel and a 15% resolving gel were prepared from a 
stock solution of 30% acrylamide and 0.8% bisacrylamide. The stacking gel was prepared in 
0.125M Tris-HC1, pH 6.8, 0.1% SDS, 0.1% tetramethylenediamine (TEMED) and 0.0525M 
ammonium persulphate (APS). The resolving gel was prepared in 0.375M Tris-HC1, pH 8.8, 
0.1% SDS, 0.0625% TEMED and 0.034% APS. 
MINIPROTEAN® 3 Cell Electrophoresis Equipment (Biorad) was used with the gel forming 
apparatus supplied with the kit assembled according to the manufacturers instructions. Resolving 
and stacking gels of 10 cm and 1.5 cm respectively were poured and allowed to polymerize over 
an hour. 
2.11.2 Sample preparation 
Biorad's Laemmli sample buffer was used. This was prepared by adding 50 pL 2- 
mercaptoethanol to 950 1.iL of sample buffer. This in turn was used to dilute bacterial samples 1:2 
and the sample was then heated in a boiling water bath for 3 minutes. Once cooled, 10 ill, of 
samples were then loaded per electrophoresis track. 
2.11.3 Electrophoresis 
Electrophoresis was performed with a reservoir buffer containing 0.025M Tris, 0.192M glycine 
and 0.1% SDS (pH 8.3) at 150 volts until the dye linked proteins had migrated within 2 mm of 
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the bottom of the gel. Dye linked protein standards were used to monitor running conditions and 
to calculate approximate molecular weights of resolved sample proteins. 
2.11.4 Staining 
Proteins were visualised by staining with Coomassie Brilliant Blue (0.1%) which was dissolved 
in water:methanol:glacial acetic acid (5:5:2 by volume) for 2 hours. Excess stain was then 
removed and destaining performed with a one hour wash with 30% methanol, 10% acetic acid 
followed by multiple washes with 7 % acetic acid alone until background stain was completely 
removed. 
For the detection of proteins in low concentrations within complex protein samples, Biorad's 
Silver Stain Plus was used according to manufacturers instructions. 
2.12 DNA sequencing 
2.12.1 Purification of PCR products 
Purified PCR product for sequencing was prepared using the QIAquickTM PCR purification 
(Qiagen) as described in the kit instructions without modification. 
2.12.2 DNA Sequencing Reactions 
All sequencing primers are listed in Table 2.3: Details of primers chosen and designed, and 
throughout the text. Purified PCR templates were sequenced using the BigDyeTM Terminator v3.0 
cycle sequencing reaction as described in the kit manual without changes to the protocol. The 
linear amplification of DNA for sequencing was performed in a Perkin Elmer 9600 DNA 
Thermal Cycler. Excess dye-terminator was removed with the DyeExTM 2.0 Spin Kit according to 
kit instructions. Samples were dried and sent to Griffith University DNA Sequencing Facility, 
Griffith University, Queensland for analysis on a ABI 3700 DNA sequencer. 
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CHAPTER 3 
EPIDEMIOLOGY 
3.1 Background 
Examination of demographic data may provide important information into the spread of 
infection and those susceptible. As such, for all cases of culture proven campylobacteriosis, 
information such as the age and sex of the patient, area of residence and time of year of the 
infection are sent by Tasmanian pathology departments to the Tasmanian Public Health 
Morbidity Database (TPHMD) maintained by the Department of Public Health. Australia 
wide information is stored at the Communicable Diseases Network Australia — National 
Notifiable Disease Surveillance Database System (NNDSS) in Canberra, ACT. 
Campylobacter isolates were collected from the Microbiology departments of the five major 
pathology providers around Tasmania; Royal Hobart Hospital, Launceston General Hospital, 
Hobart Pathology, Launceston Pathology and North West Pathology from January 1998 to 
March 1999. All strains of Campylobacter were originally isolated on Oxoid Campylobacter 
media with antibiotic supplement CAT SR174 added, and incubated at 42 °C in an Oxoid 3.4 
litre anaerobic jar with Campylobacter gas generating kits to generate a microaerophilic 
atmosphere. During this time period, 249 isolates were obtained from faecal samples of 
patients presenting with gastroenteritis and one isolate from blood cultures. 
3.2 Campylobacter Notifications 
3.2.1 Campylobacter notifications in Australia 
Data on Campylobacter infections in all states and territories of Australia (except NSW as 
campylobacteriosis was reported as 'foodborne disease' or 'gastroenteritis in an institution' and 
exact numbers a therefore not known) are held in the NNDSS and have shown a steady 
increase in numbers over the period 1991 —2000 (Figure 3.1). 
This increase may represent improvements in isolation techniques or increased reporting of 
isolations over the last 10 years. In comparison, notifications of Salmonella and Shigella 
combined do not exceed total Campylobacter isolations over the corresponding time period 
and have remained relatively stable. 
3.2.2 Campylobacter notifications in Tasmania 
Numbers given to the database over the period of 1990 — 2000 show are relatively stable 
isolation rate in Tasmania except for a sharp peak in 1991 (Figure 3.2). 
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Figure 3.2:  Tasmania Campylobacter notifications 1991-2000 
Source: Year 1990:Tasmanian Public Hospital Morbidity Database 
Years 1991-2000: Communicable Diseases — Australia (NNDSS notification table) 
http://www. health .gov .au/pubh lth/cdi/nndss/year005 .htm 
3.2.3 Rates of Campylobacter infection 
The rate of Campylobacter infection per 100,000 population in Tasmania was less than the 
Australia-wide average (99.2 and 112.6 respectively), mainly due to the higher rates of 
infection experienced in the Northern Territory and South Australia (Table 3.1). While 
equivalent case numbers were seen in both the sauth and north of Tasmania over the time 
period studied (January 1998 — March 1999), figures obtained from the TPHIVID show that 
over the longer period 1990-97, the rate of infection per 100,000 population was higher in the 
north of the state compared to the south (118 and 94.7 respectively) (Figure 3.3). Reports to 
the Centers for Disease Control and Prevention in the USA have shown the annual infection 
rate seen in that country to be 5-6 per 100,000 population. However more intensive reporting 
from population based studies estimate the true rate to be closer to 1000 per 100,000 
population with under-reporting and testing by general practitioners the likely cause of the 
discrepancy (Blaser, 1997). 
Table 3.1: Total number of Campylobacter cases and rates per 100,000 
population for Australian states, 1996 
ACT NT QLD SA TAS VIC WA Total 
No. of 
cases 
256 262 3030 2638 456 3555 1961 12158 
Rate/ 
100,000 
85.5 134.3 89.9 184.7 99.2 81.3 113.6 
AVG 
112.6 
Compiled from:1.Communicable Diseases — Australia (NNDSS notification table) — 
Information does not include NSW. 
http://www.health.gov.au/pubhlth/cdi/nndss/year005.htm  
2. Australian Bureau of Statistics: 1996 Census of Population and Housing 
http://www.abs.gov.au/websitedbs  
3.3 Guillain Barre syndrome notification rates in Tasmania 
Up to two thirds of cases of GBS have a proven antecedent illness. Respiratory infections are 
the most commonly reported antecedent illness followed by gastrointestinal infections, of 
which C. jejuni is the most frequently identified cause. A documented outbreak of 
Campylobacter jejuni gastroenteritis in Jordan during 1978 and affecting >5,000 people, 
subsequently produced 16 cases of GBS, 8 to 24 days after the onset of diarrhoea (Khoury, 
1978). 
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Figure 3.3: Age standardised notification rate for campylobacteriosis by region, 
Tasmania, 1990-97. 
Source:Tasmanian Public Hospital Morbidity Database 
The GBS rate for Tasmania over the period 1990-97 was only 2.3 per 100,000 population 
(TPHMD, Figure 3.4) compared with 106.4 per 100,000 population for Campylobacter 
infection rates over the same time period. Quite clearly Campylobacter infection does not 
always result in progression to GBS. Two possible explanations for this occurrence are that 
only some patients have a predisposition to developing this neurological disorder following 
campylobacterial infection or else an infrequently encountered strain of Campylobacter, 
possessing an unknown neurological pathogenic mechanism, leads to GBS. 
3.4 Collection of Tasmanian Campylobacter isolates for this study 
3.4.1 Annual Distribution 
The isolation of Campylobacter species in Tasmania throughout the year as determined from 
isolates sent to the Royal Hobart Hospital, for this study is shown in Figure 3.5. 
The peak of isolation rates occurred in August to October 1998 followed by a second peak in 
January 1999. This pattern of Campylobacter notifications was not seen throughout the rest of 
Australia, where one major peak occurred between October 1998 and January 1999 (Figure 
3.6). Monthly data supplied to the Tasmanian Public Health Morbidity Database (TPHIVID) 
maintained by the Department of Public Health for the period 1997-1999 also showed clearly 
the two major peaks occurring on a yearly basis (Figure 3.7). 
3.4.2 Age Distribution 
Age distribution analysis of Campylobacter notifications shows a bimodal population (Figure 
3.8) with major prevalence occurring in the less than 5 years of age and the 21 —30 year age 
groups. This is in agreement with other studies of developed countries in which the highest 
age-specific attack rates occur in children < 1 year old with a second lower but broader peak 
in incidence occurring between 15 and 30 years of age (Blaser, 1997). In contrast, developing 
countries have only one major peak, occurring in children less than 2 years of age (Calva et 
al, 1988). 
3.4.3 Sex Distribution 
A slightly higher isolation rate of Campylobacter species was seen in male patients presenting 
with gastroenteritis, making up 55.8% of the patient's studied. Other epidemiological studies 
have also found slightly higher rates of Campylobacter infection in males (Blaser, 1997) and 
also higher rates of GBS with a male to female ratio of 1.25:1 (Hughes and Rees, 1997). 
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Figure 3.5: Number of isolates of Campylobacter species in Tasmania by month 
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Figure 3.7:  Number of isolates of Campylobacter species in Tasmania by month 
(1997-1999) 
Source: Tasmanian Public Hospital Morbidity Database 
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Figure 3.8: Age distribution of patients presenting with gastroenteritis caused by 
Campylobacter species in Tasmania. 
3.4.4 Intra-state laboratory compliance rates 
All laboratories in the state were contacted prior to commencing this study and all agreed to 
pass on Campylobacter isolates for this study. Compliance rates of the laboratories to pass on 
their isolates to the study laboratory can be seen in Figure 3.9. Isolates from the south of the 
state were more frequently sent to the testing laboratory which is also located in the southern 
half of the state. This is in spite of the fact that an excellent daily transport system around the 
state between pathology providers was in place at the time of the study. Isolates from the two 
pathology providers in the south (Hobart Pathology and Royal Hobart Hospital) contributed 
67% of their isolates (as determined by the notification rates from these laboratories) to the 
study compared with 35% for northern Tasmania laboratories (Launceston Pathology and 
Launceston General Hospital) and 25% from the north-west regional pathology laboratories 
(North-West Pathology). 
3.5 Epidemiological typing of Campylobacter isolates using Pulsed Field Gel 
Electrophoresis (PFGE) 
The ability of PFGE as an epidemiological typing tool has been well documented for a range 
of bacteria and in particular for suspected outbreaks of gastoenteritis caused by C. jejuni 
(Jackson et al, 1996) and C. hyointestinalis (Salama et al, 1992). 
3.5.1 Method 
PFGE was performed on all isolates as given in Section 2.9 Pulsed Field Gel Electrophoresis. 
As the aim of PFGE is to produce an electrophoresis gel pattern consisting of a few, high 
molecular weight DNA fragments, the choice of restriction endonuclease used depends upon 
the G+C ratio of the genomic DNA being cleaved. As Campylobacter species genomic DNA 
has a G+C ratio of 35% (i.e. relatively low content), a restriction enzyme with a 6 base pair 
recognition sequence such as SmaI which recognises the DNA sequence "CCCGGG", was 
chosen. A RFLP software package from AAB (Advanced American Biotechnology) was 
chosen to detect and calculate molecular weights of the individual bands seen on 
electrophoresis gels. Patterns of isolates were also stored in the AAB software database for 
comparison of new isolates and dendrograms produced to show relative similarities between 
isolates. 
3.5.2 Results 
PFGE patterns obtained after SmaI digestion of genomic DNA contained between 4 to 11 
bands varying in size from — 50 kbp to 600 kbp in size. Figure 3.10 demonstrates a 
representative PFGE gel of Tasmanian strains. 
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Figure 3.10:  Pulsed Field Gel Electrophoresis of Campylobacter jejuni strains 
restricted with Smal 
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Lane 1: Molecular Weight Marker, Lane 2-12 Tasmanian enteritis isolates of C. jejuni 
Using a percentage similarity cutoff of 95%, computer analysis discriminated 77 different 
Smal patterns (Table 3.2), with C. jejuni producing 68 different profiles, 7 C. co/i profiles and 
2 C. lari profiles. Of 250 isolates, 8 Campylobacter isolates did not produce a RFLP when 
Sinai was used as the cutting agent. These 8 isolates (7 C. jejuni and 1 C. upsaliensis) were 
therefore digested with Sall, which recognises the genomic DNA sequence "GTCGAC" 
which resulted in 6 different RFLP profiles (Figure 3.11). 
Table 3.2: Number of PFGE profiles following digestion with Smal and Sall 
Number 
of 
Isolates 
Identification Different profiles: 
digested with Smal 
Different profiles: 
digested with Sall 
242 
230 C. jejuni 68 NT 
10 C. coll 7 NT 
2 C. lari 2 NT 
8  
7 C. jejuni No profile 5 
1 C. upsaliensis No profile 1 
(NT: not tested) 
By using the unweighted-pair group method with arithmetic averages (UPGMA) using simple 
band match, with a tolerance of 3.2%, dendrograms were produced to demonstrate the 
relationship between strains. Clustering can be seen within species and between C. jejuni and 
C. co/i using Smal (Figure 3.12). This affect can also be seen when Sall was used differentiate 
C. jejuni from C. upsaliensis for the untypable isolates (Figure 3.13). 
The ability of PFGE to differentiate between C. jejuni and C. co/i strains has been previously 
reported (de Boer et al, 2000), as has its use to subspeciate both C. fetus and C. hyointestinalis 
(On, 2001). Large scale studies as to the usefulness of PFGE to distinguish the other 
Campylobacter species have not yet been investigated. A PFGE study of 21 strains of C. fetus 
clearly shows a homology between strains and a uniqueness that would separate them also 
from other Campylobacter species (Fujita et al, 1995). 
While the 250 Campylobacter strains studied could be separated into 83 different PFGE 
profiles, 28 % of strains were made up of only three patterns (Types 2, 11 & 28). A further 
33% of strains belonged to seven more patterns (Types 1, 6, 10, 12, 15, 17 & 21) with the 
remaining 98 strains able to be separated into 73 types (Figure 3.14). This distribution of 
strains is typically found in other studies, with the majority of isolates belonging to a few 
genotypes only (Hanninen et al, 2000). 
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Fi2ure 3.11: Pulsed Field Gel Electrophoresis of Campylobacter species strains 
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Figure 3.12: PFGE dendrogram analysis of C. jejuni and C. coil isolates folowing 
restriction with Smal 
Strains prefexed CJ and CC = Tasmanian C. jejuni and C. co/i strains respectively 
Dendograms produced by the unweighted-pair group method with arithmetic averages 
(UPGMA) using simple band match, with a tolerance of 3.2%. (RFLP software: AAB) 
Figure 3.13: PFGE dendrogram analysis of Campylobacter isolates untypable 
with Smal and restricted with Sal 
Strains prefexed CJ and CU = Tasmanian C. jejuni and C. upsaliensis strains respectively 
Dendograms produced by the unweighted-pair group method with arithmetic averages 
(UPGMA) using simple band match, with a tolerance of 3.2%. (RFLP software: AAB) 
Figure 3.14: Distribution of Tasmanian Campylobacter PFGE types 
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3.5.3 Discussion 
The usefulness of PFGE as an epidemiological tool can be demonstrated by plotting the 
isolation rates of particular genotypes over time. For example, one of the common 
genotypes, type 11, was seen throughout the entire time period studied in small numbers only. 
In the last month of the study, a marked increase in the isolation of type 11 was noted, 
comprising of 53% of all isolates typed for that month (Figure 3.15). 
With this information, public health authorities can be notified about a possible outbreak of 
Campylobacter. Questioning those patients with this strain could elucidate the common 
source of infection. 
In addition, those patients with PFGE profiles seen infrequently but isolated within a 
short period of time would probably have the same source. During September of 1998, a 
seven year old male presented to the casualty department of Launceston General Hospital in 
the north of the state, complaining of diarrhoea. The Campylobacter strain isolated from this 
patient had not been encountered in the study to date but one week later, a strain with the 
same PFGE profile was isolated from a 20 year old male by Hobart Pathology in the south. 
The evidence suggests that these two cases are linked even though they were isolated more 
than 200 km apart. The same strain has not been isolated since. 
3.6 Summary 
Epidemiological information gained from examination of demographic data has provided 
useful information in the spread of Campylobacter within Tasmania. Whilst rates of infection 
per 100,000 population in Tasmania are less than the national average, the north of the state 
has a higher infection rate than the population in the south. Furthermore, increased isolation 
rates are seen in both early spring and summer in Tasmania in contrast to the national trend of 
only one peak in summer. Further investigation is therefore needed to determine the unusual 
distribution of Campylobacter infection within Tasmania and the seasonal irregularities that 
are seen. Increased knowledge of the causes will then allow intervention with a subsequent 
improvement in public health of the state. 
Many new molecular based epidemiological.methods are now available for the tracking of 
bacterial infections. One such method, PFGE, was used in this study to characterise the 
genotypes of Campylobacter present in the community between January 1998 and March 
1999. Information gained from this study allows public health authorities to improve tracking 
of potential outbreaks of gastroenteritis caused by this bacterium by determining increased 
prevalence rates of particular strains in the community. Furthermore, subtyping of 
Campylobacter isolates by PFGE, may elucidate which particular genotypes are associated 
with diseases such as GBS and allow a more reliable prediction of outcome for those infected 
with these strains. 
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FiEure 3.15: Number of PFGE type 11C jejuni isolated in Tasmania by month 
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CHAPTER 4 
DEVELOPMENT OF A CAMPYLOBACTER SPECIES IDENTIFICATION 
SCHEME  
4.1 Aim 
Over recent years, the genus Campylobacter has grown and now includes a number of non-C. 
jejuni species that are occasionally isolated from the faecal samples of patients presenting with 
gastroenteritis. A large scale PCR-based study by Lawson et al (1999), determined that C. 
jejuni/C. coli represented 97% of all enteropathogenic campylobacters causing diarrhea with C. 
upsaliensis 2.2%, C. hyointestinalis 0.6% and C. lari 0.2% making up the balance of the isolates. 
Most laboratories however only identify isolates to the genus level due to the difficulties involved 
in identifying this group of organisms. In the present study isolates were collected from around 
Tasmania in order to determine the prevalence of various species causing diarrhea within the 
Tasmanian community. Furthermore, while the majority of strains isolated from GBS patients 
have been C. jejuni, other species such C. upsaliensis have also been implicated (Ho eta!, 1997). 
Accurate speciation of isolates may therefore provide further information about those strains that 
are neuropathogenic. The aim was to therefore determine a robust and rapid identification system 
based upon a multiplex PCR (16S rRNA/Hippurate gene)/Dot Blot Hybridisation test and to 
compare the accuracy of this test for the spec iation of Campylobacter isolates to standard 
biochemical tests. 
4.2 Background 
4.2.1 Biochemical identification 
Most Australian medical laboratories only identify Campylobacter isolates to the genus level as 
they lack the expertise and range of tests needed for speciation (RCPA: QAP results, 2002). 
When relying upon a limited number of tests, even the commonly isolated C. jejuni can be 
misidentified, particularly when hippurate negative strains are encountered (Morris et al, 1985). 
To overcome this problem, several researchers have produced identification schemes based upon 
a wide range of biochemical reactions. One of the earlier attempts was a dual-purpose 
identification and biotyping scheme developed by Bolton, Holt and Hutchinson (1984). Twelve 
biochemical tests were used to produce_ a numerical code which was then compared to a database 
of reference strain codes. The original scheme differentiated the six species known at that time 
therefore, application of this system today, following the discovery of a number of new species in 
subsequent years, renders this scheme obsolete. However, a number of reference laboratories 
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continue to use the Bolton scheme for the valuable information it provides as a biotyping and 
epidemiological tool. 
More recently, computerised schemes based upon probability matrices have been used with more 
success. A commercial identification kit for campylobacters produced by Biomerieux Ltd. (API 
Campy) utilising this system can differentiate 18 species and subspecies with 21 tests. While this 
system provides an easy to use, standardised method that is available to all laboratories, no large-
scale studies have been performed to evaluate accuracy of identification to the species level. 
Several reports have highlighted discrepancies while utilising this kit such as the misidentification 
of C. concisus as C. mucosalis (On, 1994) and Arcobacter butzleri as either C. cinaedi or A. 
clyaerophilus (Jacob, Lior and Feuerpfeil, 1993). While smaller studies have evaluated this kit, 
they have only assessed its ability to identify the more commonly isolated C. jejuni, C. coli and 
C. lari (Huysmans, Turnidge and Williams, 1995). Another identification matrix with 18 
biochemical tests was recently evaluated and could differentiate between 37 species and 
subspecies of Campylobacter, Arcobacter, Helicobacter and related organisms (On, 1996b). 
While the study confirmed that this matrix was useful for identifying typical strains, difficulties 
were encountered when trying to differentiate between certain species. 
4.2.2 Molecular identification 
In recent years, the introduction of DNA-DNA hybridisation studies has been a major 
advancement in the identification of bacteria. Although providing definitive species 
identification, the method was time consuming requiring special facilities for the handling of 
radioactivity and was also not optimised for rapid identification of large numbers of isolates. A 
number of other molecular techniques have been developed over subsequent years to differentiate 
this group of bacteria. Firstly, nucleic acid probes that are genus or species specific have been 
described. These include genus specific probes designed from 16S rRNA gene sequence data for 
Arcobacter spp. (Wesley eta!, 1995) and species specific probes for C. jejuni subsp. jejuni, C. 
coli, C. Ian, C. fetus subsp. fetus, C. hyointestinalis, C. sputorum and C. upsaliensis (Chevrier et 
al, 1989). A number of commercial kits are also available based on 16S rRNA gene sequences 
and detect the more common thermophilic campylobacters, C. jejuni subsp. jejuni, C. coli and C. 
lari. These include the SNAP system (Syngene, San Diego, Calif.) and AccuProbe (Gen-Probe 
Inc., San Diego, Calif.) The first system requires immobilization of target DNA on a suitable 
membrane before hybridisation to alkaline-phosphatase labeled probes, while the AccuProbe is a 
chemiluminescence assay performed in solution and requiring a luminometer for reading of 
results. 
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The polymerase chain reaction (PCR) has revolutionised studies of bacterial identification. Many 
•of these assays are designed using conserved and variable regions of the 16S rRNA gene 
sequence to differentiate bacteria to the genus and species level. PCR amplification of the 16S 
rRNA gene of Campylobacter, Arcobacter and Helicobacter species and subsequent restriction 
enzyme digestion has been used to identify to the genus (Marshall et al, 1999) and species levels 
(Harrington et al, 1999). 
Multiplex PCR using both 16S rRNA and other Campylobacter genes has also been used to 
differentiate the two most commonly isolated human pathogens C. jeuni and C. co/i. Isolates 
containing the 857 bp 16S rRNA Campylobacter specific amplicon as well as the 589 bp map A 
amplicon would be identified as C. jejuni. Similarly, if the isolate possessed the 857 tip genus 
specific fragment and the smaller 462 bp. ceuE amplicOn, it would be designated C. co/i (Denis et 
al, 1999). Other non-16S rRNA PCR tests include detection of the hippurate gene, hipo, directly 
from faecal samples. This assay correctly identified both hippurate positive and hippurate 
negative isolates of C. jejuni from other Campylobacter species (Linton et al, 1997). 
A PCR-enzyme linked immunosorbent assay (ELISA) was developed to identify C. jejuni, 
C. coli, C. lari, C. upsaliensis, C. hyointestinalis, C. helveticus and C. fetus directly from faecal 
samples (Metherell, Logan and Stanley, 1999). Initially, a PCR was performed from stool-
extracted DNA or purified DNA from isolates to amplify a large 16S rRNA fragment and the 
product added to a microtitre tray bound with various internal 16S rRNA specific probes for each 
of these species. These results correlated with culture positive stools for C. jejuni and C. co/i. In 
addition, 2 faecal samples produced PCR-ELISA results for the C. hyointestinalis and 
C. helveticus probes which were not subsequently cultured. 
•Therefore, not only is this dual detection and identification system a more rapid method 
•than the current culture techniques, it also detects non-viable isolates of Campylobacter and 
possible multiple species infections. 
4.3 Biochemical Identification 
4.3.1 Methods 
As the testing laboratory for this study was not a Campylobacter reference laboratory and had 
limited availability to various biochemical reagents, a basic set of tests was used in this study to 
identify the most commonly isolated Campylobacter species from humans, C. jejuni, with all 
other isolates being identified with a commercial multi-test system. The screening test set 
consisted of growth at 42°C, the hippufate test and susceptibilities to cephalothin and naladixic 
acid. All isolates which produced a positive hippurate test, grew at 42°C, and which were both 
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resistant to cephalothin and sensitive to naladixic acid were identified as C. jejuni subsp. jejuni as 
recommended by Nachamlcin (1999). Those with the same biochemical patern but which were 
sensitive to cephalothin were identified as the infrequently encountered C. jejuni subsp. doylei. 
While the commercialy available biochemical identification system API Campy from 
bioMerieux was shown to be no more accurate than standard biochemical tests (Huysmans, 
Tunidge and Wiliams, 1995), it was chosen for non-C. jejuni isolate identification as it was 
readily available and easy to use. 
4.3.2 Results 
Campylobacter isolates were as given in Section 2.2: Sample colection and storage. 
Of the 250 strains tested, 237 (94.8%) were identified as C. jejuni subsp. jejuni (235 by a 
positive hippurate hydrolysis and 2 with negative hippurate results subsequently identified by 
Campy API). The remaining 13 hippurate negative strains were identified as: 10 C. co/i (4.0%), 1 
C. lari (0.4%), 1 C. upsaliensis (0.4%) and 1 unidentified (0.4%) (Table 4.1). 
Table 4.1:  Biochemical identification of Campylobacter species 
Number of 
isolates 
Hippurate 
hydrolysis 
Cephalothin 
Sensitivity 
Naladixic 
Acid 
Sensitivity Identification 
233 POSITIVE RESISTANT SENSITIVE C. jejuni subsp. jejuni 
2 POSITIVE* RESISTANT RESISTANT C. jejuni subsp. jejuni 
15 NEGATIVE* 
RESISTANT SENSITIVE 2 C. jejuni subsp.jejuni 
RESISTANT SENSITIVE 10 C. coil 
RESISTANT RESISTANT 1 	C. lari 
SENSITIVE SENSITIVE 1 	C. upsaliensis 
SENSITIVE RESISTANT 1 	Unidentified 
* Identified by bioMerieux API Campy identification system 
These results are similar to previous studies in the Netherlands in which C. jejuni (91.9%), C. coil 
(7.5%) and C. upsaliensis (0.6%) were also isolated utilising 5 diferent selective media and the 
filtration method (Endtz et al, 1991a). With such a wide variety of growth media supplemented 
by the filtration system, it is somewhat surprising that the Netherlands study did not isolate more 
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of the infrequently encountered species of Campylobacter and Arcobacter. Although the best 
culture schemes would include a variety of culture media at both 37 °C and 42°C, large-scale 
studies have shown that the proportion of other Campylobacter and Arcobacter species causing 
diarrhea is relatively small. Whilst accepting that a few strains may only grow at 37°C and an 
occasional strain will be sensitive to the antimicrobial agents in the media, it would seem that 
Tasmanian diagnostic laboratories have not been greatly disadvantaged by utilising only one 
medium type at 42°C. Unfortunately, those few isolates that are missed may be associated with 
GBS and therefore accurate data on other Campylobacter/Arcobacter responsible for GBS may 
be lost. 
The detection of two strains of C. jejuni subsp. jejuni with resistance to naladixic acid is not 
typical of this species. In one Australian study, Huysmans and Turnidge (1997) tested the 
susceptibilities of 100 human isolates of Campylobacter to various antimicrobial agents. These 
included 79 strains of C. jejuni subsp. jejuni, 19 C. co/i and 2 strains of C. Ian. Resistance to the 
quinolones was only found in C. lari, a marker commonly used for identification of this species. 
No C. jejuni or C. co/i strains were found to be resistant to naladixic acid. Interestingly, they also 
found two strains of C. jejuni subsp. jejuni that were sensitive to cephalothin. Previous overseas 
studies in Finland and United Kingdom have reported increased resistance to naladixic acid and 
the fluoroquinolones in C. jejuni and C. co/i (Rautelin, Renkonen and Kosunen, 1991; Bowler. 
and Day, 1992). In these countries, widespread use of fluoroquinoles in animal husbandry, 
especially poultry farming has been implicated as a cause of increased resistance (Endtz et al, - 
1991b). As laboratories often rely on the resistance profiles of c.ephalothin and naladixic acid for 
identification, misidentification will occur as resistance to naladixic acid becomes more prevalent 
and atypical strains with variable sensitivities to cephalothin are encountered. 
Two strains of hippurate negative C. jejuni subsp. jejuni were also found in the present study 
which were subsequently speciated by the API-Campy system. While relatively uncommon, 
hippurate negative C. jejuni have been reported in a number of studies (Nicholson and Patton, 
1995; Totten et al, 1987). The basic hippurate hydrolysis tube test used by most researchers is 
based upon the detection of glycine within an incubated suspension of the bacteria. This is done 
by the addition of ninhydrin to the suspension and the development a purple colour within the 
tube. False negatives have been seen with a number of variations to this procedure with more 
sensitive results being reported with the use of gas-liquid chromatography (GLC) (Morris et al, 
1985). However, subsequent reports showed the presence of some strains of C. jejuni, as 
confirmed by DNA-DNA hybridisation studies, to be hippurate hydrolysis negative even by GLC 
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(Totten et al, 1987). Clearly, the need for a definitive genetically based test to define speciation 
is needed. 
4.4 Molecular Identification: 
As the majority of Campylobacter species isolated from human faeces in patients suffering 
gastroenteritis are C. jejuni (CDI, 1997), a multiplex PCR was designed to both confirm that the 
isolates sent to our laboratory were indeed Campylobacter species or Arcobacter species and to 
quickly identify those that were C. jejuni. All non-C. jejuni isolates were further identified using 
the dot blot hybridisation with species-specific biotinylated probes to the 16S PCR product from 
the Multiplex PCR assay. 
4.4.1 Multiplex PCR (16S sRNA/Hippurate gene) 
4.4.1 (a) Method 
Gene sequences for 16S rRNA and hippurate genes were obtained from Genbank using the 
nucleotide search engine at the National Centre for Biotechnology (NCBI) web site 
(http://www.ncbi.nlm.nih.gov). Designed primers were compared for specificity against 
Genbank's database using the computer program Basic BLAST (NCBI web site). 
Crude bacterial DNA preparations were prepared by heating a MacFarland 1.0 suspension of 
bacteria (equivalent to a transmission of 70% as determined by a Vitek colorimeter), to 95 °C for 
10 minutes, after which the suspension was cooled to 4°C and used immediately for PCR. The 
optimised reaction mixture for PCR and the thermal cycling conditions using the Perkin Elmer • 
DNA Thermal Cycler Model 9600 are given in Tables 4.2 and 4.3 respectively. 
Table 4.2: Optimised reaction conditions for Multiplex PCR assay 
Reagent Final Concentration 
I 0 X PCR Buffer II IX 
Magnesium Chloride (mM) 4.2 
Hippurate Sense Primer (AM) 0.45 
Hippurate Anti-sense Primer (AM) 0.45 
16S rRNA Sense Primer (AM) 0.45 
16S rRNA Anti-sense Primer (AM) 0.90 
dNTPs (dATP, dGTP, dCTP, dUTP) 200 AM of each 
AmpliTaqg Gold DNA Polymerase 0.5 U 
Water Volume ad'usted to 50 L 
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Table 4.3: Optimised thermal cycling conditions for the Multiplex PCR 
Amplification Step Conditions 
DNA Polymerase Enzyme activation 
(AmpliTaq® Gold DNA Polymerase) 
5 minutes, 94°C 
40 cycles — Denaturation 1 minute, 94°C 
Annealing 1 minute & 20 seconds, 63°C 
Extension 1 minute, 72°C 
1 cycle — Final Extension 5 minute, 72°C 
Based upon the 16S rRNA and hippurate genes (Figure 4.1), a 842 bp 16S rRNA amplicon 
fragment and 377 bp. hippurate amplicon was detected in isolates of C. jejuni with other species 
of Campylobacter/Arcobacter possessing only the 842 bp genus specific fragment. The 
identification scheme was complete after a 3 hour PCR cycle followed by lhour detection on an 
agarose electrophoresis gel. Figure 4.2, demonstrates the presence of both PCR products in the 
C. jejuni control strain ATCC 700297 and ATCC 43431, and the larger 16S rRNA product in 
various other Campylobacter species and an Arcobacter species. 
4.4.1 (b) Results 
All isolates tested produced the larger 842 bp fragment with 237 strains also producing the 
smaller 377 bp fragment (Table 4.4). There were 13 isolates that only produced the larger 842 bp 
16S rRNA product, signifying the presence of a non-C. jejuni species or Arcobacter species. The 
PCR product for these strains was used in the dot blot hybridisation test described below. The two 
C. jejuni control strains produced both PCR fragments with other Campylobacter/Arcobacter sp. 
control strains only producing the larger 842 b.p. fragment. Control strains that were not 
Campylobacter or Arcobacter did not produce DNA fragments of any size using the multiplex 
PCR. 
4.4.2 Dot Blot Hybridisation 
4.4.2 (a) Method 
The Dot Blot Hybridisation assay was developed to speciate non C. jejuni isolates as determined 
by the multiplex PCR assay and was as given in Section 2.8 Dot Blot Hybridisation. 
Biotinylated 16S rRNA probes were designed after identifying unique 16S rRNA sequences gene 
sequences (Figure 4.3) for C. Ian, C. upsaliensis, C. fetus and Arcobacter species that were 
internal to the 16S rRNA gene fragment generated from the multiplex PCR (Table 4.5). The gene 
sequences were obtained from Genbank using the nucleotide search engine at NCBI. Probes used 
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Figure 4.1:  PCR primers for the multiplex PCR (16S rRNA/Hippurate gene) 
1554 
Hippurate gene 
1931 
377 
165 rRNA gene 
1219 
Source: Genebank — Hippurate gene (cjhippurc) , 16S rRNA gene: (C. jejuni strain 98/E599/10) 
Figure 4.2:  PCR products of various Campylobacter and Arcobacter strains using the 
Multiplex PCR for 16S rRNA and hippurate gene 
501 bp 404 bp 331 bp 
842 bp 
377 bp 
Lanes 1 	 2 3 	 4 6 	 6 	 7 	 8 	 9 
Lane 1: Molecular weight marker, 2: C. jejuni ATCC 700297, 3: C. jejuni ATCC 43431, 
4: C. co/i NCTC 11353, 5: C. lari ATCC 35221, 6: C. fetus NCTC 5850, 7: UPTC NCTC 11937, 
8: C. upsaliensis Lab. Strain, 9: Arcobacter species Lab Strain. 
Figure 4.3:  Design of species specific probes: 16S rRNA sequence alignment for 
various Campylobacter and Arcobacter species 
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31 CT T TTA TA TAAGAAGA TAA TGACGGTA TTA 60 
31 CT T T TCT TAGGGA AGA A T TCTGACGGTACC 60 
31 CT T T TGT TAGGGA AGA ACCA TGACGGTACC 60 
31 CT T T TCT TAGGGA AGA A T TCTGACGGTACC 60 
31 CT T T TCT T TGGGAAGAA TTTTGACGGTACC 60 
31 CT T T TCT TAGGGAAGAA TTCTGACGGTACC 60 
61 TA TGAA TA AGCACCGGCTA ACTCCGTGCCA 90 
61 TAAGGAA TA AGCACCGGCTA ACTCCGTGCC 90 
61 TAACGAA TA AGCACCGGCTA ACTCCGTGCC 90 
61 TA AGGAA TA AGCACCGGCTA ACTCCGTGCC 90 
61 A AAGGAA TA AGCACCGGCTAACTCCGTGCC 90 
61 TAAGGAA TA AGCACCGGCTA ACTCCGTGCC 90 
91 GCA GCCGCGGTA A T ACGGAGGGTGCA AGCG 120 
91 AGCAGCCGCGGTA A TACGGAGGGTGCAAGC 120 
91 A GCAGCCGCGGTA A TACGGAGGGTGCAAGC 120 
91 AGCAGCCGCGGTA A TACGGAGGGTGCNAGC 120 
91 AGCAGCCGCGGTA A TACGGAGGGTGCAAGC 120 
91 AGCA GCCGCGGT A A TACGGAGGGTGCAAGC 120 
121 T TACTCGGA A TCACTGGGCGTAAAGAGCGT 150 
121 GT TACTCGGAA TCACTGGGCGTAAAGGACG 150 
121 GT TACTCGGA A TCACT TGGGCGT AA AGGAC 150 
121 GT TACTCGGA A TCACTGGGCGTAAAGGGCG 150 
121 GT TACTCGGA A TCACTGGGCGTA AAGGGCG 150 
121 GT TACTCGGAA TCACTGGGCGTA AAGGGCG 150 
151 GTAGGCGGA T TAA TGAGT T TGAAGTGA A A T 180 
151 CGTAGGCGGA T TA TCAAGTCT T T TGTGA AA 180 
151 GCGTAGGCGGA T TA TCAAGTCT T TTGTGAA 180 
151 CGTAGGCGGA T TA TCAAGTCTCT TGTGA AA 180 
151 CGTAGGCGGA T TA TCAAGTCTCT TGTGA A A 180 
151 CGTAGGCGGA T TA TCAAGTCTCT TGTGA A A 180 
181 CCTA TAGCT TA ACT A TAGAACTGCTT TGA A 210 
181 TCTAATGGCTTAACCATTAAACTGCT TGAG 210 
181 A TCTAACAGCT TA ACTGT TAA ACTGCT TGA 210 
181 TCCAACGGCTTAACCGTTGAACTGCT TGGG 210 
181 TCTAATGGCTTAACCA TTAAACTGCT TGGG 210 
181 TCCAACGGCT TA ACCGT TGAACTGCT TGGG 210 
211 A ACTGT TAA TCTAGA A TGTGGGAGAGGTAG 240 
211 A AACTGA TA A TCTAGAGTGAGGGAGAGGCA 240 
211 GAAACTGA T A A TCTAGAGTGAGGGAGAGGC 240 
211 A A A rTGP,TA A Tr.TAnAGTGGGGGAGAGGCA 240 
211 AAACTGA TAGTCTAGAGTGAGGGAGAGGCA 240 
211 A AA CTGGTA GTCTAGAGTGAGGGAGAGGCA 240 
241 A TGGAA T T TCTGGTGTAGGGGT A AA A TCCG 270 
241 GA TGGAA T TGGTGGTGTAGGGGTAA A A TCC 270 
241 AGA TGGA A T TGGTGGTGTAGGGGTA A A A TC 270 
241 GA TGGAA T TGGTGGTGTAGGGGTAA A A TOO 270 
241 GA TGGAA T TGGTGGTGTAGGGGTAA A A TCC 270 
241 GA TGGAA T TGGTGGTGTAGGGGTAA A A TOO 270 
acob 271 TAGAGATCAGAAGGAATACCGATTGCGAAG 300 
COI 271 GTAGAGATCACCAAGAATACCCATTGCGAA 300 fetus 271 CGTAGAGATCACCAGGAATACCCATTGCGA 300 
'al 271 GTAGATATCACCAAGAATACCCATTGCGAA 300 
Tsai 271 GTAGATATCACCAAGAATA000ATTGCGA4 -  300 
	 UriC 271 GTAGATATCACCAAGAATACCCATTGCGA4 -  300 
atob 301 GCGATCTACTGGAACAATATTGACGCTGAG 330 
COI 301 GGCGATCTGCTAGAACTCAACTGACGCTA4 330 fetus 301 AGGCGATCTGCTGGAACTCAACTGACGCT ,4: -  330 
lal 301 GGCGATCTGCTGGAACTTAACTGACGCTA4 -  330 
LPSal 301 GGCGATCTGCTGGAACTCAACTGACGCTAA 330 LIM 301 GGCGATCTGCTGGAACTTAACTGACGCTAA 330 
aCOO 331 ACGCGAAAGCGTGGGGAGCAAACAGGATTA 360 
Cd 331 TGCGTGAAAGCGTGGGGAGCAAACAGGATT 360 
fetus 331 ATGCGTGAAAGCGTGGGGAGCAAACAGGAT 360 
331 GGCGCGAAAGCGTGGGGAGCAAACAGGATT 360 
LPSal 331 GGCGCGAAAGCGTGGGGAGCAAACAGGA TT 360 uptc 331 GGCGCGAAAGCGTGGGGAGCAAAACAGGAT 360 
acob 361 GATACCCTGGTAGTCCACGCCCTAAACGAT 390 
OCi 361 AGATACCCTGGTAGTCCACGCCCTAAACGA -  390 
fetus 361 TAGATACCCTGGTAGTCCACGCCCTAAACG 390 	Ii 361 AGA TACCCTGGTAGTCCACGCCCTAAACGA 390 
... 361 AGATACCCTGGTAGTCCACGCCCTAAACGA 390 	 uptc 361 TAGATACCCTGGTAGTCCACGCCCCTAAAC 390 
acob 391 GTACACTAGTTGTTGTGAGGCTCGACCTTG 420 
COI 391 TGTATACTAGTTGTTGCTCTGCTAGTCAGG 420 
fetus 391 ATGTATACTAGTTGTTGCTGTGCTAGTCAC 420 
391 TGTATGCTAGTTGTTGGGGTGCTAGTCATC 420 
	Lictsal 391 TGTATGCTAGTTGTTGGGGTGCTAGTCATC 420 
	 uptc 391 GATGTACACTAGTTGTTGGGGTGCTAGTCA 420 
acob 421 CAGTAATGCAGTTAACACATTAAGTGTACC 450 
COI 421 GCAGTAATGCACCTAACGGATTAAGTATAC 450 
fetus 421 GGCAGTAATGCACCTAACGGATTAAGTATA 450 
lai 421 TCAGTAATGCAGCTAACGCATTAAGCATAC 450 
Tsai 421 TCAGTAATGCAGCTAACGCATTAAGCATAC 450 
... 421 TCTCAGTAATGCAGCTAACGCATTAAGTGT 450 
acob 451 GCCTGGGGAGTACGGTCGCAAGATTAAAAC 480 
COI 451 CGCCTGGGGAGTACGGTCGCAAGATTAAAA 480 
fekiS 451 -  000GCCTGGGGAGTACGGT000AAGATTA 4 480 
451 CGCCTGGGGAGTACGGTCGCAAGATTAAAA 480 
Weal 451 -  CGCCTGGGGAGTACGGTCGCAAGATTAAA A 480 uptc 451 - ACCGCCIGGGGAGTACGGTCGCAAGATTA 4 480 
mob 481 TCAAAGGAATAGACGGGGACCCGCACAAGC 510 
COI 481 CTCAAAGGAATAGACGGGGACCCGCACAAG 510 
fetus 481 -  AACTCAAAGGAATAGACGGGGACCCGCACA 510 
lai 481 CTCAAAGGAATAGACGGGGACCCGCACAAG 510 
LPSEd 481 CTCAAAGGAATAGACGGGGACCCGCACAAG sio 	 uptc 481 -  AACTCAAAGGAATAGACGGGGACCCGCACA 510 
acob 511 GGTGGAGCATGTGGTTTAATTCGANNNNAC 540 
COI 511 -  CGGTGGAGCATGTGGTTTAATTCGATGATA 540 
fetus 511 AGCGGTGGAGCATGTGGTTTAATTCGAAGA, - 540 
... 	lai 511 CGGTGGAGCATGTGGTTTNATNCGAAGATA 540 
Tsai 511 -  CGGTGGAGCATGTGGTTTAATTCGATGATA 540 Ut 511 AGCGGTGGAGCATGTGGTTTAATTCGAAGA 540 
mob 
COI 
fetus 
Ian 
Licsal 
.uptc 
mob 
COI 
fetus 
Ian 
Liosal 
......uptc 
arat 
CCE 
fetus 
LIMA 
Upt 
acob 
COI 
fetus 
lad 
upsal 
uptc 
acob 
COI 
fetus 
lai 
Lpsal 
Upt 
arcob 
COI 
fetus 
lai 
tpsal 
uptc 
aCOb 
COI 
fetus 
tal 
Lpsa 
Upt 
mob 
COI 
fetus 
tEll 
LPsal 
..... ..uptc 
541 ACGAAGAACCTTACCTGGACTTGACATAGT 570 
541 CGCGAAGAACCTTACCTGGGCTTGATATCC 570 
541 TACGCGAAGAACCTTACCTGGGCTTGA TAT 570 
541 CGCGAAGAACCTTACCTGGGCTTGATATCC 570 
541 CGCGAAGAACCTTACCTAGGCTTGATATCC 570 
541 TACGCGAAGAACCTTACCTGGGCTTGATAT 570 
571 AAGAATGATTTAGAGATAGATTAGTGTCTG 600 
571 TAAGAACCTTTTAGAGATAAGAGGGTGCTA 600 
571 CCAACTAATCTCTTAGAGATAAGAGAGTGC 600 
571 TAAGAACCTTATAGAGATATGAGGGTGCTA 600 
571 AACAAATTCTGTAGAGATACGGAAGTGCTA 600 
571 CCTAAGAACCTTTTAGAGATAAGAGGGTGC 600 
601 CTTGCAGAAACTTGCATACAGGTGCTGCAC 630 
601 GCTTGCTAGAACTTAGAGACAGGTGCTGCA 630 
601 TAGCTTGCTAGAAAGTTGAGACAGGTGCTG 630 
601 GCTTGCTAGAACTTAGAGACAGGTGCTGCA 630 
601 GCTTGCTAGAATGTTGAGACAGGTGCTGCA 630 
601 TAGCTTGCTAGAACTTAGAGACAGGTGCTG 630 
631 GGCTGTCGTCAGCTCGTGTCGTGAGATGTT 660 
631 CGGCTGTCGTCAGCTCGTGTCGTGAGATGT 660 
631 CACGGCTGTCGTCAGCTCGTGTCGTGAGAT 660 
631 CGGCTGTCGTCAGCTCGTGTCGTGAGATGT 660 
631 CGGCTGTCGTCAGCTCGTGTCGTGAGATGT 660 
631 CACGGCTGTCGTCAGCTCGTGTCGTGAGAT 660 
661 GGGTTAAGTCCCGCAACGAGCGCAACCCTC 690 
661 TGGGTTAAGTCCCGCAACGAGCGCAACCCA 690 
661 GTTGGGTTAAGTCCCGCAACGAGCGCAACC 690 
661 TGGGTTAAGTCCCGCAACGAGCGCAACCCA 690 
661 TGGGTTAAGTCCCGCAACGAGCGCAACCCT 690 
661 GTTGGGTTAAGTCCCGCAACGAGCGCAACC 690 
691 GTCCTTAGTTGCTAACAGTTCGGCTGAGAA 720 
691 CGTATTTAGTTGCTAACGGTTCGGCCGAGC 720 
691 CACGTATTTAGTTGCTAACAGTTCGGCTGA 720 
691 CGTATTTAGTTGCTAACACTTCGGGTGAGC 720 
691 CGTCCTTAGTTGCTAACGATTCGGTCGAGC 720 
691 CACGTATTTAGTTGCTAACGGTTCGGCCGA 720 
721 CTCTAAGGAGACTGCCTACGCAAGTAGGAG 750 
721 ACTCTAAATAGACTGCCTTCGTAAGGAGGA 750 
721 GCACTCTAAATAGACTGCCTTCGCAAGGAG 750 
721 ACTCTAAATAGACTGCCTTCGTAAGGAGGA 750 
721 ACTCTAAGGAGACTGCCTTCGTAAGGAGGA 750 
721 GCACTCTAAATAGACTGCCTTCGTAAGGAG 750 
751 GAAGGTGAGGATGACGTCAAGTCATCATGG 780 
751 GGAAGGTGTGGACGACGTCAAGTCATCATG 780 
751 GAGGAAGGTGTGGACGACGTCAAGTCATCA 780 
751 GGAAGGTGTGGACGACGTCAAGTCATCATG 780 
751 GGAAGGTGGGGACGACGTCAAGTCATCATG 780 
751 GAGGAAGGTGTGGACGACGTCAAGTCATCA 780 
781 CCCTTACGTCCAGGGCTACACACGTGCTAC 810 
781 GCCCTTATGCCCAGGGCGACACACGTGCTA 810 
781 TGGCCCTTATGCCCAGGGCGACACACGTGC 810 
781 GCCCTTATGCCCAGGGCGACACACGTGCTA 810 
781 GCCCTTACGCCTAGGGCGACACACGTGCTA 810 
781 TGGCCCTTATGCCCAGGGCGACACACGTGC 810 
mob 811 AATGGGGTATACAAAGAGCAGCAATACGGT 840 
COi 811 CAATGGCATATACAATGAGACGCAATACCG 840 
fetus 811 TACAATGGCATATACAATGAGATGCAATAT 840 
.....lai 811 CAATGGCATATACAATGAGACGCAATACCG 840 
(-PM] 811 CAATGGCATATACAATGAGACGCAATACCG 840 
uptc 811 TACAATGGCATATACAATGAGACGCAATAC 840 
mob 841 GACGTGGAGCAAATCTCAAAAATGCCTCCC 870 
COI 841 CGAGGTGGAGCAAATCTATAAAATATGTCC 870 
fetus 841 CGCGAGATGGAGCAAATCTATAAAATATGT 870 
lal 841 CGAGGTGGAGCAAATCTATAAAATATGTCC 870 
L4Dsal 841 CGAGGTGGAGCAAATCTATAAAATATGTCC 870 
Upt 841 CGCGAGGTGGAGCAAATCTATAAAATATGT 870 
_ 
Biotinylated probe 
ccl 
cc2 
lari 
upsal 
fetus 
arco 
16S rRNA Multiplex PCR primers 
  
    
Forward 
Reverse 
  
  
Table 4.4: First stage identification using the Multiplex PCR for 16S rRNA and 
hippurate gene 
Number of 
isolates 
16S PCR 
positive _ 
Hippurate 
PCR positive 
Identification 
250 
237 237 C. jejuni 
13 0 
non-C. jejuni Campylobacter or 
Arcobacter spp. 
17 
control 
strains 
2 2 
C. jejuni ATCC 700297 
C. jejuni ATCC 43431 
6 0 
C. coil NCTC 11353 
UPTC NCTC 11937 
C. lari ATCC 35221 
C. fetus NCTC 5850 
C. upsaliensis (Lab. Strain) 
Arcobacter sp. (Lab. Strain) 
0 0 
Proteus vulgaris ATCC 8427 
Aeromonas hydrophila ATCC 2433 
Pseudomonas aeruginosa NCTC 10662 
Legionella pneumophila ATCC 33152 
Escherichia coil NCTC 11560 
Haemophilus influenzae NCTC 4560 
Salmonella typhimurium ATCC 3598 
Shigellaflexneri ATCC 12022 
Pseudomonas fluorescens ATCC 13525 
Table 4.5: Biotinylated 16S rRNA oligonucleotide probes to various Campylobacter 
and Arcobacter species 
Probe Organism 
Detected 
Length Sequence (5' to 3') Reference 
ccl 
C. coli 
UPTC 22 n.t. 
BiotinTTTGCGGTACACTT 
AA TGCGTT 
Metherell, 
Logan and 
Stanley, 1999 
cc2 C. co/i 20 n.t. 
BiotinTAAGCTCGGCCGAA 
CCGTTA 
Metherell, 
Logan and 
Stanley, 1999 
lari C. lari 23 n.t. BiotinATATTAGAGTGCTC 
ACCCGAAGT 
this study 
upsal C. upsaliensis 23 n.t. BiotinTAAACTTCCGTATC 
TCTACAGAA 
this study 
fetus C. fetus 25 n.t. BiotinATATCTCTTATCTCT 
AAGAGATTAG 
this study 
arco Arcobacter 
species 
22 n.t. BiotinAATAGCTATAGGAT 
TTCACTTC 
this study 
UPTC: urea positive thermophilic Campylobacter; n.t.: nucleotides 
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for C. co/i and urea positive thermophilic Campylobacter strains (UPTC) were from a previous 
study (Metherell, Logan and Stanley, 1999). 
The hybridisation probe strategy is shown in Figure 4.4. 
Incubation was performed overnight with biotinylated probes (concentration of 10 nM) ccl, cc2 
and lari at 50°C to detect C. co/i (Figure 4.5). UPTC and C. lari. C. coil strains are positive with 
both ccl and cc2 probes; with the urea positive variant of C. lari (UPTC) positive in only the ccl 
probe and C. lari positive with only the lari probe. If the isolates are negative using these probes, 
the hybridisation experiment is repeated at 43 °C with the C. upsaliensis probe (Upsal) and then 
39°C for Arcobacter spp probe (Arco) and then 34°C with the C. fetus probe (Fetus). The 
conjugate (Streptavidin-alkaline phosphate) was used in a 5% blocking solution (1:5000 dilution). 
Identification of control strains was confirmed by 16S rRNA sequencing as given in Section 2.12: 
DNA sequencing. As large epidemiological studies have shown that C. jejuni and C. co/i are the 
most commonly isolated species (91.9% and 7.5% respectively)(Endtz eta!, 1991a), using the 
multiplex PCR would identify the majority of strains as C. jejuni within 5 hours, with C. co/i 
strains identified 24 hours later. 
4.4.2 (b) Results/Discussion 
Of the 13 isolates identified as non-C. jejuni campylobacters using the multiplex PCR, 10 were 
identified as C. co/i using the ccl and cc2 probes and 2 isolates bound the lari probe (C. lari). Dot 
blot hybridisation was performed at the lower temperature of 43 °C using the 
• C. upsaliensis probe which produced a positive identification in the remaining 1 unidentified 
strain. (Table 4.6) 
The molecular based identification scheme identified all the C. jejuni subsp. jejuni strains found 
by API-Campy biochemical system including the two hippurate negative strains encountered. 
Also the 10 C. coil, 2 C. lari and 1 C. upsaliensis strains identified biochemically were correctly 
identified by the dot blot hybridisation assay. The single strain that could not be biochemically 
identified was found to be C. lari using the lari probe in the hybridisation assay. This isolate more 
closely resembled C. fetus being sensitive to cephalothin and resistant to naladixic acid. It also 
grew well at 37°C and poorly at 42°C, growth characteristics seen with isolates of C. fetus. 
Furthermore, C. lari sensitivity to cephalothin has not been reported previously, making this 
isolate quite atypical in its presentation. 
Repeat hybridisation testing showed strong binding to the lari probe and no binding of 
the fetus probe. Unusual isolates have previously been reported following identification with 
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al negative 
ccl - 
cc2 - 
lari + 
Probe: 
upsal 
430C 
—Negatives. 
Positive 
<Arcobacter sp. 
Figure 4.4: Flowchart for PCR/Dot Blot Hybridisation Assay 
793 bp + 
379 bp + 
C. jejuni 
no 793 bp 
no 379 bp 
793 bp + 
379 bp - 
Not 
Campylobacter 
or Arcobacter 
sp. 
500C 
11r  KProbes ccl cc2 lari 
ccl + 
cc2 + 
Ian - 
ccl + 
cc2 - 
lari - 
Probe: 
Arco 
399C 
<Dot Blot Hybridisation 
Probe: —Negative—P. 	 Fetus 
340C 
Positive Positive 
C. fetus 
Figure 4.5: Dot blot hybridisation using the C. coil specific probe cc2 
A B C D E lit• 	 40 
2 1110• • fr, 
3.1100 
Al, A2, A3, Bl, B2, B3, Cl, C2, C3, Dl: patient strains, D2: C. co/i NCTC 11353, D3: C. fetus 
NCTC 5850, El: C. lari patient strain 1, E2: C. lari patient strain 2, E3: C. upsaliensis patient 
strain 
Table 4.6: Second stage identification using the dot blot hybridisation with probes 
internal to the 16S rRNA PCR product 
Number 
of 
isolates 
jej/col 1 
probe 
positive 
jej/col 2 
probe 
positive 
lari 
probe 
positive 
upsal 
probe 
positive 
Identification 
13 
10 10 0 NT C. coil 
0 0 2 NT C lari 
0 0 0 1 C. upsaliensis 
6 
control 
strains 
1 1 0 0 C. coli NCTC 11353 
1 0 0 0 
Urea positive thermophilic 
Campylobacter (UPTC) 
NCTC 11937 
0 0 1 0 C. lari ATCC 35221 
0 0 0 0 C. fetus NCTC 5850 
0 0 0 1 C. upsaliensis Lab strain 
0 0 0 0 Arcobacter species Lab. 
strain 
NT: not tested 
the API-Campy identification system. Huysmans, Turnidge and Williams (1995), found that 3 out 
of 100 Campy/obacter isolates were not identified by this system. DNA hybridisation studies 
subsequently identified those 3 isolates as being C. coil . They also concluded that conventional 
biochemical testing alone was satisfactory for the routine identification of thermophilic 
campylobacters. While our results agree with their findings, it should be noted that conventional 
biochemical testing alone would have failed to detect the hippurate negative strains 
of C. jejuni subsp. jejuni and to correctly identify unusually presenting strains such as the C. lari 
isolate encountered in our study. 
4.5 Summary 
The simple biochemistry scheme correctly identified the majority of C. jejuni subsp. jejuni 
isolates encountered in this study and is still useful to rapidly identify the species that is most 
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commonly isolated by routine laboratories. While large numbers of non-C. jejuni isolates were 
not tested in this study, the bioMerieux API-Campy identification system identified 12/13 
non-C. jejuni strains encountered and also correctly identified both hippurate negative C. jejuni 
subsp.jejuni strains and therefore should still be considered for smaller laboratories that have 
limited resources and the need for off-the-shelf identification systems. For larger reference 
laboratories, a molecular based identification scheme such as the multiplex PCR/dot blot 
hybridisation system would give a definitive result for those less frequently encountered species 
as well as detection of the hippurate gene for accurate identification of hippurate negative strains 
of C. jejuni. 
An adaptation of the system is possible allowing for the development of a PCR-enzyme linked 
immunosorbent assay (ELISA) for detection of Campylobacter and Arcobacter species directly 
from faecal samples similar to the system developed by Metherell, Logan and Stanley (1999). 
Such a system would decrease identification time by eliminating the need for culturing the 
organism initially. Other advantages of such a system would be the detection of mixed species 
infections and also the identification of strains unable to grow on the media and incubation 
temperatures used in routine laboratories. 
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CHAPTER 5 
POTENTIAL MARKERS OF CAMPYLOBACTER ASSOCIATED WITH THE 
DEVELOPMENT OF GBS 
Studies of GBS associated strains of Campylobacter show that they, as a group have a number 
of attributes in common. Firstly, certain serotypes such as Penner serotype 0:19, are isolated 
from GBS patients at an increased frequency compared to other serotypes. Secondly, GBS 
associated strains have cell wall structures that mimic human gangliosides such as Gm 1. The 
prevalence of potentially neuropathogenic strains of Campylobacter may therefore be 
determined by testing for these attributes in Tasmanian gastrointestinal isolates. 
5.1 Penner Serotype 0:19 strains 
5.1.1 Background 
The epidemiology of Campylobacter-associated GBS has been made possible by the use of a 
number of different typing systems. One of the first schemes to produce valuable information 
was the Penner 0 serotyping system which could differentiate 60 types of C. jejuni and 
C. co/i. 
In one Japanese study using this technique, it was found that of 12 isolates of C. jejuni 
associated with GBS, 10 (83%) belonged to serotype 0:19 (Kuroki etal, 1993). In that same 
study, only 1.7% of 1,150 enteritis-associated isolates of C. jejuni belonged to serotype 0:19. 
While serotype 0:19 is over-represented in GBS patients, it would seem that the high 
isolation rate of this serotype in the Japanese study might be a regional population 
phenomenon. Geographical distribution of a particular serotype can also be seen in a study 
from South Africa. In that particular region, serotype 0:41 was found in 6 of 9 (67%) isolates 
of C. jejuni from patients that developed GBS, compared with only 0.1% of enteritis isolates 
from patients in the same region. These are significant results considering that serotype 0:19 
was found to be three times more prevalent in this community than serotype 0:41 (Wassenaar 
et. al, 2000). Other studies from around the world have reported serotypes 0:19 and to a 
lesser degree 0:41along with serotypes 0:1, 0:2, 0:4, 0:4 complex, 0:5, 0:10, 0:16, 0:23, 
0:37, 0:44, 0:64 (Nachamkin and Blaser, 2000). 
As serotyping is expensive and restricted to reference laboratories and does not detect all 
GBS-associated strains (Endtz et al, 2000), alternate methods to detect those strains of 
Campylobacter would aid in the elucidation of the mechanism of GBS induction. 
In 1998, a PCR for the detection of C. jejuni serotype 0:19 strains was first published 
(Misawa , Allos and Blaser, 1998). The test detected a single base pair difference in the DNA 
gyrase subunit B gene of C. jejuni isolates. A total of 42 isolates (18 0:19 and 24 non-0:19 
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strains) from five different countries were examined with 0:19 strains being distinguishable 
from non-0:19 strains in each case. Non-serotype 0:19 strains tested included: 0:1, 0:2, 0:6, 
0:7, 0:8, 0:11, 0:15, 0:16, 0:17, 0:23, 0:25, 0:36, 0:38, 0:50, 0:64 and four non-typable 
strains. 
5.1.2 Serotype 0:19 PCR method 
In our hands, the 0:19 PCR test as described by Misawa, Allos and Blaser (1998) did not 
detect the 0:19 control strain. The method was therefore modified by optimising the primer, 
magnesium chloride concentration and increasing amplification annealing temperatures, such 
that the assay was able to detect control strains before commencing large scale testing of our 
isolates. Following completion of our testing, an erratum was published by Misawa, Allos 
and Blaser (2000) in the same journal 2 years later stating that primer concentration was 
incorrectly published in their original paper. 
In our study, crude bacterial DNA preparations were prepared by heating a MacFarland 1.0 
suspension of bacteria (equivalent to a transmission of 70% as determined by a Vitek 
colorimeter), to 95 °C for 10 minutes, after which the suspension was cooled to 4°C and used 
immediately for PCR. The optimised reaction mixture for PCR and the thermal cycling 
conditions using the Perkin Elmer DNA Thermal Cycler Model 9600 are given in Tables 5.1 
and 5.2 respectively using primer sequences as given in Table 2.3: Details of primers chosen 
and designed. 
The combined program outlined in Table 5.2, was originally designed by Misawa, Allos and 
Blaser (1998) to eliminate non-specific fragments being produced by non-0:19 strains. This 
program originally had an annealing temperature in the first round PCR of 50 °C and an 
annealing temperature of 48°C in the second round PCR. Using these conditions a fragment of 
the correct size was still observed when testing the 0:19 negative control strain (serotype 
0:3). To eliminate this problem, the annealing temperatures were increased to 52°C and 50°C 
Table 5.1: Optimised reaction conditions for serotype 0:19 PCR assay 
Reagent Final Concentration 
10 X PCR Buffer II 1X 
Magnesium Chloride (mM) 4.65 
GyrB Sense Primer (uM) 0.7 
GyrB Anti-sense Primer (0:19) 0.7 
dNTPs 
(dATP, dGTP, dCTP, dUTP) 
200 jiM of each 
AmpliTaq® Gold DNA Polymerase 0.5 U 
Water Volume adjusted to 50 jL 
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Table 5.2:  Optimised amplification conditions for serotype 0:19 PCR assay 
Amplification Step 
• Conditions 
DNA Polymerase Enzyme activation 
(AmpliTaq® Gold DNA Polymerase) 
10 minutes, 94°C 
10 cycles — Denaturation I minute, 94°C 
Annealing 1 minute, 52°C 
Extension 	 . 1 minute, 72°C 
30 cycles — Denaturation 1 minute, 94°C 
Annealing 1 minute, 50°C 
Extension 1 minute, 72°C 
respectively. Furthermore, the PCR was repeated on al isolates to detect non-0:19 
Campylobacter using the GyrB Antisense (non-0:19) primer as given in Table 2.3: Details of 
primers chosen and designed. This PCR was performed with the same reaction mixture (Table 
5.1) and optimised thermal cycling conditions (Table 5.3). 
Extracted DNA from ATCC 700297 (serotype 0:19) and ATCC 43431 (serotype 0:3) was 
used as positive/negative controls in the 0:19 PCR and negative/positive controls in the 
non-0:19 PCR. 
Table 5.3:  Optimised amplification conditions for non-serotype 0:19 PCR assay 
Amplification Step Conditions 
DNA Polymerase Enzyme activation 
(AmpliTaq® Gold DNA Polymerase) 
10 minutes, 94°C 
40 cycles — Denaturation 1 minute, 94°C 
Annealing 1 minute, 54°C 
Extension 1 minute, 72°C 
5.1.3 Serotype 0:19 PCR results 
Of the 250 strains of Campylobacter tested at the RHH, 8 (3.2%) produced a positive 0:19 
PCR result (Figure 5.1) and were also negative by the non-0:19 PCR (Figure 5.2). However, 
when these 0:19 positive isolates were sent to a reference laboratory, Melbourne Diagnostic 
Unit -University of Melbourne (MDU) for serotype confirmation, 3 strains were found to be 
Penner serotype 0:18 with the remainder being non-typable. Due to the possibility of the PCR 
cross-reacting with serotype 0:18, 7 further strains of serotype 0:18 were obtained from the 
reference laboratory for testing by the 0:19 PCR. Unlike the 3 serotype 0:18 strains 
identified in our study, al of the serotype 0:18 strains obtained from MDU produced negative 
0:19 PCR results and a positive non-0:19 PCR. While only a smal number of serotypes were 
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Figure 5.1: PCR to detect Serotype 0:19 Campylobacter — agarose gel 
electrophoresis stained with ethidium bromide 
435 bp 
Lane I 2 3 4 5 6 7 8 9 10 11 
Lane 1: MWM, Lane 2: Positive control (serotype 0:19) C. jejuni, Lane 3: Negative control 
(serotype 0:3) C. jejuni, Lane 4-11: Tasmanian gastroenteritis strains of C. jejuni 
Figure 5.2: PCR to detect non-Serotype 0:19 Campylobacter — agarose gel 
electrophoresis stained with ethidium bromide 
435 bp 
Lane 1 2 3 4 5 6 7 13 9 10 11 
Lane 1: MWM, Lane 2: Negative control (serotype 0:19) C. jejuni, Lane 3: Positive control 
(serotype 0:3) C. jejuni, Lane 4-11: Tasmanian gastroenteritis strains of C. jejuni 
tested in the original paper (Misawa , Allos and Blaser, 1998) and these did not include 0:18 
strains, our results prove that other serotypes may produce a positive reaction with this PCR 
which should thus only be used as a preliminary screening tool before being serotyped by the 
Penner system. Furthermore, the original PCR method only tested C. jejuni isolates. To 
exclude the possibility of false positive PCR results for other Campylobacter species, the 
0:19 PCR and non-0:19 PCR were repeated on all non-C. jejuni isolates found in our study. 
All 13 non-C. jejuni isolates tested produced a negative result for both the 0:19 and non-0:19 
PCR; a feature of this PCR test not reported in the original paper (Table 5.4). 
Table 5.4: Serotype 0:19 and non-0:19 PCR results for Campylobacter isolates 
Number of 
isolates 
0:19 PCR Non-0:19 
PCR 
Identification 
8 POSITIVE NEGATIVE C. jejuni subsp. jejuni 
229 NEGATIVE POSITIVE C. jejuni subsp. jejuni 
13 NEGATIVE NEGATIVE 
10 C. coli 
2 C. lari 
1 C. upsaliensis 
5.2 Cholera Toxin Binding Inhibition EIA 
5.2.1 Background 
Patients presenting with GBS are found to possess a high prevalence of autoantibodies 
against the monoganglioside Gml present on peripheral neurons (Schwerer et al, 1995). Gm-
like epitopes have also been detected in the lipopolysaccharide (LPS) of many GBS-
associated strains of C. jejuni (Aspinall et al, 1994b). It has therefore been suggested that 
infection with these strains of Campylobacter may stimulate an autoimmune response against 
peripheral nerves (Griffin et al, 1996). An ELISA was developed by Sack et al, (1998) to 
detect the presence of Gml in the LPS of Campylobacter strains. 
The assay was based upon the ability of Gml ganglioside to bind to Cholera toxin (Ctx). A 
pre -incubation step of Campylobacter LPS with Ctx binds Gml-like epitopes in the LPS, 
therefore blocking available antibody binding sites, thus producing a negative result in the 
assay. With this assay, Sack eta! (1998) found 27 of 118 (23%) C. jejuni subsp. jejuni 
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isolates, 1 of 5 (20%) C. col isolates and 9 of 17 (53%) Helicobacter pylori isolates tested 
positive. 
Other bacteria tested including 34 isolates of various non-C. jejuni1C. coli campylobacters and 
18 Escherichia coli isolates, produced negative results. In another study, Lastovica and Sack 
(1999) also detected Gml epitopes in one isolate of Campylobacter mucosalis , two isolates 
of C. jejuni subsp. doylei and one Helicobacter acinonyx. In this study, two C. jejuni isolates 
associated with GBS were found to be Gml negative. Diker and Hascelik (1999), performed 
Gml analysis upon 90 animal strains of Campylobacter. They found 21% of strains were 
Gml positive and were found in a variety of hosts including chickens, sheep, dogs and catle. 
5.2.2 Method 
Testing was performed as given in Section 2.7: Cholera Toxin Inhibition ETA for the 
detection of Gml epitopes on bacterial cel wals. 
5.2.3 Results 
In our study, 87 of 237 (37%) C. jejuni subsp. jejuni isolates were positive, with al 10 
isolates of C. co/i, 2 isolates of C. lari and 1 isolate of C. upsaliensis producing a negative 
result (Table 5.5) and 10 of 10 (100%) GBS-associated Campylobacter strains testing positive 
(Table 5.6). The assay was easy to perform and al positive strains showed a decrease of 
greater than 90% of the OD relative to the negative control (Figure 5.3). 
Table 5.5:  Gml positive rates: Cholera Toxin Binding Inhibition Assay 
Number of 
isolates 
Cholera toxin binding 
Inhibition EIA 
Identification 
87 POSITIVE C. jejuni subs p. jejuni 
163 NEGATIVE 
150 C. jejuni subsp. jejuni 
10 	C. coil 
2 	C. lari 
1 	C. upsaliensis 
5.2.4 Discussion 
The relatively common occurrence of the Gml epitope found in the Tasmanian 
Campylobacter isolates and the low incidence of GBS within the Tasmanian community 
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Figure 5.3: Detection of Gml epitopes in Campylobacter species by the Cholera 
Toxin Binding Inhibition Assay 
Fl 11: positive control, H 12: negative control, all other wells: patient Campylobacter strains 
suggests that other factors such as host genetic predisposition and/or the presence of 
undetermined bacterial virulence factors are important in the development of GBS. 
Furthermore, other researchers have found that non-Gm! positive C. jejuni strains associated 
with GBS possess other ganglioside like epitopes in their core LPS (Nachamkin eta!, 1999). 
While this adds weight to the molecular mimicry theory, it does not aid researchers in the 
detection of potentially neuropathic strains of Campylobacter before the onset of GBS. 
It is therefore imperative to find more specific markers for the detection of these strains. 
Table 5.6: GBS control strains of C. jejuni 
STRAIN COUNTRY 
OF ORIGIN 
SEROTYPE 
(Penner) 
Ctx PFGE 
type 
MLST 
type * 
HB 9529 
(GBS1) 
China 0:19 + 1 22 
HB 9313 
(GBS2) 
China 0:19 + 1 22 
HB 9643 
(GBS3) 
China 0:19 + 1 22 
INP 26 
(GBS4) 
Mexico 0:19 + 
• 
1 22 
INP 8 
(GBS5) 
Mexico 0:19 + 1 22 
ATCC700297 
(GBS6) 
China 0:19 + 1 22 
SDY 
(GBS7) 
Australia NT + 1 NT 
28134:94 
ASM 
(GBS8) 
South Africa 0:41 + 4 5 
6491 AZR 
(GBS9) 
Unknown 0:23 + 5 42 
260:94 RXM 
(GBSIO) 
South Africa 0:41 + 3 362 
DJ5 
(TASGBS) 
Australia NT + 
. 
2 525 
, 
Ctx: Cholera Toxin Binding Inhibition Assay, PFGE: Pulsed Field Gel Electrophoresis, 
MLST: Multi Locus Sequence Typing. NT: Not tested, +: positive. 
* MLST results provided by Dr. Dingle, The Peter Medawar Building for Pathogen Research 
and Department of Zoology, Oxford University, England. 
5.3 Pulsed Field Gel Electrophoresis 
5.3.1 Background 
Neither the Gml typing of Campylobacter, nor the detection of serotype 0:19 isolates 
by PCR has provided scientists with a definitive testing method to detect strains of 
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neuropathogenic campylobacters. One aim of this project was to determine if a genetic based 
bacterial typing method could differentiate community gastrointestinal isolates of 
Campylobacter found in Tasmania from strains isolated from GBS patients, something that 
the phenotypic methods were not able to do. The typing method chosen for this purpose was 
PFGE. 
5.3.2 Method 
Testing was performed as described in Section 2.9: Pulsed Field Gel Electrophoresis. 
5.3.3 Results 
Clustering of GBS-associated strains by PFGE can be seen when compared with the ten most 
predominant strains seen in Tasmania (Figure 5.4). Interestingly, a Tasmanian GBS-
associated strain of C. jejuni which was recently isolated and not part of the original 250 
strains studied, grouped with the Tasmanian strains rather than the GBS strains. A review of 
this patient showed that this was clearly a case of GBS. The clustering of patterns may 
therefore be a clonal effect in a geographically isolated area, such as Tasmania, rather than the 
uniqueness of GBS strains as the GBS type strains were obtained from an overseas source. 
5.3.4 Discussion 
In this study, the similarity amongst the serotype 0:19 GBS strains (GBS1 —6) can clearly be 
seen and variable patterns seen with the other serotypes studied (GBS8 & GBS10: serotype 
0:41, GBS 9: serotype 0:23) when using PFGE, MLST typing systems (Table 5.6). This 
clonal nature of certain serotypes has been previously reported. Molecular characterization of 
C. jejuni associated with GBS using amplified fragment length polymorphism (AFLP) and 
flagellin typing of 10 serotype 0:41strains showed a marked degree of homology (Wassenaar, 
T.M., et al, 2000) as did serotype 0:19 (Nishimura eta!, 1997). Other serotypes such as 0:1 
and 0:2 on the other hand have shown to be quite genetically heterogeneous as a group 
(Fayos et al, 1993). 
As a group, the GBS strains did not have distinctive PFGE banding or patterns that 
differentiated them from non-GBS isolates. This is in agreement with a study of 18 GBS and 
MFS strains of C. jejuni (Endtz eta!, 2000) in which analysis by AFLP, PFGE,flaA 
polymorphism and randomly amplified polymorphic DNA (RAPD) showed no clustering 
effect when compared with non-GBS/MFS strains and no unique molecular markers. 
5.4 Summary 
Current knowledge of GBS associated strains of Campylobacter show that they, as a group 
have a number of attributes in common. Firstly, certain serotypes are isolated from GBS 
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Figure 5.4: PFGE dendrogram analysis of GBS associated and Tasmanian 
community acquired Campylobacter isolates folowing digestion with Smal 
TYPE Strains: Commonest Tasmanian PFGE types of C. jejuni, TASGBS: Tasmanian GBS 
strain of C. jejuni, GBS1-GBS10: GBS strains of C. jejuni from various countries 
patients at an increased frequency compared to other serotypes. However, not all patients who 
are infected with these serotypes develop GBS. Secondly, GBS associated strains have cell 
wall structures that mimic human gangliosides such as Gml. However not all Campylobacter 
enteritis patients with Gml positive strains develop GBS (prevalence rates for Gml positive 
strains and GBS patients in Tasmania; 37.2 and 2.3 per 100,000 population respectively). 
Genetic epidemiological techniques such as PFGE have the ability to differentiate isolates 
into a number of subgroups as determined by their restriction digest profiles and hopefully to 
be able to separate GBS isolates from those that cause enteritis. However this was not to be 
the case as no distinctive profiles or bands were found using this technique. Other genetic 
studies which also look at a small number of genetic regions, such as variation in the flagellin 
region (flaA polymorphism), have also not shown distinctive subgrouping that mark 
potentially neuropathogenic strains. Therefore, a definitive marker has not yet been found to 
identify GBS associated strains from others that cause enteritis. 
It was hypothesised that GBS isolates of Campylobacter not only require certain attributes as 
described above but also require a further unknown pathogenic determinant which is not 
present in all Gml positive strains and all members of serotypes associated with GBS. 
Characterisation of this pathogenic determinant might therefore provide the information 
necessary to understand the aetiology of GBS development and develop screening to identify 
such strains. Comparative genomic methods, such as subtractive hybridisation offer ways to 
investigate subtle differences in the genetic makeup of strains of bacteria. 
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CHAPTER 6 
IDENTIFICATION OF GENOMIC SPECIFIC DNA SEQUENCES IN GBS 
RELATED STRAINS OF C. ieiuni 
6.1: Introduction 
It has been known since 1993 that some strains of Campylobacter jejuni synthesise sialic acid 
and have sialylated carbohydrate residues in the lipopolysaccharide of their cell walls that are 
identical to human gangliosides. The "molecular mimicry" hypothesis put forward by some 
researchers suggests that these strains elicit an autoimmune "response (Griffin et al, 1996). The 
evidence from various studies however shows many discrepancies. For example, C. jejuni 
containing Gml like epitopes have been isolated from some GBS patients but these same 
patients do not demonstrate detectable levels of serum antibodies to Gml (Hao eta!, 1998). 
Furthermore, anti-Gml antibodies were detected in only 2 of 6 GBS patients infected with a 
clonally indistinguishable Penner 0:41 strain of C. jejuni (Gregson and Lastovica, 1999). In 
addition, sialylated lipo-oligosaccharides are found in other pathogenic bacterial genera 
including Neisseria and Haemophilus but these organisms have not been shown to be 
associated with GBS. Current evidence therefore suggests that molecular mimicry between 
cell wall sialylated carbohydrate residues in C. jejuni and human gangliosides cannot solely 
account for C. jejuni associated GBS. Other factors may play an important role in the 
pathogenesis of GBS, such as host susceptibility, molecular mimicry of molecules other than 
the lipopolysaccharide, the presence of a currently unknown bacterial virulence factor or a 
combination of any of these factors. The aim of this section of the study was to investigate the 
last point by examining GBS-associated strains of C. jejuni for unique DNA regions, not 
associated with Gml expression in order to identify other important molecules in the 
pathogenesis of GBS. Subtractive hybridisation techniques were used to locate specific DNA 
sequences present in the genome of a strain of C. jejuni that has been associated with GBS 
development (Penner serotype 0:19) that were not present in the genome of a strain of C. 
jejuni from a serotype never isolated from a GBS patient (Penner serotype 0:3). An overview 
of the experimental approach is given in Figure 6.1 
6.2: Subtractive Hybridisation 
6.2.1 Background 
Subtractive hybridisation is a powerful technique for the isolation of genes present in one 
bacterial cell population but absent in another and is based upon a process called driver excess 
hybridisation. Basically, the genomic DNA from the organism that potentially contains genes 
of interest (the tester) is hybridised to complementary genomic DNA that should lack these 
sequences (the driver). The driver DNA is present at a much higher concentration than the 
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Figure 6.1: Detection of a GBS specific DNA sequence in C. jejuni 
tester DNA (at least 10:1) and this dictates the speed of the reannealing reaction. The tester 
and driver nucleic acid populations are allowed to hybridise and sequences common to both 
populations form hybrids. Following hybridisation, both the tester-driver hybrids and excess 
unhybridised driver are removed leaving behind tester DNA that is enriched with tester 
specific DNA sequences. This DNA can then be used to prepare a library enriched in tester-
specific clones or to make a probe that can be used to screen a library for tester-specific 
clones. 
This approach has been used for the identification of virulence factors in uropathogenic 
strains of E. coli (Janke et al, 2001). Furthermore, the genome of Burkholderia pseudomallei 
has also been subtracted against the closely related avirulent species Burkholderia 
thailandensis producing a number of DNA sequences specific for B. pseudomallei (Brown 
and Beacham, 2000) encoding putative virulence factors. The usefulness of this technique has 
also been utilised in the plant kingdom with studies on Brassica napus (Buchanan-Wollaston 
and Ainsworth, 1997), the animal kingdom on cloning of carp (Cyprinus carpio) C-type lectin 
(Fujiki eta!, 2001) and in human tumour cell studies (Beyer-Sehlmeyer eta!, 1999). 
6.2.2 Method 
Testing was performed as given in Section 2.10.1: Subtractive hybridisation — DNA 
subtraction. 
In this study, the tester DNA was extracted from a GBS-associated Campylobacter jejuni 
(ATCC 700297) and the reference driver DNA from an ATCC 43431 strain, Campylobacter 
jejuni serotype 0:3 (a serotype not known to be associated with GBS). The CLONTECH 
PCRSelectTM Bacterial Genome Subtraction Kit was used to obtain the subtracted DNA 
library and a generalised overview of the experimental process can be seen in Figure 6.2. 
Briefly, the genomic DNAs of the two bacterial strains being compared (1.5 —2 pig of DNA 
per subtraction) were digested with Alul. The tester DNA was then subdivided into two 
portions, each of which was ligated to a different adaptor. Excess driver DNA was then 
added to both aliquots and allowed to hybridise. The resultant mixtures were heat denatured 
and then cooled to anneal, generating molecules A, B, C and D as outlined in Figure 6.3. 
The two primary hybridisation samples were then pooled. Only single stranded tester DNA 
sequences that are not present in the driver DNA can hybridise at this stage producing a 
double stranded DNA molecule with different adaptors on each end (Molecule E, Figure 6.3). 
Following the ends of the molecules being filled in by DNA polymerase, a PCR was 
performed using primers complimentary to the adaptor sequences. Only type E molecules 
were amplified exponentially to produce a mixture of tester specific DNA sequences. Next a 
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Fi2ure 6.2: Overview of the CLONTECH PCR-Selectn4 Subtractive Hybridisation 
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secondary PCR amplification was performed using nested primers to further reduce any 
background PCR products and enrich tester-specific sequences (Figure 6.4). 
6.3: Cloning of subtractive hybridisation enriched DNA 
6.3.1 Method 
The cloning and transformation protocol was as given in Section 2.10.2: Subtractive 
hybridisation — Cloning. 
Cloning of the subtractive library was performed using the AdvanTAgeTm PCR Cloning Kit 
from CLONTECH Laboratories, Inc. The PCR products enriched with tester-specific 
sequences from the subtractive hybridisation experiment was ligated into the pT-Adv 3.9 kb 
cloning vector without prior purification (Figure 6.5). Ligation of products was performed 
overnight at 14°C into cloning vector followed by transformation into TOP1OF' Escherichia 
colt cells and plated onto LB/X-gal/IPTG agar plates containing 50 1g/m1 of kanamycin. 
Transformants were screened using lcanamycin resistance and P-galactosidase a-
complementation testing (blue/white screening). White colonies growing on the kanamycin 
containing media should contain inserts and were screened further (Figure 6.6). 
6.4: Screening cloned DNA 
6.4.1 Method 
One hundred individual positive clones were selected and grown overnight on LB plates 
containing kanamycin. As the cloned DNA still had the adaptor DNA attached from the 
hybridisation experiment, these adaptor sequences were used as targets to amplify the 
fragments to obtain concentrated DNA. A 0.5 MacFarland suspension was made of each 
clone and incubated at 95°C for ten minutes. The sample was subsequently cooled and then 
used in a PCR with the nested primers 1 and 2R according to the methods outlined in the 
CLONTECH PCRSelectTM  Bacterial Genome Subtraction Kit. This produced concentrated 
DNA from the cloning site of each individual clone of E. coli which was then bound to 
HybondTM -N+ nylon nucleic acid transfer membrane. Dot blot hybridisation was then 
performed as given in Section 2.8 Dot Blot Hybridisation and probed sequentially with 
digoxigenin labeled probes (DIG DNA Labeling Kit - Boehringer Mannheim) made from 
DNA digested with restriction enzyme Alul of the following four strains; Campylobacter 
strains serotype 0:19 (GBS strain), serotype 0:3, a Tasmanian Gml positive isolate and a 
Tasmanian Gml negative isolate at concentrations of 25 ng/mL. An anti-digoxigenin-alkaline 
phosphatase conjugate was used at a dilution of 1:5000 in 1% blocking solution. 
DNA samples were selected that hybridised at 45 °C to the serotype 0:19 probe but not to the 
other three probes. 
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Figure 6.4: Subtractive hybridisation library of serotype 0:19 specific DNA 
sequences 
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Figure 6.5: Restriction Map and Multiple Cloning Site (MCS) of pT-Adv Cloning 
vector 
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Figure 6.6: AdvanTAge PCR cloning experiment 
Screening of cloned library, seen in Figure 6.4, for recombinant plasmids. 
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and inserts respectively) 
MCS REGION 1413 Room. Pinter 
Each DNA sample with the above criteria was then digoxigenin labeled and used as a probe in 
individual dot blot hybridisation experiments against purified DNA from strains of 
Campylobacter jejuni isolated from patients with (as given in Table 5.6) and without GBS. 
6.4.2 Results 
One clone was detected (Clone 3.21) that reacted with DNA from 100 % (11/11) of GBS 
isolates but only 14.5% (7/48) of the Tasmanian community strains of C. jejuni tested. This 
DNA was sequenced as given in Section 2.12: DNA sequencing to provide 559 b.p. sequence 
(Figure 6.7). The Genbank database was searched for comparisons with the data from the 
sequencing analysis to determine any previously described identities for this sequence. 
Genbank DNA matches are shown in Figure 6.8 with the highest level of homology found to 
be to a 138 nucleotide sequence from C. jejuni subsp jejuni NCTC 11168. This region 
corresponds to designated gene "Cj1013c", a probable membrane protein of undefined 
function (Figure 6.9) as determined by the C. jejuni sequencing data held at the Sanger Centre 
and available on the World Wide Web (URL: http://ww %v.sanger.ac.uk/Projects/Ciejunif).  
6.5: Clone 3.21 PCR 
6.5.1 Method 
The sequence information for clone 3.21 was used to identify regions of DNA suitable for 
amplification by PCR. Designed primers were compared for specificity against the Genbank 
database using the computer program Basic BLAST (NCBI web site). 
The optimised reaction mixture for PCR and the thermal cycling conditions using the Perkin 
Elmer DNA Thermal Cycler Model 480 are given in Tables 6.1 and 6.2 respectively. 
Table 6.1: Optimised reaction conditions for PCR assay (3.21) 
Rea2ent Final Concentration 
10 X PCR Buffer II 1 X 
Magnesium Chloride (mM) 1.65 
3.21 Sense Primer (p.M) 0.45 
3.21 Anti-sense Primer (1.1M) 0.45 
dNTPs 
(dATP, dGTP, dCTP, dUTP) 
200 1.IM of each 
AmpliTaq0 Gold DNA Polymerase 0.5 U 
Sample 100 ng of genomic DNA 
Water Volume adjusted to 501.11, 
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Figure 6.7: Sequence data of cloned DNA fragment from Clone 3.21 
GCAATNCTATCATCAAAATGCAAATTTCTTTTAATAATGAAAGCA 
AAGAAATTTTACTTTTTNCAAATTACAACAATGAAAATGTTTTAC 
CTTTTAGATTAGGAGGTGAAATTTTTGCACTCAACTGGGGTCCTG 
AAGAGATTAAACTGCCTTTTTCTTTGGCTTTAAAAGATTTTATCCT 
TGATCGCTACGCAGGTTCTATGAGTCCTTCTTCTTATGCTTCAGAT 
ATCGAAGTGATCGATCAAGATAAAAGTTTTGAGTATAAAATTTTT 
ATGAATAATGTTTTAGATTATGGCGGATATAGATTTTTTCAAAGT 
TCTTATGATCAAGACGAACAAGGCACCATACTTTCAGTCAATAAA 
GATCCTGGAAAAATTCCAACTTATATAGGCTATACTTTGCTGACT 
TTAGGTTTTTTATGGGATTTTATTTGCTAAAAACTCAAGATTTCAA 
AAATTATCAAACTATCTTAAAAATCAAAAAAATCTTTTATTAATT 
CTTTTTTGNCTTTTTGCTTTTAACATAAAAAAGGTTTTGCCCGATG 
AAAACACCTTAAAGACCTC 
Figure 6.8: Genbanks analysis of clone 3.21 DNA 
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Figure 6.9: Probable gene function of Clone 3.21 DNA match at Genbank 
ORGANISM Campylobacter jejuni subsp. jejuni NCTC 11168 Bacteria; Proteobacteria; epsilon 
subdivision; Campylobacter group; Campylobacter. 
gene complement(3961.7206) /gene="Cj1013c" CDS complement(3961.7206) /gene="Cj1013c" 
/note="CjI013c, probable membrane protein, len: 1081 aa; contains three domains; aa 1-90 contains 
three membrane spanning domains; aa 90-780 is non-membrane, and aa 780-1081 contains ten possible 
membrane spanning 
Source: C. jejuni sequencing data at the Sanger Centre ( htp:/www.sanger.ac.uk/Projects/C iejunif). 
Table 6.2: Optimised amplification conditions for PCR assay (3.21) 
Amplification Step Conditions 	 . 
DNA Polymerase Enzyme activation 
(AmpliTaq® Gold DNA Polymerase) 
5 minutes, 94°C 
36 cycles — Denaturation 30 seconds, 94°C 
Annealing 30 seconds, 56°C 
Extension 1.5 minutes, 72°C 
6.5.2 Results 
The resultant PCR experiment with purified C. jejuni DNA produced the expected 162 bp 
fragment (Figure 6.10) in 10 of 11(91%) GBS isolates of C. jejuni and only 6 of 57(10.5%) 
Tasmanian enteritis isolates of C. jejuni (Table 6.3). 
PFGE analysis of these isolates showed the 57 Tasmanian isolates could be subdivided into 
27 diferent profiles with the 6 PCR positive isolates belonging to 5 of these. 
Gml analysis of the 57 Tasmanian strains tested showed the 3.21 gene could be detected in 
only 5% of Gm 1 positive isolates and 15.6% of Gml negative isolates (Table 6.4). 
Table 6.3: PCR 3.21 results for GBS associated isolates and Tasmanian enteritis 
isolates of C. jejuni 
PCR GBS isolates Tasmania enteritis 
isolates 
3.21 10/11 POSITIVE 6/57 POSITIVE 
Table 6.4: Gene 3.21 PCR/Gml analysis of Tasmanian C. jejuni isolates 
Positive for 
Gm! 
Negative for 
Gm! 
PCR 
Positive 
for 3.21 
1 5 
PCR 
Negative 
for 3.21 
19 32 
6.5.3 Discussion 
This confirms that the 3.21 gene is not associated with the Gml gene but could stil be 
associated with some other sialylated carbohydrate residue in the lipopolysaccharide or other 
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Figure 6.10: PCR For Gene 3.21 — agarose gel stained with ethidium bromide 
LANE 1: Molecular Weight Marker, LANES 2-10: GBS strains of C. jejuni, LANES 11-16: 
Tasmanian clinical isolates of C. jejuni 
unrelated protein structure. As 91% of GBS-associated Campylobacter strains were 
Gml/gene 3.21 positive but only 5% of community isolates of Campylobacter were 
Gml/gene 3.21 positive, this suggests that both are required for neuropathogenicity. To test 
this hypothesis, gene 3.21 negative mutants could be produced from a strain of GBS-
associated C. jejuni by a suitable mutagenesis system. Animal model studies with the 3.21 
negative mutant and wild type strain of GBS-associated C. jejuni would then be performed. 
Data collection regarding nerve damage would then provide valuable information into the 
dependant relationship of these two genes. 
Outer membrane characteristics are often important virulence determinants in bacteria. While 
the genome of C. jejuni has recently been sequenced, only a few definite protein antigens 
have so far been characterized. For example, serological studies have shown that the 65-1cDa 
flagellin, the 44-1cDa surface protein and the 25- to 29-1cDa surface proteins all react to the 
convalescent sera of patients with Campylobacter gastrointestinal infections (B laser, Hopkins 
and Vasil, 1984; Nachamlcin and Hart, 1985; Wenman eta!, 1985; Dunn, Blaser and Snyder, 
1987). Also, protein PEB1 is thought to function as an adhesion for attachment to eukaryotic 
cells (Pei and Blaser, 1993) and the heat shock protein GroEL elicits an immune response in 
infected rabbits (Wu et al, 1994) as does the Campylobacter trigger factor in humans 
(Griffiths, Park and Connerton, 1995). These studies have characterized common proteins 
found in gastrointestinal isolates of Campylobacter. This is the first study to report a GBS-
specific "probable" membrane protein which is found in a high proportion of GBS-associated 
control strains of C. jejuni whilst being relatively uncommon in community isolates from 
patients with gastrointestinal infections. 
6.6: Clone 3.21 gene expression experiments 
6.6.1 Method 
To determine if the probable membrane protein that the gene associated with clone 3.21 codes 
for could be detected by SDS-polyacylimide gel electrophoresis (SDS-PAGE), a number of 
different experiments were performed. Firstly, SDS-PAGE of whole cell protein extracts was 
performed on two related C. jejuni isolates (as determined by PFGE), a clone 3.21 positive 
C. jejuni and a clone 3.21 negative C. jejuni. Secondly, SDS-PAGE was performed on E. coli 
transformed with the pT-Adv vector containing the 3.21 DNA insert identified from the 
subtracted library. This was compared to the same strain of E. coli with a non-recombinant 
plasmid. Thirdly, as the open reading frame of gene 3.21 was unknown, three PCRs were 
developed to amplify clone 3.21DNA using three forward primers of varying length (Vehl8, 
Vehl9 and Veh20) and the same reverse primer (VehRev) (Figure 6.11). The optimised 
reaction mixture for PCR and the thermal cycling conditions using the Perkin Elmer DNA 
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Figure 6.11: Primer design for gene 3.21 cloning experiment 
GcluvrsrcrAirAm=ccAAATTTCTTTTAATAATGAAAGCA 
AAGAAATTTTACTTTTTNCAAATTACAACAATGAAAATGTTTTAC 
CTTTTAGATTAGGAGGTGAAATTTTTGCACTCAACTGGGGTCCTG 
AAGAGATTAAACTGCCTTTTTCTTTGGCTTTAAAAGATTTTATCCT 
TGATCGCTACGCAGGTTCTATGAGTCCTTCTTCTTATGCTTCAGAT 
ATCGAAGTGATCGATCAAGATAAAAGTTTTGAGTATAAAATTTTT 
ATGAATAATGTTTTAGATTATGGCGGATATAGATTTTTTCAAAGT 
TCTTATGATCAAGACGAACAAGGCACCATACTTTCAGTCAATAAA 
GATCCTGGAAAAATTCCAACTTATATAGGCTATACTTTGCTGACT 
TTAGGTTTTTTATGGGATTTTATTTGCTAAAAACTCAAGATTTCAA 
AAATTATCAAACTATCTTAAAAATCAAAAAAATCTTTTATTAATT 
CTTTTTTGNCTTMGCTTTTAACATAAAAAAGGTTTTGCCCGATG 
AAAACACCTTAAAGACCTC 
Veh 18 Forward primer 
Veh 19 Forward primer 
Veh 20 Forward primer 
VehRev Reverse primer 
Thermal Cycler Model 480 were the same as given in Tables 6.1 and 6.2 respectively with the 
following exceptions. The annealing temperature was lowered to 50 °C and the Magnesium 
Chloride concentration altered to 3.3 mM. The subsequent products of 569 b.p, 570 b.p and 
571 b.p in size were ligated into the expression vector, pQE 30 UA (QIAGEN) and 
transformed into TOP1OF' Escherichia coli cells and plated onto LB/X-gal/IPTG agar plates 
containing 50 pg/mL of kanamycin. SDS-PAGE was performed on white colonies containing 
DNA of clone 3.21 and compared to E. coil containing the same expression vector with no 
extra inserted DNA. 
6.6.2 Results 
All three experiments showed no apparent differences in protein profiles compared to their 
relative controls (Figure 6.12). 
6.7 Summary 
Subtractive hybridisation has been successfully used to identify a DNA region that is found in 
the majority of GBS strains tested and that is relatively uncommon in community 
gastrointestinal isolates of Campylobacter. As only a small number of GBS strains were 
tested in this study, screening of larger GBS Campylobacter culture collections is needed to 
determine the true incidence of the gene across other serotypes that have been associated with 
GBS, however for reasons referred to previously, Campylobacter isolates from GBS patients 
are rare. 
A PCR method based upon this gene has been developed that allows for rapid identification 
of those strains that are potentially neuropathogenic. 
Preliminary.protein analysis has so far provided no information about the nature of the 
"probable" membrane protein associated with this gene. Further sequence information must 
be obtained upstream and downstream of the known DNA sequence described here in order to 
determine the entire coding region for the gene so that expression experiments can be 
repeated. Furthermore, a high efficiency mutagenesis system could be developed to produce 
gene knock-out mutants allowing for identification and characterization of expressed proteins 
in the wild-type strain but not the mutants. Both of these experiments are outside the scope of 
this study. 
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Figure 6.12: SDS-PAGE analysis of whole cel extracts of E. coli containing 
expression vector containing clone 3.21 DNA 
Lane 1 2 3 4 	 5 
Lane 1: Molecular Weight Marker, Lanes 2-4: E. coli containing clone 3.21 DNA/Expression 
vector, Lane 5: Control E. coli with expression vector only 
CHAPTER 7 
7.1 CONCLUSIONS 
The first reported case of Campylobacter-associated GBS was published by Rhodes and 
Tattersfield (1982). As GBS often presents many weeks following a gastrointestinal infection 
with Campylobacter making isolation of the bacterium from faeces impossible in the majority of 
cases, the link between infection and GBS has been made by serological studies. Over the last 20 
years, with improved culture techniques, more isolates have been collected and today, study 
groups around the world have large, characterised collections of C. jejuni strains associated with 
GBS. 
The reasons why some patients develop GBS and others do not is still unknown. Some 
researchers have hypothesised that individual patient susceptibility is the key factor predisposing 
them following infection with this organism. Others have theorised that the organisms themselves 
have some unique neuropathogenic characteristic. Studies of the bacterium have shown that cell 
wall lipopolysaccharides can mimic human neuronal ganglioside structures such as Gml. 
Antibodies produced following gastrointestinal infection with Campylobacter are therefore 
'thought to lead to autoimmune responses to the patient's neurones resulting in this neurological 
symptom. While many serotypes of Campylobacter possess these cell surface molecules, certain 
serotypes, in particular Penner serotype 0:19, appear to be over represented in most studies of 
GBS. Other serotypes isolated from GBS patients include 0:1, 0:2, 0:4, 0:4 complex, 0:5, 0:10, 
0:16, 0:23, 0:37, 0:41, 0:44 and 0:64. 
Recent epidemiological studies have been applied to characterising this group of organisms. 
Analysis of GBS and MFS strains by AFLP, PFGE,f/aA polymorphism and randomly amplified 
polymorphic DNA (RAPD) analysis have not shown a unique type that can differentiate GBS-
associated strains from non-GBS/MFS strains. 
In the present study, PFGE was shown to be an effective epidemiological technique allowing for 
the differentiation of gastrointestinal Campylobacter isolates for the identification of outbreak 
strains. Furthermore, cluster analysis of PFGE profiles of C. jejuni and C. co/i by available 
computer software allowed for identification to species level. Only a limited range of other 
species were studied, however, and as such, the use of PFGE to differentiate them cannot be 
assessed. As was the case in the study by Endtz et al, (2000), PFGE could not be used to 
differentiate GBS strains from non-GBS strains. While there was close homology with serotype 
0:19 GBS isolates by this technique, all other serotyped GBS isolates had variable profiles. 
Cluster analysis of PFGE profiles did however differentiate overseas GBS strains as a group from 
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Tasmanian community isolates of Campylobacter. As the one Tasmanian GBS strain in our study 
clustered with the Tasmanian community strains and not with the GBS strains, it might be 
concluded that this was due to a geographical phenomenon rather than a characteristic of GBS 
strains. 
Characterisation of Tasmanian community Campylobacter isolates to determine the presence of 
Gmlepitope and the prevalence of serotype 0:19 have also been performed as part of this study. 
The rate of Gml positive Campylobacter strains seen in Tasmania was 37.2 per 100,000 
population over the time period studied. As the GBS rate in Tasmania over the same period was 
2.3 per 100,000 population, it can be concluded that factors other than the presence of Gml -like 
epitopes in the cell wall of Campylobacter species are needed for development of GBS. 
Furthermore, while serotype 0:19 is not the only serotype associated with GBS, due to its high 
prevalence in previous GBS studies, it was important to determine the prevalence of this 
particular serotype in the Tasmanian community. As such, a previously published PCR assay for 
the serotype 0:19 specific gyrase B gene (Misawa , Allos and Blaser, 1998) was used to 
investigate 0:19 incidence in the Tasmanian population. No isolates in our study were found to 
belong to this serotype. This result was surprising as a study from USA found that 2% of patients 
with uncomplicated gastroenteritis were infected with the serotype 0:19 strain (Mishu, Patton and 
Blaser, 1993). Furthermore, in this study some serotype 0:18 and non-typable strains produced 
false positives using this assay in 3.2% of isolates tested. 
C. jejuni has been the predominant Campylobacter species isolated in association with GBS, but a 
recent isolation of C. upsaliensis has been reported (Ho et al, 1997). Speciation of isolates was 
therefore important to characterise other species that may be potentially neuropathogenic. 
As this group of organisms is biochemically inert and difficult to identify, a molecular based 
method was developed in our study to rapidly identify Campylobacter isolates. A multiplex PCR 
was developed to detect both genus specific 16S rRNA for Campylobacter and Arcobacter 
species as well as the hippurate gene for C. jejuni. In our study, 237 of 250 isolates (94.8%) were 
identified as C. jejuni within 4 hours, including 2 isolates that were biochemically hippurate 
negative. The remaining 13 isolates were identified as belonging to the 
Campylobacter/Arcobacter group with positive 16S rRNA PCR detection. This PCR product was 
subsequently used in a dot blot hybridisation assay with species specific biotinylated probes to C. 
co/i, C. upsaliensis, C. fetus, C. lari and a genus specific probe to Arcobacter. Using this system, 
10 isolates were identified as C. co/i, 2 as C. lari and 1 C. upsaliensis. As isolation of non-C. 
jejuni Campylobacter are infrequent, their neuropathic nature is hard to assess. Future 
improvements to culturing techniques and/or PCR detection methods from faecal samples may 
77 
provide more accurate data regarding the prevalence of other Campylobacter species within the 
community and potential associations with GBS. 
Serotyping, Gml analysis and PFGE provide useful information about the nature of GBS 
associated strains of Campylobacter but lack the ability to discriminate between those that only 
cause gastroenteritis and those that may invoke GBS. A closer study of GBS-related strains at the 
genomic level may provide information on unique characteristics of these strains and 
subsequently lead to development of detection methods to quickly identify these strains allowing 
prompt medical intervention. 
The comparative genomic method, subtractive hybridisation, is a powerful technique for the 
isolation of genes present in one bacterial cell population but absent in another. It was used to 
compare a known strain of C. jejuni associated with GBS (serotype 0:19) with a strain from a 
serotype that has not been associated with GBS (serotype 0:3). Unique regions of DNA were 
cloned into Escherichia coli and analysed by hybridisation to digoxigenin labeled DNA from a 
GBS C. jejuni strain to remove non-specific fragments. After testing one hundred such clones, 
one positive clone which contained the DNA fragment (Veh) was identified which hybridised to 
DNA from 11 GBS control isolates (representing 5 strains) and 14.5% of gastroenteritis strains of 
Campylobacter. 
Following sequence analysis of this Veh fragment, primers were designed and a PCR-based 
method developed to rapidly detect the Veh gene. Utilizing this assay, the Veh gene was detected 
in 91% of control GBS strains of C. jejuni and 10.5% of community isolates of Campylobacter. 
This method detected fewer positives than the crude Veh gene probe used previously due to the 
specific nature of the designed PCR primers. Importantly, community isolates that were detected 
by this method, comprised both Gml positive and Gml negative strains, indicating that the 
unique Veh region detected was not related to the genes coding for Gml -like epitopes found in 
the lipopolysaccharides of some isolates. 
Genbank DNA matches of the sequenced DNA showed that the highest level of homology was 
found to be to a 138 nucleotide sequence from C. jejuni subsp jejuni NCTC 11168. This region 
corresponds to designated gene "Cj1013c", a probable membrane protein of undefined function 
as determined by the C. jejuni sequencing data held at the Wellcome Trust Sanger Institute, 
Cambridge, UK. This represents the first non-ganglioside based marker of GBS-associated 
Campylobacter reported to date. 
7.2 Further work 
It is hypothesised that the Veh gene may be important in the pathogenesis of campylobacters that 
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are associated with GBS. While current evidence suggests the gene codes for a membrane 
protein, we still have limited knowledge of the function of this gene product and therefore a 
suitable, high efficiency mutagenesis system for C. jejuni will need to be developed for further 
research. Once optimized, the mutagenesis system could be used to produce Veh isogenic mutants 
which could then be used for proteome analysis using two dimensional SDS-PAGE and high-
sensitivity mass spectrometry. Comparison of these mutant strains deficient in the Veh gene with 
the wild type strain would provide valuable information into the nature of the unknown protein. 
An important future development to aid the study of Campylobacter-associated GBS would be 
the development of a good animal model, something that has not been available to researchers to 
date. This would allow challenge studies of Veh immunised animals to be performed. 
While a rapid 4 hour PCR method has been developed in the present study to detect isolates of 
Campylobacter possessing the Veh gene, purification of the Veh protein and production of 
antisera to various epitopes of the Veh gene product would allow the development an antigen 
detection system. Production of a rapid latex agglutination test for laboratory staff to identify 
neuropathogenic strains within 10 minutes of isolation would then be possible. 
If the hypothesis that the Veh gene is important in the pathogenesis of C. jejuni-associated GBS is 
proved to be correct, then it would become possible to direct the development of prophylactic and 
therapeutic interventions for C. jejuni-associated GBS. 
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APPENDIX A: Phenotypic properties of Campvlobacter species 
Organism Catalase Nitrate 
reduction 
Nitrite 
reduction 
H2 
required 
Urease H2S 
(TSI) 
Hippurate 
hydrolysis 
Indoxyl 
acetate 
hydrolysis 
C. jejuni subsp. jejuni + + - - - - + + 
C. jejuni subsp. doylei V - - - - V + 
C. co/i + + - - - - - + 
C. fetus + + - - - - - - 
C. fetus subsp.venerealis + + - - - - - 
C. lari + + - - V - - - 
C. upsaliensis W + - - - - - + 
C. hyointestinalis + + - V - + - - 
C. sputorum biovar 
sputorum 
- + + - - + - - 
C. sputorum biovar 
bubulus 
- + + - - + - - 
C. sputorum biovar 
fecalis 
+ + + - - + - - 
C. helveticus - + ND - ND - + 
C. mucosalis - + + + - + - - 
C. concisus - + + + - + - - 
C. curvus - + + + - + - + 
C. rectus - + + + - + - + 
C. showae + + ND + - + - + 
A. cgaerophilus group IA . 	 + V - . 	 - - - - 
A. clyaerophilus group 1B + V ND - - - 	 • + 
A. butzleri W + - - - - - + 
A. nitrofigilis + + - - - - - - 
A. skirrowi ± + ND - 	 - _ - + 
TSI, triple sugar iron; W, weak reaction V, variable reaction; ND, not determined (Nachamkin, 1999) 0 
Organism Growth 
at 
15°C 
Growth 
at 
25°C 
Growth 
at 
42°C 
Growth 
in 
3.5% NaC1 
Growth 
in 
1%Glycine 
Growth 
on MCA 
Susceptiblity 
to 
Nalidixic acid 
Susceptibility 
to 
Cephalothin 
C. jejuni subsp. jejuni - - + - + + V R 
C. jejuni subsp. doylei - - - . + - S S 
C. co/i - + - + + S R 
C. fetus - + - + + V S 
C. fetus subsp. 
venerealis 
- + - _ + R S 
C. lari - 	 • + - + + R R 
C. upsaliensis - - + - V - 	 . S S 
C. hyointestinalis - + + - + + R S 
C. sputorum biovar 
sputorum 
- + - + + S S 
C. sputorum biovar 
bubulus 
- + + + - R S 
C. sputorum biovar 
fecalis 
- + - + R 
C. helveticus - + V V ND S S 
C. mucosalis• - + - + + R S 
C. concisus - + - + + R R 
C. curvus - + - + ND S ND 
C. rectus - W - + ND S ND 
C. showae - + - V ND R S 
A. oyaerophilus group lA + + - - - - V R 
A. cryaerophilus group 1B + + - - - + S V 
A. butzleri + + V V + + S R 
A. nitrofigdis + + + - - S S 
A. skirrowi + + V V V - S S 
MCA, MacConkey Agar; W, weak reaction; V, variable reaction; ND, not determined; S, susceptible; R, resistant (Nachamkin, 1999) 
00 
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APPENDIX B: Preparation of LB (Luria-Bertani) medium (pH 7.0) with antibiotics. 
Taken from Clontech AdvanTAgeTm PCR Cloning Kit User Manual. 
LB (Luria-Bertani) medium (pH 7.0) 
for 1 L: 
1.0% Bacto-tryptone 10 g 
0.5% Yeast extract 5 g 
1.0% NaC1 10 g 
Dissolve ingredients in 950 ml of deionized water. Adjust the pH to 7.0 with 5 M NaOH and 
bring the volume up to 1 L. Autoclave on liquid cycle for 20 min at 15 lb/in 2 . Store at room 
temperature or at 4 °C. 
LB/antibiotic plates 
Prepare LB medium as above, but add 15 g/L agar before autoclaving. Autoclave on liquid cycle 
for 20 mm at 15 lb/in2 . Let cool to — 55 °C, add antibiotic (50 [tg/mL of either ampicillin or 
kanamycin), and pour into 10 cm plates. Let harden, then invert and store at 4 °C. 
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APPENDIX C: Reagents and solutions used for the dot blot hybridisation 
identification assay. Taken from "The DIG System User's Guide for Filter 
Hybridisation manual (Boehringer Mannheim) 
Solution Constituents 
Prehybridisation solution 5 X SSC, 0.1% sodium-lauroylsarcosine, 
0.02% SDS, 1% blocking solution 
Blocking solution (10%) 150 mM NaCl, 100 mM maleic acid, 
pH 7.5, 10% (w/v) Blocking Reagent 
Washing solution 1 2 X SSC, 0.1% SDS 
Washing solution 2 0.5X SSC, 0.1% SDS 
Washing solution 3 150 mM NaC1, 100 mM maleic acid, 
pH 7.5 
Detection solution 100 mM Tris-HC1, 100 mM NaC1 
pH 9.5 
20X SSC solution 3 M NaCl, 0.3 M sodium citrate, pH 7.0 
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APPENDIX D: Reagents and solutions used for Pulsed-Field Gel Electrophoresis 
Smith and Cantor, 1987. 
Solution Constituents 
PIV solution 10 mM Tris-C1 (pH7.6), 1M NaC1 
ESP solution 0.5M EDTA (pH9.5), lmg/m1 Proteinase K, 
1% N-laurylsarcosine, sodium salt 
TEl solution 10 mM Tris-C1 (pH7.6), 1 mM EDTA (3118.0) 
5 X TBE solution 0.445M Tris Base, 0.445M Boric acid, 
10 inM EDTA (pH 8.0) 
Restriction buffer A 33 mM Tris-acetate, 66 inM Potassium-acetate 
10 mM Magriessium-acetate, 
0.5 mM dithioerythritol (pH 7.9) 
Restriction buffer H 50 mM Tris-HC1, 100 mM Sodium Chloride, 
10 mM Magnessium Chloride, 
1 mM dithioerythritol, (pH 7.5) 
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